# **CERTIFIED COPY**

### BEFORE THE CITIZENS FINANCIAL ACCOUNTABILITY OVERSIGHT COMMITTEE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION:

CALIFORNIA PUBLIC UTILITIES COMMISSION

505 VAN NESS AVENUE

SAN FRANCISCO, CALIFORNIA

DATE:

TUESDAY, NOVEMBER 27, 2007

9 A.M.

REPORTER:

BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 79867



BARRISTERS, REPORTING SERVICE

1072 SOUTH EAST BRISTOL STREET SUITE 100 SANTA ANA HEIGHTS CALIFORNIA 92707

714.444.4100 FAX 714.444.4411 1.800.622.6092

www.depo1.com E-MAIL: depo@depo1.com

#### INDEX

ITEM DESCRIPTION	PAGE	NO
OATH OF OFFICE FOR NEW MEMBERS		3
CALL TO ORDER		5
ROLL CALL		5
OPENING STATEMENT		6
ADOPTION OF MINUTES OF 9/14/06 MEETING		7
ADOPT CONFLICT OF INTEREST CODE PURSUANT TO FAIR POLITICAL PRACTICES COMMISSION REGULATION	ű	11
STATUS UPDATE OF CIRM'S FINANCIAL STATEMENTS, GRANT AWARDS PROCESS, BEST PRACTICE CONSIDERATIONS, AND INTELLECTUAL PROPERTY REGULATIONS		11
PRESENTATION OF THE 2005-06 INDEPENDENT FINANCIAL AUDIT BY MACIAS, GINI & O'CONNELL, CIRM'S AUDIT REPONSE, AND THE STATE CONTROLLER'S OFFICE AUDIT REVIEW REPORT	-	14
PRESENTATION OF THE BUREAU OF STATE AUDITS REPORT REGARDING CIRM AND CIRM'S RESPONSES	7	72
CONSIDERATION OF DRAFT AGENDA FOR NEXT MEETIN	1G S	90
PUBLIC COMMENT	Ç	91
BOARD MEMBER TIME	10	)3
ADJOURNMENT	1(	7

2

1	SAN FRANCISCO, CALIFORNIA; TUESDAY, NOVEMBER 27, 2007
2	9 A.M.
3	
4	CHAIRMAN CHIANG: IT IS 9:07, AND I'D LIKE TO
5	CONVENE THE CITIZENS FINANCIAL ACCOUNTABILITY OVERSIGHT
6	COMMITTEE. LET US BEGIN BY PAYING TRIBUTE TO OUR COUNTRY
7	IN SAYING THE PLEDGE OF ALLEGIANCE.
8	(THE PLEDGE OF ALLEGIANCE.)
9	CHAIRMAN CHIANG: ITEM NO. 2, WE WILL
10	ADMINISTER THE OATH OF OFFICE FOR THE NEWLY APPOINTED
11	CFAOC MEMBERS, DR. GURBINDER SADANA AND DR. LOREN LIPSON
12	IS THE SECOND MEMBER. BEFORE I ADMINISTER THE OATH,
13	DR. LIPSON UNFORTUNATELY HAD A COMMITMENT TO BE AN EXPERT
14	WITNESS FOR A TRIAL BEING HELD ON THE EAST COAST AND IS,
15	THEREFORE, UNAVAILABLE.
16	IN ADDITION, SHOULD ANYONE FROM THE PUBLIC LIKE
17	TO MAKE PUBLIC REMARKS, YOU ARE ENCOURAGED TO DO SO. WE
18	WILL TAKE PUBLIC REMARKS AT THE END OF EACH ITEM. PLEASE
19	LIMIT YOUR REMARKS TO THREE MINUTES OR LESS. FOR ANY
20	PARTICULAR ITEM, PLEASE GO TO THE BACK AND SIGN IN SO
21	THAT WE CAN ESTABLISH YOUR WILLINGNESS AND WANT TO
22	TESTIFY. AND ALSO PLEASE TURN OFF YOUR CELL PHONES.
23	DR. SADANA, PLEASE STAND AND LET ME ADMINISTER
24	THE OATH OF OFFICE.
25	(THE OATH WAS THEN ADMINISTERED TO DR.

1	SADANA.)
2	CHAIRMAN CHIANG: CONGRATULATIONS. IS THERE
3	ANY PUBLIC COMMENT ON THIS ITEM?
4	MR. SIMPSON: YES, MR. CHAIRMAN.
5	CHAIRMAN CHIANG: GOOD MORNING. PLEASE
6	INTRODUCE YOURSELF FOR THE RECORD.
7	MR. SIMPSON: GOOD MORNING. I'M JOHN SIMPSON
8	WITH THE FOUNDATION FOR TAXPAYER AND CONSUMER RIGHTS. I
9	HEAD OUR STEM CELL PROJECT OVERSIGHT AND ACCOUNTABILITY
10	PROJECT, WHICH IS FUNDED BY THE NATHAN CUMMINGS
11	FOUNDATION.
12	CHAIRMAN CHIANG: EXCUSE ME, JOHN. IS YOUR
13	MICROPHONE ON?
14	MR. SIMPSON: IS IT BETTER NOW? I APOLOGIZE.
15	SAW A RED LIGHT THERE. I THOUGHT IT WAS SOMETHING ELSE.
16	I SEE I NEED A GREEN.
17	IN ANY EVENT, WE HAVE TRIED TO ENSURE THAT THE
18	PEOPLE OF CALIFORNIA HAVE AFFORDABLE ACCESS TO THE CURES
19	FOR WHICH THEY'RE PUTTING OUT THE MONEY. AS PART OF THAT
20	PROJECT, WE'VE DONE THINGS LIKE CHALLENGE SOME VERY
21	RESTRICTIVE HUMAN EMBRYONIC STEM CELL PATENTS. AND ALSO
22	AS PART OF THAT EFFORT, I APPEARED BEFORE YOU LAST YEAR
23	AND CHALLENGED THE SEATING OF ONE OF THE BOARD MEMBERS,
24	JOHN HEIN, WHO AT THE TIME I SAID I THOUGHT WAS A GREAT
25	INDIVIDUAL, BUT HE DID NOT HAVE THE QUALIFICATIONS

1	SPECIFIED IN THE LAW. I'M DELIGHTED TO SEE THAT
2	APPARENTLY THAT CHALLENGE FELL ON LISTENING EARS BECAUSE
3	THE SPEAKER HAS APPOINTED A NEW VERY QUALIFIED CANDIDATE
4	TO THE BOARD, AND WE'RE DELIGHTED TO SEE THAT THAT HAS
5	HAPPENED. AND I JUST WANTED TO WELCOME HIM HERE AND SAY
6	THAT I'M GLAD THAT THE PROCESS SEEMS TO WORK WHERE THE
7	PUBLIC SPEAKS UP AND POINTS THINGS OUT. AND AT LEAST
8	WITH THIS COMMITTEE, THE COMMITTEE SEEMS TO BE
9	RESPONSIVE. SO I THANK YOU VERY MUCH.
10	CHAIRMAN CHIANG: THANK YOU, JOHN. NEXT ITEM.
11	INTRODUCE THE ITEM.
12	MR. O'TOOLE: YES. THE NEXT ITEM IS THE CALL
13	TO ORDER AND ROLL CALL.
14	CHAIRMAN CHIANG: OKAY. PLEASE TAKE ROLL.
15	MR. O'TOOLE: CHAIRMAN JOHN CHIANG.
16	CHAIRMAN CHIANG: AYE.
17	MR. O'TOOLE: DANIEL BRUNNER.
18	MR. BRUNNER: HERE.
19	MR. O'TOOLE: JIM LOTT. MYRTLE POTTER.
20	MS. POTTER: HERE.
21	MR. O'TOOLE: GURINDER SADANA.
22	DR. SADANA: HERE.
23	CHAIRMAN CHIANG: VERY GOOD. WE HAVE A QUORUM
24	PRESENT. NEXT ITEM IS OPENING STATEMENT. LET ME BEGIN.
25	I WOULD LIKE TO THANK EVERYBODY FOR ATTENDING
	5

1	TODAY, AND I WOULD LIKE TO WELCOME ONE OF OUR NEW
2	MEMBERS, DR. SADANA, TO THIS IMPORTANT REVIEW COMMITTEE.
3	THREE YEARS AGO THIS VERY MONTH CALIFORNIA SHOWED THEIR
4	OVERWHELMING SUPPORT FOR STEM CELL RESEARCH WHEN THEY
5	APPROVED PROPOSITION 71. NOT ONLY DID CALIFORNIA VOTERS
6	SUPPORT STEM CELL RESEARCH, THEY ALSO SAID THEY WERE
7	WILLING TO PAY FOR IT AND COMMITTED MORE THAN \$3 BILLION
8	IN PUBLIC FUNDS, WHICH WILL BE CLOSER TO \$6 BILLION WITH
9	BOND FINANCING, TO PURSUE THIS PROMISING RESEARCH.
10	I TOO STRONGLY BELIEVE THAT STEM CELL RESEARCH
11	HOLDS THE KEY TO CURES FOR CHRONIC AND LIFE-THREATENING
12	DISEASES THAT AFFECT MILLIONS OF AMERICANS. THE MEMBERS
13	OF THIS COMMITTEE NOT ONLY HAVE THE OPPORTUNITY, BUT HAVE
14	THE OBLIGATION TO PROVIDE EXPERT FISCAL REVIEW AND
15	GUIDANCE TO THE INSTITUTE FOR REGENERATIVE MEDICINE AND
16	THEREBY ENSURING ITS FISCAL PRACTICES ARE SOUND AND THAT
17	THE INVESTMENT OF PUBLIC FUNDS MADE BY CALIFORNIA VOTERS
18	IS FIERCELY PROTECTED AS WE CONTINUE TO MAKE INROADS INTO
19	THIS REVOLUTIONARY FIELD OF SCIENCE AND MEDICINE.
20	WOULD ANY OTHER MEMBERS LIKE TO MAKE COMMENTS?
21	NEXT ITEM. WE WILL DISCUSS THE MINUTES OF THE
22	SEPTEMBER 14, 2006, CFAOC MEETING. ARE THERE ANY
23	QUESTIONS OR SUGGESTED AMENDMENTS TO THE MINUTES? MAY I
24	HAVE A MOTION TO APPROVE?
25	MR. BRUNNER: SO MOVED.

1	CHAIRMAN CHIANG: WE HAVE A MOTION. DO WE HAVE
2	A SECOND?
3	DR. SADANA: SECOND.
4	CHAIRMAN CHIANG: IS THERE OBJECTION? WITHOUT
5	OBJECTION, THE MOTION PASSES. VERY GOOD.
6	THE NEXT ITEM IS THE CONFLICT OF INTEREST CODE
7	PURSUANT TO FPPC REGULATION 187512(C)(3). THIS REQUIRES
8	ACTION.
9	I AM INTERESTED IN NOTICING THE OFFICE OF
10	ADMINISTRATIVE LAW IN HAVING THE MEMBERS OF THIS BODY
11	ADOPT A CONFLICT OF INTEREST CODE. I WOULD LIKE TO
12	EXPLAIN WHY I BELIEVE IT IS ABSOLUTELY IMPORTANT THAT WE
13	OPERATE IN A FULLY TRANSPARENT MANNER.
14	THE PURPOSE OF THIS COMMITTEE IS TO REVIEW
15	FINANCIAL RECORDS IN AN OPEN AND PUBLIC FORUM. IF WE
16	REQUIRE TRANSPARENCY FROM OTHER VISIONS, WE CERTAINLY
17	CANNOT MAINTAIN A DOUBLE STANDARD FOR OURSELVES. BECAUSE
18	WE ARE CHARGED WITH OVERSEEING HOW THE INSTITUTE IS
19	SPENDING MORE THAN \$3 BILLION IN PUBLIC FUNDS TO FURTHER
20	THIS PROMISING RESEARCH, WE MUST ENSURE THAT WE ON THE
21	BOARD ARE ABOVE REPROACH, AND I BELIEVE WE ARE, AND THAT
22	THE CITIZENS OF CALIFORNIA HAVE THE UTMOST CONFIDENCE IN
23	OUR ABILITY TO PROTECT THEIR EXTREMELY GENEROUS
24	INVESTMENT AND TO ALWAYS ACT IN THE PUBLIC'S BEST
25	INTEREST.

1	LAST YEAR THIS COMMITTEE VOTED TO HOLD ITS
2	MEMBERS ACCOUNTABLE TO THE PUBLIC BY ABIDING BY ITS
3	ECONOMIC DISCLOSURE LAWS. IT WAS THE RIGHT ACTION THEN,
4	AND I BELIEVE IT WOULD BE THE RIGHT ACTION TODAY.
5	I BELIEVE WE HAVE TED PRIMM, I DON'T BELIEVE, I
6	SEE WE HAVE TED PRIMM WITH US HERE TODAY FROM THE
7	ATTORNEY GENERAL'S OFFICE. MR. PRIMM, THANK YOU FOR
8	BEING HERE. WOULD YOU PLEASE TELL US ABOUT THESE
9	CONFLICT OF INTEREST DISCLOSURES AND WHAT RELEVANCE AND
10	PURPOSE THEY SERVE ON COMMITTEES SUCH AS THIS ONE?
11	MR. PRIMM: WELL, THE PURPOSE OF THE CONFLICT
12	OF INTEREST CODE IS TO MAKE SURE THAT THE PRIVATE
13	FINANCIAL INTERESTS OF THE MEMBERS OF A BODY ARE
14	DISCLOSED TO THE PUBLIC FOR TWO REASONS. I GUESS, ONE TO
15	LET THE PUBLIC KNOW WHAT FINANCIAL INTERESTS ARE INVOLVED
16	IN CASE THEY WANT TO MONITOR ANY POTENTIAL CONFLICTS AND
17	ALSO AS A WAY OF REMINDING THE INDIVIDUALS WHO ARE ON THE
18	BOARD OF WHAT THEIR FINANCIAL INTERESTS ARE SO THAT
19	THEY'RE AWARE OF THOSE AND DON'T COMMIT ANY CONFLICTS
20	ALONG THE WAY.
21	NOW, ONCE YOU ADOPT A CONFLICT OF INTEREST
22	CODE, THEN YOUR DISCLOSURE IS GOVERNED BY WHAT'S IN THE
23	CONFLICT OF INTEREST CODE. PRIOR TO THAT TIME, AS A NEW
24	AGENCY, THERE'S A PROVISION IN THE POLITICAL REFORM ACT
25	THAT REQUIRES YOU TO DISCLOSE TO PROVIDE FULL CATEGORY

1	1 DISCLOSURE OF YOUR INTERESTS UP UNTIL THE TIME THAT YOU
2	ACTUALLY ADOPT THE CODE. SO THAT'S THE PROVISION YOU'RE
3	UNDER AT THE CURRENT TIME.
4	CHAIRMAN CHIANG: COULD YOU FURTHER ELABORATE
5	ABOUT SPECIFICALLY WHAT IS REQUIRED UNDER THAT CATEGORY?
6	MR. PRIMM: UNDER THE INTERIM SITUATION THAT
7	WE'RE IN RIGHT NOW?
8	CHAIRMAN CHIANG: THAT'S CORRECT.
9	MR. PRIMM: OKAY. GOVERNMENT CODE SECTION
10	87302.6 REQUIRES THAT NEW AGENCIES FILE IN THE SAME WAY
11	THAT THE GOVERNOR AND THE LEGISLATURE DO PENDING THE
12	ADOPTION OF A CODE. NOW, THE CODE COULD CONCEIVABLY HAVE
13	A NARROWER SET OF DISCLOSURES. IN YOUR PARTICULAR CASE
14	AND WHAT YOU'RE RECOMMENDING, YOU WOULD HAVE THE SAME
15	LEVEL OF DISCLOSURE AFTER THE ADOPTION OF THE CODE AS YOU
16	HAVE UNDER THIS PROVISION. AND THAT MEANS THAT YOU
17	DISCLOSE ON YOUR ANNUAL STATEMENTS OF ECONOMIC INTEREST
18	ALL SOURCES OF INCOME, ALL INTEREST IN REAL PROPERTY, AND
19	ALL INVESTMENTS.
20	CHAIRMAN CHIANG: THANK YOU VERY KINDLY. ARE
21	THERE ANY QUESTIONS FOR MR. PRIMM? ARE THERE ANY
22	COMMENTS? IS THERE A MOTION?
23	MR. LOTT: SO MOVED.
24	CHAIRMAN CHIANG: WE HAVE A MOTION TO NOTICE TO
25	THE OAL THAT WE'RE GOING TO SUBJECT OURSELVES TO THE FPPC
	^

1	CONFLICTS REGULATIONS. IS THERE A SECOND?
2	MS. POTTER: SECOND.
3	MR. SIMPSON: IS THERE PUBLIC COMMENT?
4	CHAIRMAN CHIANG: I'M SORRY. THERE'S A SECOND.
5	WE HAVE A SECOND. WE WILL TAKE PUBLIC COMMENT.
6	MR. SIMPSON: LAST YEAR'S ACTION, I THINK,
7	ESSENTIALLY WAS A DEFAULT ACTION. THIS APPEARS TO BE AN
8	AFFIRMATIVE ONE, WHICH IS A GOOD STEP FORWARD. JOHN
9	SIMPSON FOR THE FOUNDATION FOR TAXPAYER AND CONSUMER
10	RIGHTS. MY ONLY QUESTION WOULD BE WHETHER YOU WOULD
11	NARROW THE REQUIREMENTS SO THAT THEY WOULD BE DIFFERENT
12	THAN THOSE, FOR INSTANCE, OF THE ICOC BOARD? AND I WOULD
13	ADVOCATE THAT YOU SHOULD END UP WITH ESSENTIALLY THE SAME
14	CONFLICT OF INTEREST AND DISCLOSURE REQUIREMENTS AS THE
15	ICOC HAS.
16	AS I UNDERSTAND IT NOW, THIS WILL SAY THAT YOU
17	WILL HAVE TO BE DRAFTING SOME SPECIFIC DISCLOSURE
18	REQUIREMENTS; IS THAT CORRECT, MR. ATTORNEY GENERAL?
19	MR. PRIMM: WELL, THE PROVISIONS THAT ARE IN
20	THIS CODE ARE THE SAME AS THE PROVISIONS FOR THE MEMBERS
21	OF THE ICOC.
22	MR. SIMPSON: THANK YOU.
23	CHAIRMAN CHIANG: THANK YOU. WE HAVE A MOTION
24	AND A SECOND. IS THERE ANY OBJECTION? WITHOUT
25	OBJECTION, THE MOTION PASSES. THANK, EVERYBODY.

1	NEXT ITEM IS THE STATUS UPDATE OF THE
2	CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE'S FINANCIAL
3	STATEMENTS, GRANT AWARDS PROCESS, BEST PRACTICE
4	CONSIDERATIONS, AND CIRM'S INTELLECTUAL PROPERTY
5	REGULATIONS.
6	WHO WILL BE SPEAKING ON BEHALF OF CIRM? THANK
7	YOU FOR BEING HERE, BOB, AND PLEASE INTRODUCE YOURSELF.
8	MR. KLEIN: GOOD MORNING. IT'S A PRIVILEGE TO
9	ADDRESS THIS OVERSIGHT BODY. IN THE HISTORY OF STATE
10	GOVERNMENT, IT'S UNIQUE TO HAVE AN OVERSIGHT BODY FOR A
11	SPECIFIC AGENCY. AND CERTAINLY IT EMPHASIZES OUR
12	TRANSPARENCY AND WILLINGNESS TO PROVIDE AS MUCH
13	INFORMATION AS WE CAN DEEM POSSIBLE TO THE STATE AND AS
14	MUCH INFORMATION AS THIS AUGUST BODY WOULD DEEM THAT WE
15	SHOULD BE PROVIDING TO THE STATE. SO IT'S A DOUBLE-CHECK
16	IN MAKING SURE THAT ON FINANCIAL MATTERS THE STATE'S
17	INFORMED.
18	SO IT'S A PRIVILEGE TO BE HERE THIS MORNING,
19	PARTICULARLY IN SAN FRANCISCO. AND SINCE LAST YEAR,
20	CALIFORNIA HAS BECOME THE LEADING FUNDER OF EMBRYONIC
21	STEM CELL STEM RESEARCH IN THE WORLD, WHICH IS A GREAT
22	ACCOMPLISHMENT FOR A STATE. CALIFORNIA HAS 50 PERCENT OF
23	ALL THE BIOTECH RESEARCH CAPACITY IN THE NATION, AND AS A
24	NATION HAS MORE CAPACITY THAN ANY OTHER NATION IN THE
25	WORLD. SO IT IS OUR PRIVILEGE THIS NEXT FEBRUARY TO HOST
	11

1	21 NATIONS AND CALIFORNIA IN A CONFERENCE IN SAN
2	FRANCISCO ON THE GLOBAL STRATEGY FOR STEM CELL RESEARCH
3	TO ADVANCE MEDICINE ACROSS A BROAD ARRAY OF CHRONIC
4	ILLNESS AND INJURY.
5	IN THOSE 21 NATIONS, THERE'S CHINA AND FRANCE,
6	WHICH WERE ADMITTED TO THIS CONCURRENTLY WITH THE STATE
7	OF CALIFORNIA, SO CALIFORNIA IS DOING VERY WELL ON A
8	GLOBAL BASIS IN TERMS OF RESPECT FOR THE INSTITUTION THAT
9	THE VOTERS OF THE STATE HAD THE VISION TO APPROVE.
10	THIS MORNING I'D LIKE TO FOCUS FIRST UNDER ITEM
11	7 ON OUR FINANCIAL STATEMENTS AND FINANCIAL MANAGEMENT
12	REPORTS FROM OUR AUDITORS, WHICH IS, OF COURSE, THE CORE
13	MISSION OF THIS OVERSIGHT ENTITY. THESE ARE FOR THE
14	2005-2006 FINANCIAL AUDIT. I WOULD LIKE TO EMPHASIZE
15	THAT WE HAVE JUST GONE THROUGH AN RFP PROCESS. AND FOR
16	THIS COMING YEAR, WE WILL HAVE A SYSTEM WHEREBY WITHIN 60
17	DAYS AFTER THE CONTROLLER CLOSES THE BOOKS FOR THIS
18	AGENCY, BECAUSE THE CONTROLLER KEEPS THE BOOKS, ISSUES
19	ALL THE CHECKS FOR OUR AGENCY, THAT WE WILL HAVE OUR
20	OUTSIDE AUDITOR IN PLACE DOING SOME WORK PERHAPS IN
21	PREPARATION BEFORE THE BOOKS ARE CLOSED, BUT WE SHOULD
22	HAVE, BEFORE WE MEET NEXT YEAR, THAT YEAR'S AUDIT
23	COMPLETED. BUT THE FISCAL YEAR '06-'07 AUDIT IS NOW JUST
24	IN PROGRESS. THEY'RE JUST AT THE TRIAL BALANCE STAGE,
25	AND WE'RE VERY PLEASED THAT WE WILL BE ABLE TO HAVE THAT

1	DONE RIGHT AFTER THE FIRST OF THE YEAR.
2	SO IN OUR INTRODUCTIONS THIS MORNING, WE HAVE
3	TWO MEMBERS OF THEIR TEAM PRESENT, AND BETWEEN THEM
4	THEY'LL DIVIDE THEIR RESPONSIBILITIES. AND WITH THE
5	PERMISSION OF THE CHAIR, WHERE IT SAYS FINANCIAL
6	STATEMENTS, HOPEFULLY THEY CAN PRESENT BOTH THE FINANCIAL
7	STATEMENTS AND THE ITEMS APPEARING UNDER ITEM NO. 8 SO
8	THEY CAN MAKE THEIR WHOLE PRESENTATION AT ONCE. IS THAT
9	ACCEPTABLE, MR. CHAIR?
10	CHAIRMAN CHIANG: I BELIEVE THAT'S POSSIBLE. I
11	WANTED TO MAKE SURE THAT DEPUTY AG, MR. PRIMM, IF THEY
12	WANTED TO ENGAGE IN DISCUSSION, BOB, IF YOU WOULD
13	ARTICULATE SPECIFICALLY, FINANCIAL STATEMENTS AND
14	MR. KLEIN: COULD WE HAVE THE AUDITORS PRESENT
15	THEIR PORTION OF ITEM 7 AND ITEM 8 AT THE SAME TIME?
16	MR. PRIMM: I DON'T SEE ANY REASON WHY NOT.
17	THEY'RE BOTH ON THE AGENDA, RIGHT?
18	MR. KLEIN: THAT'S CORRECT.
19	MR. PRIMM: YOU CAN MOVE YOUR AGENDA AROUND
20	HOWEVER YOU WANT UNLESS YOU'VE SAID SOMETHING ON YOUR
21	AGENDA THAT PREVENTS YOU FROM DOING SO.
22	CHAIRMAN CHIANG: OKAY. WE HAVE NOT.
23	MR. KLEIN: THANK YOU, MR. CHAIRMAN. THANK
24	YOU, MR. PRIMM.
25	WITH THAT, I'D LIKE TO INTRODUCE OUR AUDITORS.
	13

1	WE HAVE BOTH THE DIRECTOR AND MANAGER HERE. HEATHER
2	JONES IS DIRECTOR OF OUR AUDITING FIRM, AND SHELLY
3	WALKER-DAVEY IS THE MANAGER.
4	MS. JONES: GOOD MORNING. HEATHER JONES WITH
5	MACIAS, GINI & O'CONNELL. I'M HERE WITH SHELLY DAVEY,
6	WHO IS THE AUDIT MANAGER WITH MACIAS, GINI & O'CONNELL.
7	OUR FIRM IS A STATEWIDE CPA FIRM HEADQUARTERED IN
8	SACRAMENTO. WE ALSO HAVE OFFICES IN SAN DIEGO, LOS
9	ANGELES, SAN FRANCISCO BAY AREA. OUR CURRENT CLIENTS
10	INCLUDE THE CITIES AND COUNTIES OF SAN FRANCISCO, SAN
11	DIEGO, SACRAMENTO, THE CITY OF OAKLAND. WE'RE ALSO
12	CURRENTLY ENGAGED TO PERFORM THE FINANCIAL AUDIT FOR THE
13	TWO LARGEST RETIREMENT SYSTEMS IN THE NATION, BOTH
14	CALPERS AND THE STATE TEACHERS RETIREMENT SYSTEM.
15	AS YOU KNOW, WE WERE ENGAGED TO PERFORM THE
16	AUDIT OF THE JUNE 30, '06, FINANCIAL STATEMENTS. AS PART
17	OF THAT AUDIT, WE'RE ISSUING THREE SEPARATE PRODUCTS.
18	THE FIRST IS OUR OPINION ON THE FINANCIAL STATEMENTS.
19	THE SECOND IS A REPORT ON INTERNAL CONTROLS AND
20	COMPLIANCE. AND THE THIRD PRODUCT IS A REPORT TO
21	MANAGEMENT WHICH INCLUDES COMMUNICATIONS THAT WE'RE
22	REQUIRED TO MAKE TO THIS COMMITTEE ALONG WITH OUR CURRENT
23	YEAR OBSERVATIONS AND RECOMMENDATIONS.
24	I'D LIKE TO START OFF BY IDENTIFYING

MANAGEMENT'S VERSUS THE AUDITOR'S RESPONSIBILITY.

25

ARE RESPONSIBLE FOR PREPARING THE FINANCIAL STATEMENTS,  THEY'RE RESPONSIBLE FOR ADOPTING ACCOUNTING POLICIES, FOR  DEVELOPING SIGNIFICANT ESTIMATES, FOR ESTABLISHING  INTERNAL CONTROLS, AND FOR FOLLOWING UP AND MONITORING  KNOWN FINDINGS AND WEAKNESSES BROUGHT TO THEIR ATTENTION.  AS THE AUDITORS PERFORMING AN AUDIT UNDER  GOVERNMENT AUDITING STANDARDS, WE'RE REQUIRED TO CONDUCT  OUR AUDIT IN ORDER TO PROVIDE YOU WITH REASONABLE  ASSURANCE THAT YOUR FINANCIAL STATEMENTS ARE FREE OF  MATERIAL MISSTATEMENT. ALSO, AS A PART OF GOVERNMENT  AUDITING STANDARDS, WE'RE REQUIRED TO CONSIDER, ALTHOUGH  WE DO NOT OPINE ON, YOUR INTERNAL CONTROLS AND COMPLIANCE  WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE  EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR  FINANCIAL STATEMENTS.  WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE  ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,  FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF  THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN  THE FINANCIAL REPORTING PROCESS AND IN THE DEBT	1	MANAGEMENT, BOTH CIRM AND THE STATE CONTROLLER'S OFFICE,
DEVELOPING SIGNIFICANT ESTIMATES, FOR ESTABLISHING  INTERNAL CONTROLS, AND FOR FOLLOWING UP AND MONITORING  KNOWN FINDINGS AND WEAKNESSES BROUGHT TO THEIR ATTENTION.  AS THE AUDITORS PERFORMING AN AUDIT UNDER  GOVERNMENT AUDITING STANDARDS, WE'RE REQUIRED TO CONDUCT  OUR AUDIT IN ORDER TO PROVIDE YOU WITH REASONABLE  ASSURANCE THAT YOUR FINANCIAL STATEMENTS ARE FREE OF  MATERIAL MISSTATEMENT. ALSO, AS A PART OF GOVERNMENT  AUDITING STANDARDS, WE'RE REQUIRED TO CONSIDER, ALTHOUGH  WE DO NOT OPINE ON, YOUR INTERNAL CONTROLS AND COMPLIANCE  WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE  EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR  FINANCIAL STATEMENTS.  WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE  ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,  FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF  THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	2	ARE RESPONSIBLE FOR PREPARING THE FINANCIAL STATEMENTS,
INTERNAL CONTROLS, AND FOR FOLLOWING UP AND MONITORING KNOWN FINDINGS AND WEAKNESSES BROUGHT TO THEIR ATTENTION.  AS THE AUDITORS PERFORMING AN AUDIT UNDER  GOVERNMENT AUDITING STANDARDS, WE'RE REQUIRED TO CONDUCT  OUR AUDIT IN ORDER TO PROVIDE YOU WITH REASONABLE  ASSURANCE THAT YOUR FINANCIAL STATEMENTS ARE FREE OF  MATERIAL MISSTATEMENT. ALSO, AS A PART OF GOVERNMENT  AUDITING STANDARDS, WE'RE REQUIRED TO CONSIDER, ALTHOUGH  WE DO NOT OPINE ON, YOUR INTERNAL CONTROLS AND COMPLIANCE  WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE  EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR  FINANCIAL STATEMENTS.  WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE  ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,  FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF  THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	3	THEY'RE RESPONSIBLE FOR ADOPTING ACCOUNTING POLICIES, FOR
6 KNOWN FINDINGS AND WEAKNESSES BROUGHT TO THEIR ATTENTION. 7 AS THE AUDITORS PERFORMING AN AUDIT UNDER 8 GOVERNMENT AUDITING STANDARDS, WE'RE REQUIRED TO CONDUCT 9 OUR AUDIT IN ORDER TO PROVIDE YOU WITH REASONABLE 10 ASSURANCE THAT YOUR FINANCIAL STATEMENTS ARE FREE OF 11 MATERIAL MISSTATEMENT. ALSO, AS A PART OF GOVERNMENT 12 AUDITING STANDARDS, WE'RE REQUIRED TO CONSIDER, ALTHOUGH 13 WE DO NOT OPINE ON, YOUR INTERNAL CONTROLS AND COMPLIANCE 14 WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE 15 EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR 16 FINANCIAL STATEMENTS. 17 WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE 18 ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06, 19 FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION. 20 WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL 21 WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF 22 THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE 23 THOSE TO YOU IN WRITING. 24 WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	4	DEVELOPING SIGNIFICANT ESTIMATES, FOR ESTABLISHING
AS THE AUDITORS PERFORMING AN AUDIT UNDER  GOVERNMENT AUDITING STANDARDS, WE'RE REQUIRED TO CONDUCT  OUR AUDIT IN ORDER TO PROVIDE YOU WITH REASONABLE  ASSURANCE THAT YOUR FINANCIAL STATEMENTS ARE FREE OF  MATERIAL MISSTATEMENT. ALSO, AS A PART OF GOVERNMENT  AUDITING STANDARDS, WE'RE REQUIRED TO CONSIDER, ALTHOUGH  WE DO NOT OPINE ON, YOUR INTERNAL CONTROLS AND COMPLIANCE  WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE  EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR  FINANCIAL STATEMENTS.  WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE  ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,  FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF  THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	5	INTERNAL CONTROLS, AND FOR FOLLOWING UP AND MONITORING
GOVERNMENT AUDITING STANDARDS, WE'RE REQUIRED TO CONDUCT  OUR AUDIT IN ORDER TO PROVIDE YOU WITH REASONABLE  ASSURANCE THAT YOUR FINANCIAL STATEMENTS ARE FREE OF  MATERIAL MISSTATEMENT. ALSO, AS A PART OF GOVERNMENT  AUDITING STANDARDS, WE'RE REQUIRED TO CONSIDER, ALTHOUGH  WE DO NOT OPINE ON, YOUR INTERNAL CONTROLS AND COMPLIANCE  WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE  EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR  FINANCIAL STATEMENTS.  WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE  ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,  FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF  THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  THOSE TO YOU IN WRITING.	6	KNOWN FINDINGS AND WEAKNESSES BROUGHT TO THEIR ATTENTION.
OUR AUDIT IN ORDER TO PROVIDE YOU WITH REASONABLE  ASSURANCE THAT YOUR FINANCIAL STATEMENTS ARE FREE OF  MATERIAL MISSTATEMENT. ALSO, AS A PART OF GOVERNMENT  AUDITING STANDARDS, WE'RE REQUIRED TO CONSIDER, ALTHOUGH  WE DO NOT OPINE ON, YOUR INTERNAL CONTROLS AND COMPLIANCE  WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE  EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR  FINANCIAL STATEMENTS.  WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE  ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,  FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF  THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  THOSE TO YOU IN WRITING.	7	AS THE AUDITORS PERFORMING AN AUDIT UNDER
ASSURANCE THAT YOUR FINANCIAL STATEMENTS ARE FREE OF  MATERIAL MISSTATEMENT. ALSO, AS A PART OF GOVERNMENT  AUDITING STANDARDS, WE'RE REQUIRED TO CONSIDER, ALTHOUGH  WE DO NOT OPINE ON, YOUR INTERNAL CONTROLS AND COMPLIANCE  WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE  EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR  FINANCIAL STATEMENTS.  WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE  ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,  FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF  THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	8	GOVERNMENT AUDITING STANDARDS, WE'RE REQUIRED TO CONDUCT
MATERIAL MISSTATEMENT. ALSO, AS A PART OF GOVERNMENT  AUDITING STANDARDS, WE'RE REQUIRED TO CONSIDER, ALTHOUGH  WE DO NOT OPINE ON, YOUR INTERNAL CONTROLS AND COMPLIANCE  WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE  EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR  FINANCIAL STATEMENTS.  WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE  ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,  FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF  THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	9	OUR AUDIT IN ORDER TO PROVIDE YOU WITH REASONABLE
AUDITING STANDARDS, WE'RE REQUIRED TO CONSIDER, ALTHOUGH WE DO NOT OPINE ON, YOUR INTERNAL CONTROLS AND COMPLIANCE WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR FINANCIAL STATEMENTS.  WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06, FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION. WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	10	ASSURANCE THAT YOUR FINANCIAL STATEMENTS ARE FREE OF
WE DO NOT OPINE ON, YOUR INTERNAL CONTROLS AND COMPLIANCE WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR  FINANCIAL STATEMENTS.  WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06, FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION. WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	11	MATERIAL MISSTATEMENT. ALSO, AS A PART OF GOVERNMENT
WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR  FINANCIAL STATEMENTS.  WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,  FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	12	AUDITING STANDARDS, WE'RE REQUIRED TO CONSIDER, ALTHOUGH
EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR  FINANCIAL STATEMENTS.  WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE  ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,  FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF  THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	13	WE DO NOT OPINE ON, YOUR INTERNAL CONTROLS AND COMPLIANCE
16 FINANCIAL STATEMENTS.  17 WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE  18 ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,  19 FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  20 WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  21 WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF  22 THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  23 THOSE TO YOU IN WRITING.  24 WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	14	WITH LAWS, REGULATIONS, CONTRACTS, AND GRANTS TO THE
WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,  FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF  THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	15	EXTENT THAT THEY MAY HAVE A MATERIAL IMPACT ON YOUR
18 ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06, 19 FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION. 20 WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL 21 WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF 22 THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE 23 THOSE TO YOU IN WRITING. 24 WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	16	FINANCIAL STATEMENTS.
FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.  WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL  WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF  THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	17	WITH THAT SAID, I'M PLEASED TO SAY THAT WE HAVE
WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	18	ISSUED AN UNQUALIFIED OPINION FOR THE JUNE 30, '06,
WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	19	FINANCIAL STATEMENTS, OTHERWISE KNOWN AS A CLEAN OPINION.
THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE  THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	20	WE NOTED NO SIGNIFICANT DEFICIENCIES OR MATERIAL
THOSE TO YOU IN WRITING.  WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	21	WEAKNESSES IN INTERNAL CONTROL. HAD WE NOTED ANY OF
WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN	22	THOSE ITEMS, WE WOULD HAVE BEEN REQUIRED TO COMMUNICATE
The same of the sa	23	THOSE TO YOU IN WRITING.
THE FINANCIAL REPORTING PROCESS AND IN THE DEBT	24	WE HAVE, HOWEVER, OBSERVED A COUPLE OF AREAS IN
	25	THE FINANCIAL REPORTING PROCESS AND IN THE DEBT

,	
1	COMPLIANCE AND GRANT COMPLIANCE AREAS WHERE WE FEEL THAT
2	INTERNAL CONTROLS COULD BE IMPROVED OR EFFICIENCIES COULD
3	BE GAINED. AGAIN, I WANT TO EMPHASIZE THAT THOSE DO NOT
4	RISE TO THE LEVEL OF SIGNIFICANT, AT LEAST NOT IN THE
5	FINANCIAL STATEMENT ARENA.
6	ALSO WANT TO CONFIRM WITH YOU THAT THERE WERE
7	NO SIGNIFICANT AUDIT ADJUSTMENTS, NOTHING THAT WE
8	CONSIDERED TO BE MAJOR TO THE FINANCIAL REPORTING
9	PROCESS. WE HAD NO DISAGREEMENTS WITH MANAGEMENT AND NO
10	DIFFICULTIES IN PERFORMING OUR AUDIT.
11	IT REQUIRES A GREAT AMOUNT OF COORDINATION
12	BETWEEN THE INSTITUTE'S MANAGEMENT, THE STATE
13	CONTROLLER'S OFFICE, AND THE AUDIT FIRM TO MAKE AN AUDIT
14	HAPPEN, TO GET THROUGH AN AUDIT PROCESS. AND WE REALLY
15	APPRECIATE THE COOPERATION THAT WAS EXTENDED TO US.
16	WITH THAT, I'D BE HAPPY TO ANSWER ANY QUESTIONS
17	YOU MAY HAVE ABOUT THE '06 AUDIT.
18	CHAIRMAN CHIANG: JUST A QUICK STATEMENT. I'M
19	ALWAYS EXCITED TO HEAR THAT THE REPORT IS UNQUALIFIED.
20	MS. JONES: SOUNDS BAD, BUT IT'S GOOD.
21	CHAIRMAN CHIANG: IT'S VERY TROUBLING ON THE
22	OTHER HAND WHEN YOU HEAR OTHERWISE. VERY GOOD. ARE
23	THERE ANY QUESTIONS FROM MY COLLEAGUES? VERY GOOD.

16

WOULD CIRM LIKE TO PROVIDE A RESPONSE TO YOUR

24

25

AUDITOR'S REPORT?

1	MS. JONES: THANK YOU.
2	CHAIRMAN CHIANG: THANK YOU VERY KINDLY.
3	MR. KLEIN: I THINK THAT THE KEY ITEM IS THAT
4	WE HAVE TAKEN PROACTIVE MEASURES, AS I INDICATED IN THE
5	OPENING, TO MAKE CERTAIN THAT WE GET THESE REVIEWS DONE
6	MORE EXPEDITIOUSLY. SO WE HAVE ACTUALLY RECEIVED THE
7	RESPONSE TO A REQUEST FOR PROPOSAL THAT WILL ALLOW US TO
8	GET OUR AUDIT FOR THIS '07-'08 YEAR DONE WITHIN 60 DAYS,
9	AT LEAST SUBMITTED TO THE CONTROLLER'S OFFICE, WHICH THEN
10	REVIEWS IT AND GIVES US COMMENTS, WITHIN 60 DAYS AFTER
11	THE STATE CONTROLLER CLOSES THEIR BOOKS. THIS YEAR THE
12	STATE CONTROLLER CLOSED THE BOOKS ON AUGUST 23D SO THAT
13	WOULD ESSENTIALLY HAVE PUT IT LATE IN OCTOBER. OUR GOAL
14	IS TO MAKE SURE, NOW THAT WE HAVE GONE THROUGH THE STATE
15	SUPREME COURT AND GOTTEN ALL OF OUR COURT CLEARANCES
16	BEHIND US, THAT WE CAN STAFF UP TO A LEVEL THAT WE CAN
17	MAKE SURE ADMINISTRATIVELY WE'RE WORKING ON AS MUCH A
18	CURRENT TIME BASIS AS POSSIBLE.
19	IT WOULD BE IT'S A GREAT IMPROVEMENT TO HAVE
20	THE STATE SUPREME COURT TELL US THAT WE HAVE AN
21	UNQUALIFIED OPINION, THAT WE'RE CONSTITUTIONAL, AND WE'RE
22	DOING EVERYTHING CORRECTLY, PARTICULARLY WHEN THE
23	OPPOSITION HAS ALLEGED THAT THERE'S 45 OR 55 INADEQUACIES
24	THAT THE COURT SAID WE WERE ABSOLUTELY PERFORMING
25	CORRECTLY AND ABSOLUTELY PERFORMING CONSTITUTIONALLY.

	BARRISTERS REPORTING SERVICE
1	WITH THAT BEHIND US, WITH OUR FIRST \$250 MILLION IN BONDS
2	BEING ISSUED AS A FIRST FOR THE NATION, WE'RE IN A
3	POSITION NOW TO STAFF UP AND GET TO A LEVEL
4	ADMINISTRATIVELY THAT WE CAN BE CURRENT WITH THE BEST
5	SCIENCE IN THE COUNTRY.
6	SO IT'S A PLEASURE AND WE ARE HOPEFUL THAT
7	WE'RE WORKING WITH THE SAME AUDITING FIRM NEXT YEAR. WE
8	CONTINUE TO LEARN. WE'RE A YOUNG AGENCY, BUT WE CONTINUE
9	TO TRY AND IMPROVE, AND IT'S A GREAT PRIVILEGE TO HAVE
10	THE BENEFIT OF THE CONTROLLER'S OFFICE DOING OUR CHECKS
11	AND OUR BOOKS FOR US AS WE GO.
12	I'D LIKE TO, IF I CAN, MR. CHAIRMAN, GO ON TO
13	THE BALANCE OF ITEM 7 AT THIS TIME IF THAT'S ACCEPTABLE.
14	CHAIRMAN CHIANG: BOB, LET'S HAVE THE
15	CONTROLLER'S OFFICE SPEAK ALSO TO THE AUDIT.
16	MS. MOORE-HUDNAL: GOOD MORNING, CONTROLLER
17	CHIANG AND COMMITTEE MEMBERS. I'M CASSANDRA
18	MOORE-HUDNAL. I'M THE CHIEF OF FINANCIAL AUDITS.
19	AS YOU KNOW, THE CONTROLLER IS REQUIRED TO
20	REVIEW THE ANNUAL AUDIT AND PUBLISH REPORTS OF RESULTS OF
21	OUR REVIEW. THIS IS REQUIRED PURSUANT TO HEALTH AND
22	SAFETY CODE SECTION 125529.30. WE PUBLISHED OUR RESULTS
23	IN APRIL OF 2007.

18

WHETHER THE AUDIT WAS PERFORMED IN ACCORDANCE WITH

THE OBJECTIVE OF OUR REVIEW WAS TO DETERMINE

24

25

1	GENERALLY ACCEPTED AUDITING STANDARDS PUBLISHED BY THE
2	AMERICAN INSTITUTE OF CERTIFIED PUBLIC ACCOUNTANTS,
3	GOVERNMENT AUDITING STANDARDS PUBLISHED BY THE CONTROLLER
4	GENERAL OF THE UNITED STATES, AND THE CALIFORNIA BUSINESS
5	AND PROFESSIONS CODE.
6	OUR METHODOLOGY WAS TO COMPARE THE FIRM'S AUDIT
7	WORK AS DOCUMENTED IN THEIR WORKING PAPERS TO THE AUDIT
8	STANDARDS AND STATE LAW TO ENSURE THAT THE FIRM'S
9	CONCLUSIONS AND OPINION THAT THE FINANCIAL STATEMENTS OF
10	CIRM'S FINANCIAL POSITION WERE FAIRLY STATED AND
11	SUPPORTED AND CORRECT.
12	CHAIRMAN CHIANG: LOVE TO HEAR YOU SPEAK
13	FINANCIAL.
14	MS. MOORE-HUDNAL: WE FOUND THAT MACIAS, GINI &
15	O'CONNEL'S AUDIT WAS PERFORMED IN ACCORDANCE WITH THE
16	MAJORITY OF AUDITING STANDARDS AND REQUIREMENTS. WE
17	NOTED ONE EXCEPTION. THAT WAS A TECHNICAL ISSUE.
18	CHAIRMAN CHIANG: ACTUALLY IF YOU COULD ELEVATE
19	A LITTLE BIT MORE.
20	MS. MOORE-HUDNAL: WE NOTED ONE EXCEPTION THAT
21	WAS A TECHNICAL ISSUE THAT DID NOT IMPACT THE QUALITY OF
22	THE AUDIT OR THE INDEPENDENT AUDITOR'S CONCLUSION. AND
23	THE FIRM AGREED WITH OUR CONCLUSION, AND IT WAS SIMPLY A
24	MATTER OF NOT REFERRING TO THE MANAGEMENT LETTER IN THE
25	REPORT ON INTERNAL CONTROL. DO YOU HAVE ANY QUESTIONS?
	19

1	CHAIRMAN CHIANG: ANY QUESTIONS FROM THE
2	MEMBERS? THANK YOU VERY KINDLY.
3	MS. MOORE-HUDNAL: THANK YOU.
4	CHAIRMAN CHIANG: BEFORE WE PROCEED BACK TO
5	ITEM 7, AS BOB REQUESTED, I'M GOING TO MAKE A COMMENT. I
6	THINK THIS IS A VERY GOOD TIME TO DISCUSS OUR FINANCIAL
7	REVIEWS, MORE SPECIFICALLY, IN LIGHT OF THE UNQUALIFIED
8	OPINION, THE TIMING OF THESE REVIEWS. I THINK IN LIGHT
9	OF THAT, IT WOULD BE GREAT FOR US TO CATCH UP. I
10	UNDERSTAND THAT IN THE PAST THERE WERE SOME DELAYS THAT
11	OCCURRED BECAUSE OF THE NEED TO HIRE AN INDEPENDENT
12	FINANCIAL AUDITOR. I WANT TO THANK CIRM FOR MOVING THAT
13	PROCESS FORWARD. I THINK, HOWEVER, THERE MAY BE
14	QUESTIONS WHY THAT IN NOVEMBER OF 2007 THAT WE ARE
15	REVIEWING AN AUDIT OF CIRM FOR THE 2005-2006 FISCAL YEAR.
16	I BELIEVE THAT IN ORDER TO HAVE TRUE
17	TRANSPARENCY AND ACCOUNTABILITY, THE CFAOC MUST HAVE THE
18	ABILITY TO PROVIDE A TIMELY AUDIT AND REVIEW OF CIRM'S
19	FINANCIAL ACTIVITIES AND AUDITS. THEREFORE, I THINK
20	WE'RE ALL ON THE SAME PAGE. I WANT TO ASK THE CFAOC AND
21	CIRM STAFF TO WORK VERY CLOSELY TOGETHER AND COME UP WITH
22	A SCHEDULE THAT WILL ENSURE THAT WE HAVE TIMELY FINANCIAL
23	REVIEWS. I THINK IT WOULD BE PRUDENT TO HAVE ANOTHER
24	CFAOC MEETING THIS SPRING TO REVIEW THE 2006 AND 7
25	FINANCIAL AUDIT, AND THE STATE CONTROLLER'S OFFICE WILL

1	REVIEW THAT AUDIT.
2	BEST OF ALL, THEN NEXT NOVEMBER WE'LL BE ON
3	TRACK TO REVIEW THE LATEST FINANCIAL REPORT, WHICH WILL
4	BE THE 2007-2008 FISCAL YEAR. THAT WAY WE CAN CONTINUE
5	TO HOLD THE CFAOC'S ANNUAL MEETINGS EACH NOVEMBER TO
6	REVIEW THE REPORTS FROM THE FISCAL YEAR ENDING THAT PRIOR
7	JUNE 30TH.
8	BOB, YOU CAN PROCEED AND WE'LL DISCUSS THE
9	SUBSTANCE OF ITEM NO. 7.
10	MR. SIMPSON: CAN WE GIVE A COMMENT ON ITEM 8?
11	MR. KLEIN: WE HAVE TWO ITEMS.
12	CHAIRMAN CHIANG: WE MERGED THEM, JOHN.
13	MR. KLEIN: WE'RE ABOUT TO FINISH ITEM 7.
14	FIRST OF ALL, I'D LIKE TO SAY THAT IT IS GOING TO BE A
15	PRIVILEGE TO MEET THE SCHEDULE THAT THE CONTROLLER'S
16	OFFICE PUTS FORWARD. TO GO FROM A STAFF OF 25, WHICH IS
17	ONLY HALF OF OUR AUTHORIZED 50, TO INCREASE OUR STAFF TO
18	THE LEVEL THAT WE CAN PERFORM AT THE LEVEL YOU WISH US TO
19	PERFORM AND WE WISH TO PERFORM ON A TIMELY BASIS WILL BE
20	A REAL PRIVILEGE, AND WE'RE LOOKING FORWARD TO THAT AUDIT
21	OVERSIGHT REVIEW IN THE SPRING.
22	IN PROVIDING AN OVERALL CONTEXT FOR OUR
23	FINANCIAL PERFORMANCE, WE HAVE A NUMBER OF OTHER ITEMS
24	UNDER ITEM 7 ON THE AGENDA THAT I'D LIKE TO TURN TO DR.
25	RICHARD MURPHY. HE IS THE INTERIM PRESIDENT OF THE

1	CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE. HE HAS
2	HAD AN EXTRAORDINARY CAREER. MOST RECENTLY HE WAS THE
3	PRESIDENT OF THE SALK INSTITUTE LOCATED IN THE SAN DIEGO
4	REGION WHERE HE HAS SERVED WITH GREAT DISTINCTION AND
5	LEADERSHIP OF A WORLD-CLASS RESEARCH INSTITUTION. IT'S
6	ONE OF THE WORLD LEADERS IN EMBRYONIC AND ADULT STEM CELL
7	RESEARCH. BEFORE THAT HE BUILT THE MONTREAL NEUROLOGICAL
8	INSTITUTE AT MCGILL UNIVERSITY INTO A WORLD LEADER IN
9	CANADA. AND HE HAD A VERY DISTINGUISHED CAREER THAT
10	STARTED ALL THE WAY BACK AT HARVARD UNIVERSITY. BUT TO
11	READ HIS LIST OF DISTINCTIONS WOULD KEEP US HERE FOR THE
12	BALANCE OF THE HEARING, SO I'D LIKE TO TURN IT OVER TO
13	HIM AT THIS POINT TO LEAD US THROUGH THE BALANCE OF THIS
14	ITEM ON THE AGENDA. THANK YOU, DR. MURPHY.
15	DR. MURPHY: THANK YOU, CHAIRMAN KLEIN.
16	CHAIRMAN CHIANG, THANK YOU. IT HAS BEEN A PLEASURE FOR
17	ME TO BE ASSOCIATED WITH THE ICOC AND ALSO WITH CIRM. I
18	WAS A MEMBER OF THE ICOC FOR THREE YEARS BEFORE BECOMING
19	THE INTERIM PRESIDENT. AND LAST YEAR, AS I WAS A MEMBER
20	OF THE ICOC, I WROTE AN OP ED PIECE FOR THE UNION TRIBUNE
21	IN SAN DIEGO IN WHICH I DESCRIBED CIRM AS A GREAT BARGAIN
22	FOR THE PEOPLE OF CALIFORNIA BECAUSE SO MUCH WAS GETTING
23	DONE WITH SUCH A SMALL SKELETON STAFF AT THAT TIME.
24	NOW THAT I'M THE PRESIDENT OF THE INSTITUTE
25	UNTIL THE PERMANENT PRESIDENT COMES, I WOULD LIKE TO

1	REWRITE THAT ARTICLE AND TURN IT INTO A BOOK. CIRM
2	REALLY IS A GOOD NEWS STORY FOR THIS STATE. IT HAS
3	ACCOMPLISHED A TREMENDOUS AMOUNT IN SUPPORTING STEM CELL
4	RESEARCH.
5	WHAT I THOUGHT I WOULD DO IS TO VERY BRIEFLY
6	DESCRIBE FOR YOU THE MECHANISMS, AS ITEM NO. 7 SAYS, OF
7	THE GRANT AWARDS PROCESS, VERY BRIEFLY THE MECHANISMS
8	THAT WE NOW USE THAT WERE IN PLACE, PUT IN PLACE BY
9	CHAIRMAN KLEIN AND PRESIDENT ZACH HALL PRIOR TO MY
10	ARRIVING.
11	IN EVERY CASE BEFORE CIRM PUTS OUT A GRANT,
12	THERE IS A CONCEPT PAPER DONE FOR THE ICOC. WHAT THE
13	CONCEPT PAPER DOES IS BASICALLY EXPLAIN TO THE ICOC WHAT
14	IS NEEDED IN THE STEM CELL FIELD. THE ICOC IS EDUCATED
15	AND MAKES AN APPROVAL ON GOING FORWARD. WHAT THEN
16	HAPPENS IS STAFF PUTS TOGETHER A REQUEST FOR APPLICATIONS
17	IN WHICH THEY LIST FOR THE SCIENTIFIC COMMUNITY WHAT KIND
18	OF GRANTS THAT CIRM WILL BE PUTTING OUT.
19	ASSOCIATED WITH THAT REQUEST FOR APPLICATIONS
20	IS A GRANT ADMINISTRATION POLICY WHICH IS PUT IN PLACE SO
21	ALL APPLICANTS KNOW WHAT THE RULES WILL BE GOVERNING THE
22	APPLICATION THAT WILL BE SUBMITTED. THE APPLICATION IS
23	THEN PUT OUT. PEOPLE ARE INVITED TO APPLY, AND THEN THE
24	APPLICATION GOES TO THE GRANTS REVIEW GROUP, THE WORKING
25	GROUP. AND AS YOU MAY KNOW, THE WORKING GROUP IS MADE UP

1	15 DISTINGUISHED SCIENTISTS ALL FROM OUTSIDE OF
2	CALIFORNIA. THIS GROUP HAS VERY CLEARLY IDENTIFIED THEIR
3	CONFLICTS, THEY'RE LEADERS IN THE FILED, AND THEY GO
4	THROUGH THE ASSESSMENT OF THESE GRANTS IN A VERY
5	METICULOUS WAY. AND FOR EACH GRANT THERE ARE TWO OR
6	THREE INTERNAL GRANT REVIEWERS AND THERE ARE MULTIPLE
7	GRANT REVIEWERS WHO CAN ACTUALLY BE PHONED IN TO GIVE
8	THEIR REVIEWS AS WELL.
9	SO IT IS AN EXTREMELY WELL-ORGANIZED AND
10	WELL-PROTECTED MECHANISM. AND I THINK THE GRANT
11	REVIEWERS ARE VERY PLEASED WITH THE WAY THIS GOES. THEY
12	KNOW THAT THE WORK IS GOOD. THEY KNOW THAT THEY'RE DOING
13	THIS AT ARM'S LENGTH. AND AT THE ONE GRANTS REVIEW THAT
14	I ATTENDED THIS PAST NOVEMBER, I WAS EXTREMELY IMPRESSED
15	WITH THE QUALITY OF HOW IT WAS DONE, THE QUALITY OF THE
16	REVIEWS, AND THE QUALITY OF THE REVIEWERS.
17	ONCE THE RECOMMENDATIONS ARE MADE BY THE GRANTS
18	PANEL, RECOMMENDATIONS ARE THEN MADE TO THE ICOC, WHICH
19	THEN REVIEWS THE RECOMMENDATIONS AND MAKES ITS OWN
20	RECOMMENDATION FOR FUNDING CERTAINLY BASED UPON THE
21	SCIENTIFIC REVIEWS PUT FORWARD BY THE EXTERNAL PANEL, BUT
22	ALSO QUITE INDEPENDENTLY THEY WILL LOOK AT SUBTLETIES OF
23	THE SYSTEM AND MAKE RECOMMENDATIONS ACCORDING TO THAT.
24	AFTER THE GRANTS ARE AWARDED, WELL, THERE IS A
25	PROCESS WHEN THE GRANTS HAVE BEEN APPROVED AND THEN THE
	•

1	ICOC SORRY THE CIRM STAFF WILL LOOK AT THE DETAILS
2	OF THE GRANT AND LOOK TO BE SURE THAT ALL OF THE RULES
3	AND REGULATIONS OF THOSE GRANTS HAVE BEEN MAINTAINED.
4	AND ONLY WHEN WE KNOW THE RULES AND THE APPLICANTS HAVE
5	FOLLOWED ALL THE RULES, ALL OF THAT IS IN PLACE, IS THE
6	GRANT AWARDED. OUR GRANTS PEOPLE THEN ARE RESPONSIBLE
7	FOR RECEIVING PROGRESS REPORTS FROM ALL OF THE WINNERS OF
8	THE GRANTS TO BE CERTAIN THAT THE FINANCIAL SIDE OF THE
9	HOUSE IS IN ORDER AND ALSO THAT THE SCIENTIFIC SIDE OF
10	THE HOUSE IS IN ORDER AS WELL.
11	THAT PROCESS HAS WORKED EXTREMELY WELL FOR AT
12	LEAST FOUR SETS OF GRANTS: COMPREHENSIVE GRANTS, WHICH
13	WERE GRANTS ON STEM CELL RESEARCH MADE TO ESTABLISHED
14	INVESTIGATORS IN THE FIELD; SEED GRANTS, WHICH WERE MADE
15	TO INVESTIGATORS WHO WERE JUST GETTING INTO THE STEM CELL
16	FIELD AND HAD GOOD IDEAS FOR NEW DIRECTIONS IN THE FIELD;
17	FACILITIES GRANTS WERE MADE. THESE WERE MINOR SMALL
18	FACILITIES SO THAT EXISTING ORGANIZATIONS THAT DID NOT
19	HAVE FACILITIES TO DO STEM CELL RESEARCH THAT WERE
20	RESTRICTED, FRANKLY, BY FEDERAL POLICY DID GET MONIES TO
21	CARRY OUT STEM CELL RESEARCH IN SMALL AREAS. ASSOCIATED
22	WITH SOME OF THESE FACILITIES GRANTS WERE ACTUALLY
23	TRAINING GRANTS TO TRAIN PEOPLE HOW TO DO STEM CELL
24	RESEARCH, AND THESE TRAINING COURSES WOULD BE OFFERED BY
25	THE ORGANIZATIONS THAT RECEIVED FUNDING. AND ALSO

1	TRAINING GRANTS FOR NEW POST DOCS AND GRADUATE STUDENTS.
2	I THINK THIS IS ONE OF THE MOST IMPORTANT
3	THINGS THAT CIRM HAS DONE. AS YOU MAY KNOW, THE NATIONAL
4	INSTITUTE OF HEALTH HAS CUT BACK DRAMATICALLY ON THE
5	FUNDING TO YOUNG INVESTIGATORS IN THIS COUNTRY. THE
6	AVERAGE AGE OF A YOUNG INVESTIGATOR GETTING HIS OR HER
7	FIRST NIH GRANT IS 43 YEARS OLD. WHAT CIRM HAS BEEN ABLE
8	TO DO IS GIVE THESE YOUNG INVESTIGATORS AT THE AGES OF 30
9	TO 35 THEIR FIRST GRANT. AND I THINK THAT'S A MAJOR
10	ADVANTAGE OF SCIENTISTS NOW WORKING IN CALIFORNIA AS
11	OPPOSED TO THE REST OF THE COUNTRY.
12	IN DECEMBER WE WILL BE ANNOUNCING ANOTHER \$65
13	MILLION APPROXIMATELY IN GRANTS THAT WILL BE AWARDED TO
14	NEW INVESTIGATORS. THESE ARE THE YOUNG ASSISTANT
15	PROFESSOR INVESTIGATORS WHO ARE NOW GETTING INTO STEM
16	CELL RESEARCH, JUST BEGINNING THEIR ACADEMIC CAREERS.
17	AND THEN SOMETIME NEXT SPRING OR EARLY IN THE SUMMER
18	WE'LL BE ANNOUNCING ANOTHER APPROXIMATELY \$250 MILLION IN
19	GRANTS FOR MAJOR FACILITIES FOR ORGANIZATIONS AROUND THE
20	STATE.
21	IN SHORT, CIRM IS NOW GOING TO BE CLOSE TO \$500
22	MILLION IN GRANTS FUNDED BY NEXT SUMMER, WHICH IS A
23	REMARKABLE RECORD IN MY VIEW. AS CHAIRMAN KLEIN SAID,
24	CALIFORNIA HAS BECOME THE WORLD LEADER IN STEM CELL
25	RESEARCH AS A RESULT OF THIS KIND OF FUNDING. AND I CAN

T	ASSURE THAT YOU THAT THE PROCESS IS BEING DONE WELL, IT'S
2	BE DONE METICULOUSLY, AND I THINK THE HIGHEST QUALITY
3	SCIENCE IS BEING FUNDED.
4	ON ITEM 7 IS ALSO A COMMENT MADE ABOUT BEST
5	PRACTICES. ONE OF THE THINGS, OF COURSE, THAT WE ARE
6	CONCERNED ABOUT ARE THE ETHICAL ISSUES THAT SURROUND STEM
7	CELL RESEARCH. ONE OF THE MOST EXCITING THINGS ABOUT THE
8	ANNOUNCEMENT MADE LAST WEEK, THAT WE CAN NOW INDUCE STEM
9	CELLS FROM CELLS FROM YOU AND ME, SAYS THAT MANY OF THE
10	ETHICAL CONCERNS THAT WE HAVE BEEN CONCERNED ABOUT WILL
11	OVER TIME BECOME LESS IMPORTANT. BUT RIGHT NOW WHEN
12	WE'RE WORKING WITH AIDS AND WE'RE WORKING WITH PRIMARY
13	MATERIAL FROM HUMANS, THE ETHICAL CONCERNS ARE, IN FACT,
14	VERY IMPORTANT.
15	SO WE HAVE A STANDARDS WORKING GROUP, AND THAT
16	STANDARDS WORKING GROUP HAS BEEN MEETING CONSTANTLY TO
17	LOOK AT THE ETHICAL ISSUES. AND, IN FACT, IT HAS NOW
18	BECOME REALLY A WORLD STANDARD FOR THE ETHICAL POLICIES
19	THAT REGULATE STEM CELL RESEARCH. AND, IN FACT, I'M TOLD
20	THAT THE STATE OF ILLINOIS ADOPTED CALIFORNIA'S POLICIES
21	IN WHOLE CLOTH BECAUSE OF THEIR QUALITY. AND I CAN TELL
22	YOU THAT WE ARE ALWAYS TALKING WITH OTHER STATES AND
23	OTHER COUNTRIES ABOUT THE ETHICAL CONCERNS THAT WE ALL
24	HAVE SO THAT WE CAN HAVE A POLICY THAT WE'RE ALL PROUD OF
25	AND CAN LIVE WITH.

1	WE WILL ALSO BE DOING AN IMPACT STUDY THAT IS
2	ACTUALLY CURRENTLY BEING CARRIED ON YOU WILL HEAR A
3	LITTLE BIT ABOUT THAT TODAY TO LOOK AT THE ECONOMIC
4	IMPACT OF CIRM AND CIRM-FUNDED RESEARCH ON THE STATE OF
5	CALIFORNIA.
6	SO WITH THAT BRIEF OUTLINE, MR. CHAIRMAN, I'LL
7	BE HAPPY TO ANSWER ANY QUESTIONS THAT YOU HAVE ABOUT THE
8	PROCESS, BUT I CAN TELL YOU, FROM MY POSITION AS INTERIM
9	PRESIDENT OF THE INSTITUTE, I'M VERY, VERY PLEASED WITH
10	CIRM. I THINK CALIFORNIA IS BEING WELL SERVED, AND THE
11	MISSION THAT WE ALL HAVE OF USING STEM CELLS HOPEFULLY TO
12	IMPROVE THE HEALTH OF PEOPLE WITH INCURABLE DISEASES IS
13	WELL ON ITS WAY.
14	CHAIRMAN CHIANG: THANK YOU, DR. MURPHY. ALONG
<b>1</b> 5	THOSE LINES OF YOUR MOST RECENT COMMENTS, IN LIGHT OF THE
16	DEVELOPMENTS THAT TOOK PLACE IN THE LAST WEEK, WHAT
17	IMPACT DO YOU BELIEVE THIS LINE OF RESEARCH WILL HAVE ON
18	EMBRYONIC STEM CELL RESEARCH? AND HOW WILL IT IMPACT
19	CIRM'S ACTIVITIES?
20	DR. MURPHY: WELL, I THINK IN THREE WAYS. ONE,
21	THE SCIENCE IS WONDERFUL. JUST THINK OF THIS, THAT CELLS
22	IN YOU AND ME THAT ARE WORKING IN OUR SKIN RIGHT NOW OR
23	IN ANY OTHER PART OF OUR BODY HAVE THE ABILITY TO TURN
24	THE CLOCK BACK. SO WHAT THESE WORKERS DID WAS THEY TOOK
25	SKIN CELLS, THEY ADDED TO THESE AFTER GROWING THEM UP

1	IN A DISH, THEY ADDED TO THESE SKIN CELLS VIRUSES THAT
2	CONTAINED FOUR SPECIFIC GENES. AND THESE FOUR SPECIFIC
3	GENES WERE ABLE TO TAKE THESE ADULT CELLS AND TURN THE
4	CLOCK BACK AND MAKE THEM EMBRYONIC CELLS. AS FAR AS WE
5	CAN TELL, THESE EMBRYONIC CELLS ARE VERY, VERY CLOSE TO
6	HUMAN EMBRYONIC STEM CELLS.
7	SO THE SCIENCE OF THAT IS WONDERFUL BECAUSE IT
8	SAYS WE CAN MANIPULATE GENES WITHIN A CELL AND TELL THAT
9	CELL TO GO BACK IN TIME. AND INSTEAD OF BEING A SKIN
10	CELL, GO BACK TO A POINT WHERE IT CAN BECOME ANY CELL IN
11	THE BODY. THAT'S EXCITING. IN THE FIELD OF STEM CELL
12	RESEARCH, THAT'S A MOON LANDING, I CAN ASSURE YOU. IT'S
13	GOING TO VERY MUCH AFFECT THE FIELD.
14	THE OTHER THING THAT'S IMPORTANT IS THERE WERE
15	NO EGGS INVOLVED IN THAT. SO IT REALLY CUTS INTO THE
16	MORAL ISSUES THAT GOOD PEOPLE DISAGREE ON. AS YOU KNOW,
17	THERE ARE FOLKS WHO SAY, WELL, IF YOU'VE GOT A HUMAN EGG
18	AND A SPERM OR A NUCLEUS IN A HUMAN EGG, THAT HUMAN EGG
19	IS A PERSON, AND SO THEREFORE IT HAS TO BE PROTECTED.
20	THERE ARE OTHERS WHO SAY, NO, THAT EGG IS A GROUP OF
21	CELLS, AND IT'S NOT GOING TO BECOME A PERSON UNTIL YOU
22	INCUBATE IT FOR NINE MONTHS IN THE UTERUS OF A WOMAN.
23	THAT DISCUSSION IS ALL OVER IF, IN FACT, THESE INDUCED
24	PLURIPOTENT CELLS THAT WE JUST TALKED ABOUT ARE FOR REAL.
25	THE THIRD THING, HOWEVER, TO REALIZE IS THAT

T	THIS IS A VERY IMPORTANT FINDING, BUT HOW DID THEY MAKE
2	THE FINDING? THEY MADE THE FINDING BY GOING BACK TO
3	HUMAN EMBRYONIC STEM CELLS AND DISCOVERING AT LEAST THREE
4	OF THESE GENES IN THESE HUMAN EMBRYONIC STEM CELLS AND
5	THEN SAYING, WAIT A MINUTE, IF WE TOOK THOSE GENES AND
6	PUT THEM INTO ADULT CELLS, COULD THEY DO THE SAME THING?
7	WHAT THEY FOUND IS THEY COULD.
8	SO THE POINT OF SAYING THAT IS THAT THE HUMAN
9	EMBRYONIC STEM CELLS ARE THE GOLD STANDARD STILL. AND WE
10	WON'T KNOW IF THESE INDUCED CELLS ARE REALLY WHAT WE HOPE
11	THEY ARE UNTIL WE CAN DO VERY CLEAR COMPARISONS WITH THE
12	HUMAN EMBRYONIC STEM CELLS, THE GOLD STANDARD. AND ONE
13	OF THE PAPERS THAT CAME OUT SHOWED THAT THERE ARE
14	DIFFERENCES BETWEEN THESE INDUCED CELLS AND THE EMBRYONIC
15	CELLS, AND THOSE DIFFERENCES ARE OUT OF ABOUT 26,000
16	GENES, THERE ARE ABOUT A THOUSAND GENES THAT DIFFER IN
17	THE INDUCED CELLS VERSUS THE EMBRYONIC CELLS. SO ARE
18	THOSE THOUSAND GENES IMPORTANT FOR TOTAL PLURIPOTENCY;
19	THAT IS, THE ABILITY TO BECOME A CELL OR NOT? WE DON'T
20	KNOW THAT.
21	SO, MR. CHAIRMAN, TO ANSWER YOUR QUESTION, I
22	THINK WHAT THIS IS GOING TO MEAN IS THAT CIRM IS GOING TO
23	CONTINUE ON ITS PATHWAY OF FUNDING WORK ON HUMAN
24	EMBRYONIC STEM CELLS BECAUSE THEY ARE THE GOLD STANDARD
25	AND THEY DO TELL US WHAT TOTAL PLURIPOTENCY MEANS, BUT AT
	20

- 1 THE SAME TIME, WE HOPE WE'LL BE FUNDING NEW WORK ON THESE
- 2 INDUCED PLURIPOTENT CELLS AS WELL. SO WE SEE TWO
- 3 PARALLEL TRACTS OF RESEARCH GOING FORWARD. AND WE THINK
- 4 THAT THEY'RE GOING TO BE COMPLEMENTARY. THE INDUCED
- 5 PLURIPOTENT SCIENTISTS, PEOPLE STUDYING THOSE CELLS, ARE
- 6 GOING TO BE LOOKING AT THE HUMAN EMBRYONIC STEM CELL
- 7 PEOPLE AND VICE VERSA, AND WE THINK THAT CALIFORNIA,
- 8 WHICH HAS THE ABILITY TO FUND BOTH PATHWAYS, IS GOING TO
- 9 BE IN AN IDEAL POSITION.
- 10 I SHOULD END THAT ANSWER BY TELLING YOU THAT
- 11 BOTH DR. YAMANAKA AND DR. THOMPSON, DR. YAMANAKA FROM
- 12 KYOTO AND DR. THOMPSON FROM WISCONSIN, ARE BOTH OPENING
- 13 LABORATORIES HERE IN CALIFORNIA. DR. YAMANAKA HERE IN
- 14 SAN FRANCISCO AND DR. THOMPSON AT UC SANTA BARBARA. SO
- THAT TELLS YOU THAT CALIFORNIA REALLY IS A VERY, VERY
- 16 GOOD PLACE TO BE DOING THIS WORK.
- 17 CHAIRMAN CHIANG: THAT'S GREAT NEWS. AGAIN,
- 18 ALONG THOSE LINES, HOW DOES IT IMPACT FUTURE BOND
- 19 ALLOCATIONS? YOU SAID YOU'RE GOING TO BE FINANCING BOTH
- 20 AREAS. HOW DOES THAT DEVIATE FROM WHAT YOU, IF YOU HAD A
- 21 PLAN, ORIGINALLY INTENDED TO DO? AND THEN HOW DO YOU
- 22 DETERMINE SCOPE AND PRIORITY?
- DR. MURPHY: I THINK WE'VE ALWAYS BEEN DRIVEN
- 24 IN PRIORITY BY THE QUALITY OF SCIENCE. WHAT WE TRY TO DO
- 25 IS FUND THE VERY BEST SCIENCE. WHO COULD HAVE PREDICTED

1	A YEAR AGO THAT RIGHT NOW WE'D BE LOOKING AT INDUCED
2	PLURIPOTENT CELLS? AND I CAN GUARANTEE YOU A YEAR FROM
3	NOW WE'LL BE LOOKING AT ENTIRELY NEW THINGS. IT'S VERY,
4	VERY DIFFICULT TO PREDICT.
5	I THINK MY ANSWER WOULD BE WE'RE GOING TO BE
6	FUNDING THE BEST SCIENCE. WE'RE GOING TO BE LETTING THAT
7	SCIENCE DIRECT US IN THE MOST PRODUCTIVE PATHWAYS TO COME
8	TO CURES AS QUICKLY AS WE CAN OR TO COME TO USING THESE
9	CELLS TO STUDY DISEASE AS QUICKLY AS WE CAN. AND MY OWN
10	FEELING IS THAT IT SHOULD NOT AFFECT THE BOND SALES AT
11	ALL BECAUSE WHAT WE'RE GOING TO BE DOING IS JUST MOVING
12	AHEAD MUCH MORE QUICKLY AS A RESULT OF THESE ADVANCES.
13	CHAIRMAN CHIANG: TALK ABOUT FUTURE BOND SALES.
14	WHAT'S THE STATUS OF THE \$150 MILLION LOAN FROM THE
15	GENERAL FUND TO THE INSTITUTE?
16	DR. MURPHY: LET ME HAVE CHAIRMAN KLEIN ANSWER
17	THAT, SIR.
18	MR. KLEIN: WE HAVE NOW REPAID THE \$150 MILLION
19	LOAN TO THE STATE WITH INTEREST, WE'RE PROUD TO SAY.
20	WE'VE ALSO REPAID OUR BOND ANTICIPATION NOTES, WHICH WERE
21	AN INNOVATIVE PROGRAM OF GAP FINANCING THAT SOME OF THE
22	GREAT CIVIC LEADERS IN THE STATE LIKE ELI BROAD AND IRWIN
23	JACOBS AND JOHN MOORE AND JOHN DOERR HAD PURCHASED TO
24	MAKE SURE THAT DURING THE LITIGATION WE COULD MOVE
25	FORWARD WITH OUR GRANT PROGRAM. SO ALL OF THOSE LOANS

1	HAVE BEEN REPAID.
2	CHAIRMAN CHIANG: THAT'S GREAT. THE STATE
3	COULD USE THE MONEY.
4	I HAVE A QUESTION THAT STAFF WANTED ME TO
5	RAISE. WHEN THIS COMMITTEE MET LAST YEAR, THERE WAS SOME
6	DISCUSSION ABOUT ACCESS TO WORKING PAPERS. AND CIRM WAS
7	TO WORK WITH THEIR COUNSEL TO ENSURE THAT THE
8	CONTROLLER'S OFFICE WILL HAVE ACCESS TO THOSE PAPERS
9	WITHOUT LIMIT TO ITS REVIEW. WHAT HAS YOUR LEGAL COUNSEL
10	DETERMINED?
11	MR. KLEIN: WE'RE TALKING ABOUT THE AUDIT
12	PAPERS. I'M GOING TO HAVE TAMAR PACHTER ADDRESS THAT,
13	AND HOPEFULLY IT'S EXACTLY WHAT YOU'D LIKE TO HEAR.
14	MS. PACHTER: THANK YOU. WE HAVE NOW INCLUDED,
15	MR. CHAIR, IN ALL OUR CONTRACTS, INCLUDING OUR CONTRACTS
16	WITH OUR INDEPENDENT AUDITOR, LANGUAGE THAT SPECIFICALLY
17	GIVES BOTH THE BUREAU OF STATE AUDITS AND THE STATE
18	CONTROLLER ACCESS TO ANY AND ALL WORKPAPERS THAT ARE
19	INVOLVED IN THE AUDIT. SO THAT SHOULD NOT BE A PROBLEM
20	ANY LONGER.
21	CHAIRMAN CHIANG: VERY GOOD. MEMBERS HAVE
22	COMMENTS?
23	MS. POTTER: I HAVE A QUESTION ABOUT THE
24	ECONOMIC IMPACT REPORT THAT YOU REFERENCE. I'D LIKE TO
25	KNOW A LITTLE BIT MORE ABOUT THAT. IT SEEMS TO ME THAT

1	CAN BE JUST A VERY, VERY IMPORTANT DELIVERABLE IN TERMS
2	OF COMMUNICATING THE FULL VALUE ESPECIALLY TO THE
3	CITIZENS OF THE STATE.
4	MR. KLEIN: WELL, THINKING THAT YOU MIGHT ASK
5	THAT QUESTION, THAT'S ONE OF THOSE ITEMS THAT REPRESENTS
6	THE PANELS IN FRONT OF YOU. SO LET ME TRY AND HIT ON
7	THAT FOR A MOMENT BEFORE MOVING TO INTELLECTUAL PROPERTY,
8	WHICH IS AN ISSUE THAT YOU ASKED ABOUT AS A PANEL LAST
9	YEAR.
10	SO AT THE TIME OF THE PROPOSITION 71 ELECTION,
11	THERE WAS AN ECONOMIC STUDY THAT WAS HEADED BY LAWRENCE
12	BAKER, AN ECONOMIST AT STANFORD MEDICAL SCHOOL, AND A
13	GROUP CALLED ANALYSIS GROUP THAT PROJECTED FUTURE
14	BENEFITS AS A POTENTIAL TO CALIFORNIA. NOW, THE BALLOT
15	ITSELF SAID THAT THESE BENEFITS, OF COURSE, AS
16	PROJECTIONS WERE PURELY SPECULATIVE; AND IT DID NOT, IN
17	FACT, REFERENCE THESE NUMBERS IN THE BALLOT ARGUMENT, BUT
18	THE LEGISLATIVE ANALYST WROTE A REPORT ON THEM THAT
19	REVIEWED THEIR METHODOLOGY AND WAS QUITE SOUND.
20	SO IN TERMS OF THE OVERVIEW FOR YOU OF FUTURE
21	ECONOMIC BENEFITS FOR CALIFORNIA, THE PANELS IN FRONT OF
22	YOU ARE IN TWO FORMS: PRESENT VALUE, THAT IS, WHAT'S THE
23	PRESENT VALUE ECONOMICALLY IN TODAY'S DOLLARS OF THOSE
24	BENEFITS? AND WHAT'S THE FUTURE VALUE 35 YEARS INTO THE
25	FUTURE? AS YOU KNOW, AS, IN FACT, THE CHAIRMAN NOTED,
	3/1

- 1 THE BALLOT MEASURE IS STATED ALL IN FUTURE DOLLARS. SO
- 2 IT CAPTURES THE WHOLE INTEREST FOR 35 YEARS AS AN
- 3 ADDITIONAL \$3 BILLION. WHAT THE VOTERS REALLY APPROVED
- 4 WAS 6 BILLION, THREE BILLION IN PRINCIPAL AND 35 YEARS OF
- 5 INTEREST FOR ANOTHER \$3 BILLION.
- 6 BUT WHAT YOU SEE IN FRONT OF YOU IN THE PANEL
- 7 BREAKS DOWN THE POTENTIAL BENEFITS. ABOUT 4 PERCENT ARE
- 8 TAX REVENUES FOR THE STATE EXPECTED TO COME FROM DIRECT
- 9 SPENDING. THAT IS, THE ACTUAL GRANTS THAT ARE PUT OUT TO
- 10 THE GRANTEE ORGANIZATIONS, WHETHER A SCIENTIST AT UC
- 11 BERKELEY OR UC IRVINE, UC SAN DIEGO OR STANFORD OR USC,
- 12 THAT SPENDING ITSELF WILL CREATE THE TAX REVENUE TO THE
- 13 STATE OF ABOUT 4 PERCENT OF THE TOTAL BENEFIT. YOU CAN
- 14 SEE IT ON THE CHART.
- 15 SECONDLY, IT'S EXPECTED OVER TIME DURING THAT
- 16 35-YEAR PERIOD THAT THE BIOTECH SECTOR WILL JOIN IN THIS,
- 17 AND THERE WILL BE SUBSTANTIAL GROWTH, LIKE THERE WAS WITH
- 18 RECOMBINANT DNA. AT THE TIME IN 1977 WHEN THE
- 19 RECOMBINANT DNA FIELD WAS FOUNDED, THERE WERE 17,000
- 20 BIOTECH JOBS IN THE STATE. TODAY, AS OF ACTUALLY TWO
- 21 YEARS AGO, THERE WERE 267,000 BIOTECH JOBS IN THE STATE.
- 22 IT'S THE SECOND HIGHEST JOB CREATOR IN THE STATE. IN
- 23 FACT, MYRTLE POTTER, WHEN SHE WAS AT GENENTECH, HAD A
- 24 GREAT DEAL TO DO WITH LEADING THAT AS THE HEAD OF THEIR
- 25 DEVELOPMENT DIVISION ON A GLOBAL BASIS.

1	SO IF YOU LOOK AT THE PIE CHART, IT SHOWS THAT
2	34 PERCENT OF THE REVENUES ARE EXPECTED TO COME FROM TAX
3	REVENUES GENERATED FROM THE GROWTH OVER THE 35 YEARS IN
4	THE BIOTECH SECTOR. THE ROYALTY REVENUE AT A 2-PERCENT
5	ROYALTY RATE WAS EXPECTED TO CREATE IN FUTURE DOLLARS
6	CUMULATIVELY OVER THE NEXT 35 YEARS 537 MILLION TO A
7	BILLION DOLLARS. REALIZE THAT'S IN FUTURE DOLLARS. THE
8	OTHER CHART IS VERY IMPORTANT TO LOOK AT.
9	THE OTHER CHART YOU SEE SAYS THAT WHILE THE
10	PERCENTAGE OF BENEFIT IS THE SAME, 8 PERCENT FROM ROYALTY
11	REVENUES, IT'S 189 MILLION IN PRESENT VALUE. THERE'S
12	BEEN QUITE A BIT OF REPORTING IN THE NEWSPAPERS THAT'S
13	CONFUSED FUTURE DOLLARS AND PRESENT DOLLARS, AND IT SAID,
14	WELL, THIS WILL NEVER PRODUCE MORE THAN \$250 MILLION IN
15	CURRENT REVENUE. WELL, THAT'S TRUE, BUT THEY'RE NOT
16	REALIZING THEY'RE PROVING OUR CASE BECAUSE WE'RE
17	PROJECTING IN PRESENT DOLLARS, IT'S 189 MILLION.
18	THE GREATEST BENEFIT TO THE STATE, IF WE JUST
19	GET A 1-PERCENT COST REDUCTION IN SEVEN OUT OF 70
20	DIFFERENT AREAS OF CHRONIC DISEASE AND INJURY, 1-PERCENT
21	BENEFIT, SOMEBODY GETS OUT OF THE HOSPITAL 1 PERCENT
22	EARLIER, SOMEONE WITH PARALYSIS HAS A PARTIAL USE OF
23	MAYBE THEIR HAND OR SOMETHING SO THEY CAN HELP CARE FOR
24	THEMSELVES, JUST MARGINAL INCREASES IN THE EFFECTIVE
25	THERAPIES FOR PATIENTS, NOT CURING THEM, WHICH WOULD BE A

1	HOME RUN, BUT CONSERVATIVELY STATED A 1-PERCENT BENEFIT
2	OVER TIME ACCOUNTS FOR 54 PERCENT OF ALL THE PROJECTED
3	BENEFIT.
4	SO UNDERSTANDING EMBRYONIC STEM CELLS AND ADULT
5	STEM CELLS, IF WE CAN REALLY MOVE FORWARD ON THERAPIES
6	HERE THAT HAVE ANY MATERIAL IMPROVEMENT IN HEALTH, WE
7	REALLY CAN HELP STOP THE MASSIVE GROWTH OF THE \$14
8	BILLION IN 2004 DOLLARS THAT THE STATE PAYS OUT FOR
9	HEALTHCARE BENEFITS. NOW, WHAT WE HAVE DONE IS ASKED
10	INTERNALLY AND PUT INTO OUR STRATEGIC PLAN THAT WE WILL
11	DO AN UPDATE OF THIS. WE'LL PUT OUT AN RFA RIGHT AFTER
12	THE FIRST OF THE YEAR OR MAYBE RIGHT BEFORE THE FIRST OF
13	THE YEAR TO GET SEVERAL FIRMS TO BID ON DOING A FULL
14	UPDATE OF THESE PROJECTIONS. THAT UPDATE SHOULD BE DONE
15	BY YOUR FALL MEETING NEXT YEAR WHERE WE HOPE TO PROVIDE
16	YOU WITH AN UPDATED ANALYSIS.
17	CERTAINLY WHEN WE WERE WORKING WITH STANFORD
18	MEDICAL SCHOOL IN THESE PROJECTIONS, IT WAS NOT EXPECTED
19	THAT CALIFORNIA WOULD BE THE LEADER OF 21 NATIONS IN THE
20	WORLD IN STEM CELL RESEARCH. THIS IS A ROLE THAT IS FAR
21	BEYOND WHAT'S EXPECTED. AND IN THE PEER REVIEW PROCESS
22	THAT DR. MURPHY HAS REFERENCED HERE, YOU HAVE IN FRONT OF
23	YOU, AND THERE IS AT THE BACK OF THE ROOM, A LIST OF PEER
24	REVIEW SCIENTISTS THAT PARTICIPATE IN OUR REVIEW, AS DR.
25	MURPHY SAID, TO AVOID CONFLICTS, THEY'RE ALL OUT OF

1	STATE. AND WHEN YOU LOOK AT THAT LIST, YOU WILL SEE THAT
2	OF OUR PRIMARY REVIEWERS, THREE ARE FROM HARVARD
3	UNIVERSITY. WE'RE ATTRACTING THE BEST PEOPLE IN THE
4	COUNTRY.
5	AND IF YOU LOOK AT OUR ALTERNATES, YOU WILL SEE
6	THAT INCLUDES A NUMBER OF PEOPLE FROM CANADA, A SCIENTIST
7	FROM SWEDEN. PEOPLE ARE PREPARED TO MOVE ACROSS THE
8	ENTIRE WORLD TO HELP CALIFORNIA IN THIS LEADERSHIP. AND
9	AS YOU WILL NOTE, DR. ALAN TROUNSON, A LEADING
10	RESEARCHER, EMBRYONIC STEM CELL RESEARCHER, IN AUSTRALIA,
11	WE'VE SUCCESSFULLY RECRUITED TO BE OUR NEW PRESIDENT, AND
12	HE WILL START, IN FACT, TOWARDS THE END OF DECEMBER.
13	SO WE'RE AT THE HEAD OF AN ECONOMIC REVOLUTION.
14	HOPEFULLY IT'S HALF AS SUCCESSFUL AS RECOMBINANT DNA. WE
15	HOPE TO LEARN FROM WHAT MYRTLE POTTER DID IN THAT
16	REVOLUTION. BUT IF WE COULD PRODUCE HALF THEIR NUMBER OF
17	JOBS, WE'D BE FAR BEYOND PROJECTIONS THAT YOU SEE HERE IN
18	ECONOMIC BENEFIT, BUT WE WILL HAVE AN UPDATE COMING.
19	CHAIRMAN CHIANG: BOB, TWO FOLLOW-UP QUESTIONS
20	TO YOUR COMMENTS. THE FIRST, I AM NOT QUITE CLEAR IN
21	REGARDS TO THIS ECONOMIC STUDY. WAS THAT WORK PERFORMED
22	BY STAFF INTERNALLY, OR WAS THAT AS EXTERNAL?
23	MR. KLEIN: THAT'S AN EXTERNAL STUDY THAT WAS
24	DONE BY LAWRENCE BAKER OF STANFORD IN THE STANFORD
25	MEDICAL SCHOOL ALONG WITH A GROUP CALLED THE ANALYSIS

1	GROUP, AN EXTERNAL GROUP THAT SPECIALIZES IN HEALTHCARE
2	STUDIES NATIONALLY AND INTERNATIONALLY.
3	CHAIRMAN CHIANG: VERY GOOD. THE SECOND
4	QUESTION FOLLOWING UPON YOUR COMMENTS WAS WHAT'S VERY
5	EXCITING FOR ME IS WE'RE DRAWING WORLD-CLASS TALENT TO
6	CALIFORNIA. I WAS ALWAYS AFRAID OF THE BRAIN DRAIN,
7	LOSING THAT TALENT ACROSS THE WORLD AS THE WORLD BECOMES
8 .	MORE GLOBALLY COMPETITIVE, WHICH IS, FRANKLY, A GOOD
9	THING. BUT WHAT TYPE OF PRACTICES IS THE INSTITUTE
10	ENGAGED IN TO MAKE SURE THAT WE HAVE NOT ONLY WORLD-CLASS
11	TALENT, BUT WE'RE ENGAGED IN, AS I TRY TO HARP ON MY
12	STAFF, THAT WE HAVE WORLD-CLASS FISCAL OPERATIONS IN OUR
13	INSTITUTIONS? SO ARE YOU CREATING THEM? ARE YOU
14	MIMICKING THEM? ARE YOU DRAWING FROM OTHER INDUSTRIES?
15	WHAT IS THE INSTITUTE DOING?
16	MR. KLEIN: WELL, THE FIRST THING THAT WE DID
17	IMMEDIATELY AFTER THE ELECTION IS WE ASKED THE NATIONAL
18	ACADEMIES OF SCIENCE TO COME TO CALIFORNIA WITH THE BEST
19	AND THE BRIGHTEST OF THE NATION AND PROVIDE US A BEST
20	PRACTICES CONFERENCE. IN FACT, AS DR. MURPHY SAID, WE
21	NOW HAVE THE GOLD STANDARD IN MEDICAL AND ETHICAL
22	STANDARDS FOR THE COUNTRY, BUT WE OWE A GREAT DEAL TO
23	NATIONAL ACADEMIES OF SCIENCE WHO ON DECEMBER 5TH AND
24	6TH, APPROXIMATELY FIVE WEEKS AFTER THE ELECTION, BROUGHT
25	A HANDPICKED TEAM FROM THROUGHOUT THE NATION TO HELP US

1	ESTABLISH THE GRANT POLICY, TO HELP US ESTABLISH, FOR
2	EXAMPLE, THE PROCEDURE OF USING ONLY OUT-OF-STATE
3	SCIENTISTS FOR OUR PEER REVIEW TO AVOID BIAS IN THAT
4	PROCESS.
5	SO WE HAVE LEARNED A GREAT DEAL FROM THE
6	NATIONAL ACADEMY OF SCIENCES IN BEST PRACTICE. FRANKLY,
7	WE WENT TO THE CONTROLLER'S OFFICE WITH YOUR PREDECESSOR,
8	STEVE WESTLY, AND WITH THE BENEFIT OF THE CONTROLLER'S
9	OFFICE, THE CONTROLLER'S OFFICE HAS HELPED US SET UP OUR
10	ACCOUNTING SYSTEM. AS I SAID, CUTS ALL OF OUR CHECKS,
11	RUNS OUR BOOKS FOR US. SO WE KNOW THAT WE'RE BENEFITING
12	FROM THE YEARS AND YEARS OF TREMENDOUS EXPERIENCE IN
13	MAKING SURE THAT WHENEVER A DISBURSEMENT IS MADE, THAT
14	IT'S FULLY VETTED AND IT'S PROPERLY RECORDED. BUT WE'RE
15	TRYING TO LEARN. AS I SAID, WE'RE A YOUNG AGENCY.
16	TRYING TO LEARN FROM THE BEST. WE'VE LEARNED FROM
17	RECOMMENDATIONS OF BUREAU OF STATE AUDIT. THE
18	LEGISLATURE HAD THEM DO AN AUDIT, AND WE WORKED WITH THEM
19	OVER THE LAST YEAR TO IMPROVE OUR SYSTEMS BASED ON THEIR
20	RECOMMENDATIONS. WE'VE LEARNED FROM OUR AUDITORS FROM
21	THEIR RECOMMENDATIONS, AND WE CONTINUE TO LEARN TO MAKE
22	SURE THAT WE GROW QUALITATIVELY.
23	I THINK DR. MURPHY MAY HAVE A POINT.
24	DR. MURPHY: CHAIR CHIANG, I THINK THE POINT
25	YOU MAKE IS A VERY IMPORTANT ONE. HOW ARE WE GETTING
	40

1	GOOD, NEW SCIENTISTS TO COME TO CALIFORNIA? AND ONE OF
2	THE THINGS I LEARNED LONG AGO AS AN ADMINISTRATOR IS THAT
3	ADMINISTRATORS DON'T HAVE ANY CONTROL OVER THAT. WHAT
4	REALLY HAS CONTROL IS GOOD SCIENCE. AND I THINK WHAT
5	WE'RE SEEING IS AS CIRM MAKES CALIFORNIA A HAVEN FOR
6	PEOPLE WHO ARE INTERESTED IN DOING STEM CELL SCIENCE, AS
7	WELL AS DEVELOPMENTAL BIOLOGY, THAT IS, UNDERSTANDING HOW
8	THE BODY DEVELOPS, WHICH IS KEY TO STEM CELL SCIENCE,
9	MORE AND MORE YOUNG PEOPLE ARE BEING ATTRACTED TO
10	CALIFORNIA ORGANIZATIONS.
11	AS I MENTIONED, WE'RE NOW IN THE PROCESS OF
12	EVALUATING GRANTS FOR MAJOR FACILITIES AT OUR
13	UNIVERSITIES AND INSTITUTES IN CALIFORNIA. KEY TO THAT
14	WILL BE CREATING NEW SPACE. AND WHEN THAT NEW SPACE IS
15	ONLINE, OUR ORGANIZATIONS ARE GOING TO BE AGGRESSIVELY
16	GOING AFTER YOUNG PEOPLE ESPECIALLY TO COME TO THESE
17	INSTITUTIONS TO FILL THE LABS. SO WHILE THE
18	ADMINISTRATION ISN'T DOING THIS, THE SCIENCE IS. AND THE
19	POLICIES OF FUNDING GOOD STEM CELL SCIENCE AND MAKING IT
20	POSSIBLE FOR THE SCIENTISTS TO DO THEIR WORK IS THE BEST
21	ATTRACTANT WE CAN HAVE FOR BRINGING NEW TALENT TO
22	CALIFORNIA AND IT'S WORKING.
23	WITH THAT STILL SAID, I CAN TELL YOU THAT THE
24	COUNTERVAILING FORCE IS THE NATIONAL INSTITUTE OF HEALTH,
25	THE NATIONAL INSTITUTE OF HEALTH HAS HAD FLAT FUNDING FOR

1	THE LAST FIVE YEARS IN THE FACE OF 8 OR 9 OR 10 PERCENT
2	INFLATION IN SCIENCE NEEDS. SO FEDERAL FUNDING IS GOING
3	DOWN WHILE CALIFORNIA FUNDING IS NOW BECOMING WELL-KNOWN
4	AND CALIFORNIA IS BECOMING WELL-KNOWN AS THE PLACE TO GO,
5	ESPECIALLY FOR YOUNG PEOPLE, TO GET THEIR CAREERS GOING.
6	SO I THINK IT'S AN IDEAL SITUATION FOR US TO BE DOING
7	EXACTLY WHAT YOU JUST SAID.
8	CHAIRMAN CHIANG: THIS RAISES A VERY TOUCHY
9	ISSUE. AS WE DRAW MORE PEOPLE TO CALIFORNIA, WHICH WE
10	WANT TO HIGHLY ENCOURAGE, HOW DO WE FULFILL OUR PUBLIC
11	RESPONSIBILITY AS TO TRANSPARENCY AND DISCLOSURE OF THAT
12	FUNDING?
13	MR. KLEIN: MR. CHAIRMAN, IN OUR BOARD
14	APPROVALS, EVERY GRANT THAT COMES WITH A RECOMMENDATION
15	TO FUND OR TO FUND IF THERE ARE AVAILABLE FUNDS, THE
16	INSTITUTION'S NAME AND THE SCIENTIFIC SCORE BY THIS
17	INDEPENDENT GROUP IS PUBLICLY DISPLAYED AT THE TIME THAT
18	THIS GRANT IS APPROVED. SO COMING OUT OF ANY APPROVAL WE
19	KNOW EVERY INSTITUTION AND WHAT THEIR SCORE WAS, AND WE
20	HAVE A PUBLIC DEBATE OVER THE FUNDING OF THESE. IN MANY
21	CASES THE BOARD ACTUALLY HAS TAKEN DIFFERENT STRATEGIC
22	PRIORITIES AND NOT FUNDED SOME RECOMMENDED, FUNDED SOME
23	THAT WERE RECOMMENDED. IF ONE OF THE GRANTS WAS NOT
24	RECOMMENDED FOR FUNDING AND IS CHOSEN TO BE FUNDED, THEN
25	THAT HAS TO BE DISCLOSED AS WELL.

1	SO THERE'S NEVER ANY GRANT, ANY LOAN, OR ANY
2	POLICY THAT'S APPROVED IN CALIFORNIA WITHOUT PUBLIC
3	DEBATE AND A PUBLIC HEARING BY THE GOVERNING BOARD. AND
4	ANY TIME ANY CALIFORNIA DOLLARS ARE APPROVED, THAT
5	SCORE THAT INSTITUTION AND ITS SCORE ARE DISCLOSED.
6	I'D LIKE TO DISTINGUISH THE FACT, AND MAYBE DR. MURPHY
7	WOULD LIKE TO COMMENT, THAT IF, IN FACT, SOMEONE IS NOT
8	RECOMMENDED FOR FUNDING AND DENIED FUNDING, WE DO NOT
9	DISCLOSE THAT INSTITUTION'S NAME OR THEIR SCORE BECAUSE
10	THE INTENT IS NOT TO DISCOURAGE PEOPLE WHO COME UP WITH
11	REALLY BRIGHT CONCEPTUAL IDEAS, BUT MAYBE AREN'T WELL
12	DEVELOPED ENOUGH. WE DON'T WANT TO TAKE A SITUATION
13	WHERE SOMEONE IS UP FOR TENURE AND PUBLICLY CASTIGATE
14	THEM AND GIVE THEM A VERY LOW SCORE BECAUSE IT COULD
15	DESTROY THEIR ABILITY TO PROGRESS.
16	IF WE LOOK BACK HISTORICALLY THROUGH THE
17	DEVELOPMENT OF SCIENCE, EVEN, FOR EXAMPLE, THE ISSUE WITH
18	ULCERS, FOR YEARS THE THEORY ON HOW ULCERS WERE CREATED
19	WAS PUBLICLY CASTIGATED. IT TOOK A NUMBER OF YEARS TO
20	PROVE HOW ULCERS WERE CREATED. AND IF WE HAD BEEN THE
21	FUNDING AGENCY AND FOR YEARS POUNDING ON THIS WITH VERY
22	LOW SCORES, IT WOULD, IN FACT, DISCOURAGE THAT PROFESSOR,
23	MAYBE EVEN DENY THEM TENURE BECAUSE OF THE STIGMA.
24	I KNOW THAT YOU HAVE MEMBERS, INCLUDING MYRTLE
25	POTTER, THAT KNOW THIS PROCESS PRETTY WELL. SO WE'RE
	40

1	TRYING TO ANY TIME THERE'S A DOLLAR APPROVED, A FULL
2	DISCLOSURE, BUT PROTECT THOSE PEOPLE WHO MAY HAVE TO COME
3	BACK SEVERAL TIMES TO REALLY HAVE ENOUGH PROOF WHERE WE
4	CONSIDER IT FOR PUBLIC DOLLARS.
5	CHAIRMAN CHIANG: ANY ADDITIONAL QUESTIONS FROM
6	BOARD MEMBERS?
7	MR. KLEIN: MR. CHAIRMAN, ARE YOU READY FOR DR.
8	PENHOET AND THE INTELLECTUAL PROPERTY AT THIS POINT?
9	CHAIRMAN CHIANG: YES.
10	MR. KLEIN: HE STEPPED OUT FOR 30 SECONDS HERE.
11	MR. SIMPSON: WOULD YOU TAKE PUBLIC COMMENT ON
12	ANY OF THE PART OF THIS THAT'S GONE SO FAR?
13	CHAIRMAN CHIANG: SURE, JOHN. GO AHEAD.
14	MR. SIMPSON: JOHN SIMPSON, FOUNDATION FOR
15	TAXPAYER AND CONSUMER RIGHTS. I JUST ALSO WANTED TO, YOU
16	SPOKE ABOUT THE AUDIT, AND BEFORE THAT GOT OUT OF MY
17	MIND, IT'S AWKWARD LANGUAGE, BUT I'M DELIGHTED IT'S
18	UNQUALIFIED. I THINK THAT THAT'S A GREAT COMMENDATION
19	FOR CIRM.
20	AND I ALSO NOTE THAT IT WAS ON A PERIOD WHEN
21	THINGS WEREN'T REALLY UP AND REVVING. SO YOUR
22	RECOMMENDATION, MR. CHAIRMAN, THAT THINGS GET BACK IN
23	SYNCH IS WONDERFULLY APPROPRIATE, AND WE GREATLY
24	APPRECIATE THAT.
25	THE OTHER THING, THERE'S BEEN REFERENCE TO,
	44

1	YOU'RE ABOUT TO HEAR ABOUT THE IP STANDARDS, AND THERE'S
2	BEEN REFERENCE TO THE MEDICAL STANDARDS. AND I THINK
3	THIS HAS BEEN A GOLD STANDARD OF INVOLVING THE PUBLIC,
4	THE AFFECTED PEOPLE, IN DEVELOPING THOSE STANDARDS. I
5	HAVE NOT ALWAYS AGREED WITH THE OUTCOME, AS THE CHAIRMAN
6	KNOWS VERY WELL, BUT THE PROCESS HAS BEEN VERY GOOD. THE
7	STAKEHOLDERS HAVE BEEN INVITED IN AND HAVE DEVELOPED
8	HAD A KEY ROLE IN DEVELOPING THOSE POLICIES, SOME OF
9	WHICH ARE STILL WORKING THEIR WAY THROUGH THE OFFICE OF
10	ADMINISTRATIVE LAW. THAT'S A GOOD THING.
11	I DO NEED TO SAY ONE THING ABOUT THE GRANTS
12	APPROVAL PROCESS. I DON'T I DON'T AGREE WITH THE
13	ARGUMENT ABOUT INDIVIDUAL RESEARCHERS WHO ARE GOING AFTER
14	PUBLIC MONEY. I THINK EVERYONE SHOULD BE DISCLOSED;
15	HOWEVER, I UNDERSTAND THE ARGUMENT. WHAT I DO NOT
16	UNDERSTAND AND WHAT I FEAR WAS GLOSSED OVER SLIGHTLY IS
17	THAT \$227 MILLION OF GRANTS THAT ARE GOING TO BUILD NEW
18	BUILDINGS AT RESEARCH INSTITUTIONS AND UNIVERSITIES. ALL
19	WE KNOW IS THAT 17 INSTITUTIONS HAVE APPLIED. WE DON'T
20	KNOW WHAT INSTITUTIONS. WE DON'T KNOW HOW MUCH THEY'RE
21	ASKING FOR, WHAT TYPE OF FACILITIES GRANT THEY WANT. WE
22	WON'T KNOW UNTIL WAY DOWN THE PROCESS.
23	THE WAY IT'S SET UP IS APPARENTLY THAT SOMEHOW,
24	YOU KNOW, THEY CAN BE THROWN OUT FOR BAD SCIENCE AND NOT
25	EMBARRASSED, BUT IN A SECOND STAGE, IF THEY SHOW THEY

1	CAN'T BUILD A DECENT BUILDING, THEN IT'S OKAY TO NAME
2	THEM. SOMETHING IS WRONG HERE WHEN WE HAVE THERE'S A
3	DIFFERENCE BETWEEN A STANFORD OR A UC OR A BURNHAM. WHEN
4	THEY APPLY AS AN INSTITUTION, THAT OUGHT TO BE PUBLIC
5	KNOWLEDGE. AND I WOULD ENCOURAGE THIS COMMITTEE TO TAKE
6	AFFIRMATIVE ACTION TO RECOMMEND THAT THE 17 INSTITUTIONS
7	BE IDENTIFIED.
8	I BELIEVE THERE'S A LETTER THAT'S COME TO THE
9	PANEL FROM THE CALIFORNIA STEM CELL REPORT MAKING THE
10	SAME POINT. THERE'S NO PUBLIC POLICY REASONS SERVED BY
11	THIS. IF THERE IS, IN FACT, SOME PARTICULAR PROPRIETARY
12	INFORMATION IN AN APPLICATION, THAT CAN EASILY BE
13	REDACTED, BUT NOT TO KNOW WHAT 17 INSTITUTIONS HAVE
14	APPLIED MAKES NO SENSE. THANK YOU VERY MUCH.
15	CHAIRMAN CHIANG: DO YOU WANT TO RESPOND?
16	MR. KLEIN: YES. THANK YOU, MR. CHAIRMAN.
17	FIRST OF ALL, AS MR. SIMPSON REFERENCED ON THE MAJOR
18	FACILITIES, THEY'RE NOW GOING THROUGH JUST THE SCIENCE
19	REVIEW. SO WE CAN'T DISCLOSE HOW MANY DOLLARS THEY'RE
20	APPLYING FOR BECAUSE THEY HAVEN'T APPLIED FOR DOLLARS.
21	THEY HAVEN'T DESCRIBED THE FACILITIES PORTION OF THE
22	APPLICATION WHERE THEY ACTUALLY COMPETE FOR DOLLARS WILL
23	START IN FEBRUARY. BUT AT OUR JANUARY MEETING, AFTER OUR
24	SCIENTIFIC REVIEW, EVERY INSTITUTION THAT IS RECOMMENDED
25	TO GO FORWARD THAT ACTUALLY WILL HAVE THE ABILITY TO

1	COMPETE FOR STATE DOLLARS WILL BE FULLY DISCLOSED EVEN
2	BEFORE THEY SUBMIT THEIR REQUEST FOR DOLLARS.
3	IN FEBRUARY THEY WILL SUBMIT THEIR APPLICATIONS
4	DESCRIBING THEIR FACILITY IN DETAIL AND THE DOLLARS.
5	RIGHT NOW WHAT'S HAPPENING IS THAT THEY HAVE SUBMITTED
6	APPLICATIONS THAT ADDRESS THEIR SCIENTIFIC PROGRAMS, WHO
7	THEY'RE RECRUITING FROM AROUND THE WORLD, WHO THEY'RE
8	RECRUITING FROM THE NATION, SOME VERY PROPRIETARY ISSUES.
9	IF YOU CAN IMAGINE, A LOT OF PEOPLE WOULD LIKE TO KNOW
10	WHO THEY'RE RECRUITING TO TRY AND GIVE THEM A
11	COUNTEROFFER TO KEEP THEM IN SOME COUNTRY OR TO KEEP THEM
12	IN ANOTHER INSTITUTION. BUT
13	MS. POTTER: MR. KLEIN, DO YOU HAVE, IN WHAT
14	YOU HAVE IN YOUR HANDS RIGHT NOW, THEY DO STATE THAT THEY
15	INTEND TO APPLY FOR FUNDING, CAPITAL FUNDING, FOR
16	BUILDINGS IN THE STAGE THAT YOU'RE IN RIGHT NOW.
17	MR. KLEIN: AT THE STAGE THAT THEY'RE IN RIGHT
18	NOW, THEY KNOW THAT THEY CANNOT APPLY UNLESS THEY COME
19	OUT OF THE SCIENTIFIC REVIEW WITH A HIGH SCORE.
20	MS. POTTER: I UNDERSTAND.
21	MR. KLEIN: SO THEY'RE NOT EVEN QUALIFIED TO
22	APPLY FOR FUNDING. DR. MURPHY, WOULD YOU LIKE TO COMMENT
23	ON THIS? THIS IS A POLICY THAT THE SCIENTIFIC STAFF
24	LEADS US WITH.

DR. MURPHY: I RESPECT JOHN'S COMMENTS ON THIS,

1	AND HE AND I HAVE TALKED ABOUT IT. THE REALITY IS THAT
2	ANY COMPETITION, SCIENTIFIC COMPETITION, HAS TO RELY ON
3	CONFIDENTIALITY TO GIVE THE APPLICANTS AN ABILITY TO BE
4	AS CREATIVE AS THEY WANT AND TO CONVINCE THE REVIEWERS
5	THAT ANY IDEA THEY HAVE, WHICH IS PROPRIETARY, IS AN
6	EXCITING IDEA, AND THEY NEED TO HAVE THAT DONE IN A VERY
7	CONFIDENTIAL WAY.
8	IN THIS COMPETITION THERE'S ALSO SOMETHING
9	ADDITIONAL. THE ORGANIZATIONS THAT CAN APPLY FOR GRANTS
10	CAN APPLY EITHER FOR BASIC SCIENCE OR FOR CLINICAL
11	SCIENCE OR FOR TRANSLATIONAL SCIENCE AND CAN APPLY FOR
12	ALL THREE IN SOME CASES. WHAT IF OUR SCIENTIFIC GROUP
13	SAYS, LOOK, PARTS 1 AND PART 2 WERE TERRIFIC, BUT PART 3,
14	THE CLINICAL PART OF THAT APPLICATION, ISN'T VERY GOOD.
15	NOW, THAT DOESN'T SAY THAT THAT ORGANIZATION ISN'T A GOOD
16	CLINICAL ORGANIZATION. IT BASICALLY SAYS THAT THE GRANT
17	THEY PUT IN WAS NOT COMPETITIVE COMPARED TO THE OTHER
18	GRANTS.
19	SO IF I WERE RUNNING ONE OF THOSE ORGANIZATIONS
20	THAT WERE APPLYING FOR ALL THREE PARTS, I WOULD WORK
21	VERY, VERY HARD TO MAKE THREE COMPELLING PARTS OF THE
22	APPLICATION; BUT IF ONE FAILED, I WOULD NOT WANT THE
23	REPUTATION OF MY ORGANIZATION TO BE TARNISHED IN A WAY
24	THAT HAD NOTHING TO DO WITH THE GRANT ITSELF. SO THAT
25	WAS PART OF THE REASONING WE HAD FOR MAINTAINING

1	CONFIDENTIALITY ON THESE GRANTS.
2	BOB IS RIGHT. AS SOON AS THESE GRANTS GO
3	THROUGH SCIENTIFIC REVIEW AND ARE EVALUATED BY THE ICOC,
4	THE IDENTITIES OF THESE ORGANIZATIONS WILL BE REVEALED
5	AND THOSE PARTS FOR WHICH THEY WERE HIGHLY RATED WILL BE
6	REVEALED AS WELL.
7	CHAIRMAN CHIANG: I UNDERSTAND BOTH SIDES.
8	BEING A PUBLIC SERVANT, I TEND TO LEAN VERY HEAVILY
9	TOWARDS PUBLIC DISCLOSURE. I UNDERSTAND THAT WE ALSO
10	OPERATE IN A SCIENTIFIC AND PROPRIETARY WORLD. HOW DO
11	YOU NOT DISCLOSE A PROPRIETARY, LEADING EDGE THOUGHT IN
12	THAT PROCESS? SO IT'S A CONSIDERED DEBATE. FRANKLY, I'D
13	LIKE TO HAVE US ENGAGE IN FURTHER DISCUSSION AS TO WHAT
14	CAN WE DO. AND I AM SENSITIVE. I DON'T OPERATE IN THE
15	WORLD OF SCIENCE AND THE APPEARANCE OR PERCEPTION OF
16	FAILURE, RIGHT. AND SO I'D LIKE TO HAVE ADDITIONAL
17	DISCUSSION AS TO PERHAPS PUBLIC DISCLOSURE OF WHY A GRANT
18	WAS NOT GIVEN, AND SO PERHAPS PROVIDING ADDITIONAL
19	DISCLOSURE. IF WE COULD FIND A BETTER BALANCE, AT LEAST
20	FROM MY PERSPECTIVE AT THIS POINT IN TIME.
21	WE'VE HAD CONSIDERABLE DISCUSSION. WHEN I WAS
22	TALKING TO MYRTLE VERY BRIEFLY AT THE VERY BEGINNING, I
23	AM VERY ENCOURAGED IN THIS AREA. AS CALIFORNIA'S CHIEF
24	FISCAL OFFICER, I'M ALWAYS TRYING TO ADVANCE CALIFORNIA'S
25	FISCAL OPERATIONS ECONOMIC ADVANTAGE. AND AS I INDICATED

- 1 TO MYRTLE, I JUST SEE THIS AS IN THE IMMEDIATE FUTURE ONE
- OF TWO GREAT PROMISING WORLD COMPETITIVE AREAS FOR
- 3 CALIFORNIA, GREEN TECHNOLOGY AND STEM CELL RESEARCH.
- 4 ALONG WITH THAT COMES A VERY, VERY IMPORTANT
- 5 RESPONSIBILITY AS TO HOW IT IS VIEWED.
- AS YOU POINTED OUT, WE HAVE 25 NATIONS LOOKING
- 7 TO CALIFORNIA. AND SO PART OF THIS IS HOW DO WE
- 8 DEMONSTRATE THAT WE'RE ENGAGED IN THE BEST PRACTICES?
- 9 HOW DO WE HAVE WORLD-CLASS PRACTICES? AND VERY
- 10 IMPORTANTLY, HOW DO WE PROTECT THE INTEGRITY OF THIS
- 11 PROCESS?
- 12 SO LET ME RAISE SOMETHING THAT TOOK PLACE
- 13 RECENTLY. LAST WEEK THERE WAS NEWS ABOUT ONE OF THE ICOC
- 14 MEMBERS, BOB, YOU AND I HAD THAT CONVERSATION, AND
- 15 PERHAPS THE INTERACTION WHICH CONSTITUTED A PROHIBITED
- 16 COMMUNICATION WHICH MAY CONSTITUTE TECHNICALLY OR IN VERY
- 17 REAL TERMS A CONFLICT OF INTEREST INVOLVING A GRANT. T
- 18 DON'T KNOW SPECIFICALLY WHAT HAPPENED, AND THAT'S WHY I
- 19 THINK IT'S VERY, VERY IMPORTANT THAT WE HAVE A FULL
- 20 DISCLOSURE OF THAT ACTIVITY BECAUSE I THINK WE HAVE TO
- 21 MAKE SURE THAT IF THERE ARE PERCEIVED OR REAL BLEMISHES
- OR CONFLICTS, THAT WE RESOLVE THOSE IMMEDIATELY AND
- 23 QUICKLY SO THAT WE CAN PROTECT THE IMPORTANT, POWERFUL,
- 24 AND BEAUTIFUL WORK OF WHAT IS TAKING PLACE WITH STEM CELL
- 25 RESEARCH.

1	OBVIOUSLY THERE'S BEEN CONSIDERABLE ATTENTION
2	DRAWN BY SOME OF THE MEDIA PUBLICATIONS, RIGHTFULLY SO.
3	THEY'VE ENCOURAGED CERTAIN ACTIONS TO TAKE PLACE. I
4	WANTED TO MAKE SURE, SINCE WE ARE PART OF THIS PROCESS,
5	THAT WE ENCOURAGE A FULL EXAMINATION OF THIS. I KNOW
6	OTHERS HAVE CALLED FOR IT, BUT I THINK IT'S CERTAINLY
7	I'LL TAKE RESPONSIBILITY AND NOT ASK ALL THE BOARD
8	MEMBERS, BUT I THINK WE OUGHT TO SEEK CLARIFICATION FROM
9	THE FPPC AS TO WHAT THE SPECIFIC FACTS OF THAT
10	INTERACTION ARE AND WHAT WE CAN DRAW FROM THAT
11	EXPERIENCE, THAT EXAMPLE, SO WE NO LONGER HAVE A
12	PERCEIVED OR REAL CONFLICT IN THE FUTURE. AND THAT,
13	FRANKLY, THE WORK THAT WILL TAKE PLACE WILL BE AN
14	EXAMINATION OF THE SCIENTIFIC AND FINANCIAL WORK WHICH IS
15	SO VITAL TO CALIFORNIA'S FUTURE.
16	SO I WILL BE SENDING, I WILL WORK WITH STAFF,
17	I'M INSTRUCTING STAFF ACTUALLY AT THIS POINT TO DRAFT A
18	LETTER FOR A FULL REVIEW OF THIS MATTER.
19	MR. KLEIN: THANK YOU, MR. CHAIRMAN. I'D LIKE
20	TO SAY WE WELCOME THE REVIEW. IT'S IMPORTANT FOR US AS A
21	YOUNG AGENCY TO CONTINUE TO LEARN. AND AS WE LEARN, EVEN
22	WITH HIGHLY ATYPICAL SITUATIONS, WHICH THAT WAS,
23	FORTUNATELY OUR FIREWALLS AND PROTECTION SYSTEMS FOR
24	CONFLICTS WORKED. AS YOU KNOW, THAT GRANT WAS ACTUALLY
25	DENIED SEVERAL MONTHS AGO AND WAS PUBLICLY ANNOUNCED THE

1	DENIAL A COUPLE OF MONTHS AGO. AND IT WAS DENIED ON A
2	FACTUAL ERROR. BUT IT'S VERY IMPORTANT EVEN TO MAKE SURE
3	WE HAVE STRICT TECHNICAL COMPLIANCE EVEN THOUGH THIS
4	GRANT WAS RATED THE SECOND HIGHEST IN THE WHOLE STATE.
5	SO WE HAVE VERY STRICT STANDARDS. THOSE FIREWALLS AND
6	PROTECTIONS PROVED THEMSELVES. THAT GRANT WAS DENIED
7	DESPITE ITS VERY HIGH SCIENTIFIC STANDARDS BECAUSE OF A
8	TECHNICAL ERROR IN THE GRANT. AND WE WELCOME THE
9	GUIDANCE FROM THE FPPC SO WE CAN LEARN AND GO FORWARD, AS
10	YOU SAY, WITH TRANSPARENCY AND MAKE SURE THAT EVERYONE
11	UNDERSTANDS WE'RE ABSOLUTELY FOCUSED ON THE MERITS AND
12	ACHIEVING THOSE MERITS.
13	CHAIRMAN CHIANG: NOT ONLY DOES THIS PROTECT
14	THE PUBLIC POLICY ELEMENTS, THE PUBLIC INTERESTS, THE
15	INSTITUTE'S INTEREST, WHAT I DON'T WANT TO BE LOST IS IT
16	ALSO PROTECTS ALL THE APPLICANTS' INTERESTS, RIGHT,
17	BECAUSE WE DO NEED CLEAR STANDARDS TO BE UNDERSTOOD SO
18	THAT THEY CAN PARTICIPATE IN THE PROCESS AND THAT WE CAN
19	HAVE THE BEST SCIENCE ADVANCED.
20	MR. KLEIN: THANK YOU VERY MUCH, MR. CHAIRMAN.
21	MR. CHAIRMAN, AT THIS POINT, BEFORE WE END THIS
22	PARTICULAR ITEM AND GO INTO PUBLIC COMMENT, COULD WE
23	PROVIDE YOU THE INTELLECTUAL PROPERTY PRESENTATION YOUR
24	PANEL ASKED FOR LAST YEAR BECAUSE WE'RE ABOUT TO GO FROM
25	ONLY FUNDING NONPROFIT INSTITUTIONS. WHICH WE HAVE FUNDED

1	TO DATE, TO FUNDING AS WELL FOR-PROFIT INSTITUTIONS WHO
2	COMPETE ON THE BEST SCIENCE TO SEE HOW WE CAN ADVANCE
3	MEDICAL THERAPIES. AND SO IT'S IMPORTANT THAT THE
4	INTELLECTUAL PROPERTY POLICY THAT WILL PROVIDE A RETURN
5	TO THE STATE, WHETHER IT'S A NONPROFIT GRANT OR A
6	FOR-PROFIT GRANT, BE CLEAR RULES, CLEARLY UNDERSTOOD BY
7	ALL THE PARTIES.
8	AND AS I SHOWED IN THE PRESENTATION, WHILE THIS
9	IS ONLY 8 PERCENT OF THE TOTAL BENEFIT TO THE STATE
10	ECONOMICALLY, IT'S AN IMPORTANT PRECEDENT BECAUSE NO ONE
11	ELSE IN THE NATION DOES IT. SO CALIFORNIA IS AGAIN THE
12	LEADER. THE NATIONAL INSTITUTES OF HEALTH PROVIDE \$28
13	BILLION A YEAR IN SUPPORT. FEDERAL GOVERNMENT DOESN'T
14	GET ANY LICENSING OR ROYALTY INCOME. SO CALIFORNIA IS
15	AGAIN BLAZING THE TRAIL. AND I'D LIKE DR. ED PENHOET,
16	WHO IS NOT ONLY THE VICE CHAIR OF THIS BOARD, BUT HE'S
17	ALSO THE PRESIDENT OF THE GORDON AND BETTY MOORE
18	FOUNDATION, A \$5 BILLION ENTERPRISE ON ITS OWN, CRUSADING
19	FOR BETTER EDUCATION, BETTER ENVIRONMENT FOR OUR NATION
20	AND OUR WORLD, IF HE WOULD HE HAS LED THIS TASK FORCE
21	OF THE BOARD, AND I'D LIKE HIM TO DO THIS PRESENTATION IF
22	THAT'S ACCEPTABLE.
23	CHAIRMAN CHIANG: YES, PLEASE. LOOK FORWARD TO
24	THIS.
25	DR. PENHOET: THANK YOU, CONTROLLER CHIANG AND
	53

1	OTHER MEMBERS OF THE COMMITTEE, FOR THIS OPPORTUNITY TO
2	BRING YOU UP TO DATE ON WHAT WE'VE BEEN DOING IN THE
3	INTELLECTUAL PROPERTY ARENA. BEFORE I START THAT
4	DISCUSSION, I WOULD LIKE TO ADD A COMMENT TO THE QUESTION
5	YOU ASKED EARLIER ABOUT THE PROGRESS OF THIS WHOLE
6	ENTERPRISE WITHIN THE STATE.
7	I THINK ONE OF THE IMPORTANT DISTINCTIONS THAT
8	WE HAVE HERE IS THAT OUR ACTIONS NOW ARE GUIDED BY A
9	STRATEGIC PLAN, WHICH IS VERY COMPREHENSIVE. IT INCLUDES
10	THE ROLE OF BASIC RESEARCH, OF TRAINING, OF FACILITIES,
11	OF THE TRANSLATIONAL MEDICINE, ETC., AND IT'S TRULY
12	UNUSUAL.
13	MOST FEDERAL FUNDING COMES FROM AGENCIES WHICH
14	SUPPORT GOOD RESEARCH, BUT DON'T REALLY HAVE AN OVERALL
15	STRATEGIC PLAN THAT THEY FOLLOW. I THINK ONE OF THE
16	IMPORTANT DISTINCTIONS OF CIRM IS THAT THERE IS A
17	WELL-DEVELOPED STRATEGIC PLAN THAT FORMS THE BASIS FOR
18	OUR PROGRAMS. SO WHEN WE PUT OUT RFA'S FOR TRAINING, AN
19	RFA FOR DEVELOPING NEW CELL LINES, THEY'RE ALL PART OF AN
20	OVERALL STRATEGY GOING FORWARD. I THINK THAT'S A VERY
21	IMPORTANT DISTINCTION THAT WILL BE VERY IMPORTANT TO THE
22	STATE GOING FORWARD.
23	SO I AM HERE TO ONE OTHER COMMENT. BOB SAID
24	WE GET PEOPLE FROM HARVARD WHO ARE THE BEST IN THE FIELD.
25	I THINK OUR CALIFORNIA COLLEAGUES WOULD BE RELUCTANT TO

1	AGREE THAT THE BEST STEM CELL RESEARCHERS ARE AT HARVARD.
2	SO, BOB, EXCUSE ME FOR CORRECTING YOU, BUT WE HAVE THE
3	BEST STEM CELL RESEARCHERS IN CALIFORNIA.
4	CHAIRMAN CHIANG: I'M PARTIAL TO CALIFORNIA.
5	DR. PENHOET: SO THANK YOU, JOHN SIMPSON, FOR
6	YOUR COMMENTS ABOUT THIS PROCESS. FIRST OF ALL, JUST TO
7	BRING YOU UP TO DATE ON WHAT WE HAVE DONE TO DEVELOP THE
8	POLICIES WE NOW HAVE LARGELY IN PLACE. FIRST OF ALL, IT
9	HAS BEEN A VERY BROADBASED AND THOROUGH DISCUSSION WITH
10	MANY DIFFERENT CONSTITUENCIES. I THINK, AS YOU HAVE BEEN
11	INFORMED IN THE PAST, OUR INTELLECTUAL PROPERTY POLICIES
12	ACTUALLY HAVE NO PRECEDENT ANYWHERE IN THE COUNTRY
13	BECAUSE THE FEDERAL GOVERNMENT DOES NOT ASK FOR A RETURN
14	TO THE GOVERNMENT FOR ANY OF ITS INVESTMENTS IN SCIENCE,
15	BASIC OR OTHERWISE.
16	IN THIS CASE PROP 71 SPECIFIED THAT THERE WOULD
17	BE A RETURN TO THE STATE. AND IN ADDITION TO THAT, WHILE
18	WE TOOK ON THE NARROW ISSUE OF RETURN TO THE STATE, WE
19	ALSO WITHIN THE INTELLECTUAL PROPERTY POLICIES ADDRESSED
20	MANY OF THE ISSUES ASSOCIATED WITH ACCESS, WITH MARCH-IN
21	RIGHTS, AND A VARIETY OF OTHER THINGS THAT YOU WILL SEE.
22	SO WE ENGAGED STAKEHOLDERS THE INDUSTRY, FROM
23	THE CONCERNED CITIZENS GROUPS, FROM THE INSTITUTIONS
24	DIRECTLY AFFECTED, AND THE NONPROFIT WORLD, ETC. WE HAVE
25	HAD, AS IT SAYS HERE, 15 PUBLIC MEETINGS OVER THE LAST
	ba ha

1	TWO AND A HALF YEARS SEEKING INPUT AND, FRANKLY, SOME
2	CONSENSUS ON THIS ISSUE. I CAN TELL YOU TODAY WE HAVE AN
3	UNUSUAL CONSENSUS IN THE SENSE THAT THERE'S PROBABLY NO
4	ONE IN THE STATE WHO IS HAPPY WITH THESE POLICIES BECAUSE
5	THEY DON'T GO FAR ENOUGH IN ANY DIRECTION TO MAKE ANY OF
6	THESE CONSTITUENCIES TOTALLY HAPPY, BUT I DO BELIEVE WE
7	HAVE REACHED A MIDDLE GROUND WHICH WILL BE EFFECTIVE AND
8	WHICH WILL ALLOW US TO PROCEED IN A GOOD WAY GOING
9	FORWARD.
10	BECAUSE THERE IS REALLY NO PRECEDENT FOR THIS
11	ANYWHERE, WE DID A LOT OF HOMEWORK. IN ADDITION TO THE
12	PUBLIC MEETINGS, WE'VE SURVEYED BEST PRACTICES OF FUNDING
13	AGENCIES THROUGHOUT THE WORLD, BOTH GOVERNMENTAL AND
14	INCREASINGLY FOUNDATIONS WHO ARE PLAYING AN IMPORTANT
15	ROLE IN THIS FUNDING OF SCIENCE GOING FORWARD. WE
16	INTERVIEWED MORE THAN A HUNDRED DIFFERENT PEOPLE,
17	ASSEMBLED A VERY SUBSTANTIAL BODY OF INFORMATION ABOUT
18	WHAT OTHER ORGANIZATIONS ARE DOING AND WHAT THE PLUSES
19	AND MINUSES OF THEIR APPROACH HAVE BEEN. SO IT'S BEEN A
20	VERY COMPREHENSIVE EFFORT.
21	IF I CAN HAVE THE NEXT SLIDE, SCOTT. WE HAVE
22	DEVELOPED AT THIS POINT TWO DIFFERENT POLICIES, ONE FOR
23	NONPROFIT ORGANIZATIONS AND ONE FOR FOR-PROFIT. BECAUSE
24	MANY OF THE FIRST GRANTS WERE ESSENTIALLY DESIGNED FOR
25	NONPROFIT AGENCIES, TRAINING GRANTS, ETC., WE TACKLED

- 1 THAT PROBLEM FIRST. THE POLICY WAS APPROVED IN FEBRUARY
- 2 OF '06. THE REGULATIONS WERE ADOPTED IN DECEMBER OF '06.
- 3 AND THE OAL APPROVED THESE EFFECTIVE JULY 2007. SO THE
- 4 POLICY FOR NONPROFITS HAS GONE THROUGH THE ENTIRE PROCESS
- 5 AND HAS BECOME EFFECTIVE AND IS CURRENTLY STATE LAW,
- 6 WHICH, FRANKLY, IS QUITE DIFFERENT THAN ANY OTHER FEDERAL
- 7 AGENCY, FOR EXAMPLE, WHERE THE POLICIES OF NIH ARE NIH
- 8 POLICIES, BUT THEY DON'T CARRY THE FULL FORCE OF LAW.
- 9 THESE REGULATIONS ARE LEGAL REQUIREMENTS UPON OUR
- 10 GRANTEES.
- 11 WE'VE ENGAGED IN PARALLEL IN SOME AREAS IN
- 12 SEQUENCE IN OTHER AREAS DEVELOPING A POLICY FOR WHEN WE
- 13 MAKE GRANTS TO PROFIT-MAKING ORGANIZATIONS. IN THE CASE
- 14 OF THE BIOTECH INDUSTRY, MANY OF THEM ARE HOPEFULLY
- 15 PROFIT-MAKING ORGANIZATIONS SOME DAY, BUT THEIR GOAL IS
- 16 TO BE A PROFIT-MAKING ORGANIZATION.
- 17 THIS POLICY WAS APPROVED LAST DECEMBER.
- 18 REGULATIONS HAVE BEEN DRAFTED. WE'VE HAD SEVERAL
- 19 DIFFERENT PUBLIC COMMENT PERIODS, AND WE HOPE TO ADOPT
- THESE AT OUR DECEMBER BOARD MEETING THE WEEK AFTER NEXT
- 21 AND ACHIEVE OAL APPROVAL IN THE SPRING OF '08. SO ONE OF
- 22 YOUR DIRECTIONS TO US AS A GROUP IN THE LAST MEETING WAS
- 23 THAT WE GET ON WITH THE FOR-PROFIT PIECE, AND WE'RE
- 24 PLEASED TO BE ABLE TO TELL YOU I THINK WE'RE VIRTUALLY AT
- THE END OF THAT PROCESS WITH A LOT OF HELP FROM SCOTT

1	TOCHER, WHO IS HERE BY MY SIDE, AND FROM MY DEPUTY MARY
2	MAXON ON THE CIRM WHO'S DONE A LOT OF WORK ON THIS
3	SUBJECT.
4	LET ME JUST REVIEW FOR YOU COMMON ELEMENTS
5	BETWEEN THE TWO POLICIES. WHETHER IT'S FOR-PROFIT OR
6	NONPROFIT, THERE ARE MANY ELEMENTS IN COMMON BETWEEN THE
7	TWO. ONE IS SHARING OF INFORMATION. THIS WAS EXTREMELY
8	IMPORTANT. WE HAD MANY DISCUSSIONS ABOUT THIS. WE WANT
9	AS MUCH SHARING OF INFORMATION, FIRST OF ALL, FOR ITS
10	TRANSPARENCY ON WHAT'S GOING ON WITH THE FUNDING, BUT
11	ESPECIALLY TO FACILITATE THE WORK OF OTHERS BECAUSE
12	SCIENCE IS BUILT ON THE SHOULDERS OF PEOPLE WHO DID
13	SCIENCE BEFORE. NEW SCIENCE IS BUILT ON OLD SCIENCE.
14	AND THE BEST NEW SCIENCE TAKES ADVANTAGE OF WHAT'S BEEN
15	LEARNED BY OTHERS. SO WE WANTED TO MAKE SURE THAT OUR
16	GRANTEES SHARED INFORMATION AND MATERIALS WITH OTHER
17	SCIENTISTS TO EMPOWER THEIR WORK.
18	SO WE HAVE ELEMENTS IN OUR POLICY THAT DEAL
19	WITH PUBLICATION, WITH BIOMEDICAL MATERIALS WHICH HAVE
20	BEEN PUBLISHED, AND IN THE CASE OF WHEN PEOPLE HAVE
21	SPECIFICALLY TAILORED STRATEGIES, THAT THE LICENSE
22	RIGHTS, ETC., AND THE LICENSEES ARE BOUND BY THE SAME
23	REQUIREMENTS AS OUR GRANTEES ARE BOUND BY. SO THERE'S A
24	LOT OF ELEMENTS OF OUR POLICY OBVIOUSLY I DON'T HAVE
25	TIME TO TAKE YOU THROUGH. IT'S A VERY LONG DOCUMENT
	58

1	HERE, BUT THESE ARE CRITICAL ELEMENTS WITH RESPECT TO
2	SHARING OF INFORMATION.
3	BY THE WAY, I MIGHT ADD THAT WHEN PEOPLE FILE
4	PATENTS, THE PATENTS BECOME PUBLISHED IN DIFFERENT
5	ENVIRONMENTS, BUT IN 12 TO 18 MONTHS AFTER THE PATENTS
6	ARE AWARDED, SO A PATENT IS A PUBLICATION AT THE END OF
7	THE DAY.
8	WE HAVE SPENT A LOT OF TIME ON THE WHOLE ACCESS
9	ISSUE. I KNOW IT'S VERY IMPORTANT TO THE LEGISLATURE IN
10	CALIFORNIA. WE HAVE TRIED TO BALANCE THE INTERESTS OF
11	VARIOUS DIFFERENT PARTIES HERE. FIRST OF ALL, WE DO HAVE
12	AN ELEMENT OF OUR POLICY WHICH DEMANDS THAT LICENSEES
13	MUST PROVIDE COMMERCIAL PRODUCTS TO UNINSURED
14	CALIFORNIANS. THERE'S A LOT OF DEBATE ABOUT HOW TO DO
15	THIS, AND WE HAVE COME DOWN ON THE SIDE OF SAYING THAT IF
16	COMPANIES DEVELOP PRODUCTS WITH CIRM FUNDING, THAT THOSE
17	PRODUCTS HAVE TO BE AVAILABLE IN ACCESS PROGRAMS WHICH
18	ARE STANDARD IN THE INDUSTRY AT THE TIME THAT THOSE
19	PRODUCTS BECOME COMMERCIAL. AND MOST BIOTECH COMPANIES
20	AND MOST PHARMA COMPANIES HAVE SUCH PROGRAMS. GENENTECH
21	HAS HAD A VERY GOOD ONE FOR MANY YEARS TO TREAT PEOPLE
22	WHO CAN'T AFFORD THE NORMAL PRICE FOR DRUGS FOR ONE
23	REASON OR ANOTHER, BUT LACK OF INSURANCE IS THE PRIMARY
24	REASON.
25	THAT SAID, THE LICENSEES OF OUR TECHNOLOGY WILL

1	HAVE TO PROVIDE ACCESS AS WILL PEOPLE WHO SELF-DEVELOP
2	THEIR OWN PRODUCTS IN CALIFORNIA. ONE OF THE UNDERLYING
3	FACTORS IN DEVELOPING A FOR-PROFIT POLICY IS WE WANTED TO
4	ACTUALLY BUILD IN SOME INCENTIVES FOR CALIFORNIA
5	COMPANIES TO DEVELOP THE PRODUCTS AND SELL THEM
6	THEMSELVES RATHER THAN LICENSE THEIR TECHNOLOGY TO THIRD
7	PARTIES OUTSIDE THE STATE. SO YOU WILL SEE OTHER ASPECTS
8	OF THAT ARE GOING FORWARD, BUT WHETHER A PARTY IS A
9	LICENSEE OF A CALIFORNIA INVENTION OR COMMERCIALIZES IT
10	THEMSELVES, THEY HAVE THE SAME OBLIGATION TO PROVIDE
11	THOSE MATERIALS TO UNINSURED CALIFORNIANS.
12	WE HAVE A PROGRAM IN PLACE THAT PROVIDES FOR
13	DISCOUNTED PRICING TO ALL PUBLICLY FUNDED PURCHASERS.
14	THIS TURNED OUT TO BE A VERY DIFFICULT ASPECT OF THIS.
1.5	WE CURRENTLY ARE PEGGING THIS PROGRAM TO THE OPERATION OF
16	CALRX, WHICH HAS BEEN PASSED, BUT NOT FUNDED, AS YOU
17	KNOW. WE LOOKED AT MANY ALTERNATIVES FOR PROVIDING LOW
18	PRICES FOR PUBLICLY FUNDED PURCHASES, AND THIS WE THINK
19	IS THE BEST SOLUTION GOING FORWARD. HOWEVER, I HAVE TO
20	TELL YOU IF CALRX NEVER COMES INTO BEING, WE WILL HAVE TO
21	MODIFY THIS POLICY SOMEDAY WHEN THESE PRODUCTS COME TO
22	MARKET.
23	AND THEN FINALLY, WE HAD A LOT OF DEBATE ABOUT
24	WHAT LEVEL OF FUNDING WOULD TRIGGER THESE OBLIGATIONS TO

PROVIDE ACCESS. AND WE DECIDED THAT THE FIRST DOLLAR IN.

25

1	IF ANY ORGANIZATION TAKES A SINGLE DOLLAR OF CIRM
2	FUNDING, THAT THEY'RE SO-CALLED IN FOR A PENNY, IN FOR A
3	POUND, THEY HAVE TO ESSENTIALLY ABIDE BY THESE ACCESS
4	REGULATIONS IRRESPECTIVE OF THE AMOUNT OF FUNDING WHICH
5	CAME FROM CIRM.
6	WE DO HAVE MARCH-IN RIGHTS TO ENSURE THAT THE
7	INVENTIONS ACTUALLY GET UTILIZED. WE CAN ENFORCE
8	COMPLIANCE WITH AN ACCESS PLAN. WE CAN ENFORCE PUBLIC
9	USE REQUIREMENTS AND DISCOUNT PROVISIONS, AND WE CAN
10	ALLEVIATE PUBLIC HEALTH EMERGENCY NEEDS IF THEY'RE
11	DECLARED BY THE GOVERNOR. I DON'T BELIEVE THAT'S EVER
12	BEEN DONE IN THE STATE OF CALIFORNIA, BUT THAT IS A
13	FEATURE HERE WHICH WE CAN COUNT ON IF NEED BE.
14	JUST TO GIVE YOU SOME SENSE OF THE MAJOR
15	DIFFERENCES BETWEEN THE FOR-PROFIT COMMUNITY AND THE
16	NONPROFIT IN TERMS OF WHAT WILL EVENTUALLY LEAD TO
17	REVENUES FOR THE STATE AND THE DIRECT REPAYMENT TO THE
18	STATE SHOWN ON THIS SLIDE. SO IF YOU LOOK AT THE
19	RIGHT-HAND SIDE OF YOUR SCREEN, YOU SEE IN THE CASE
20	WHEN WE FUND A NONPROFIT, THEY CARRY OUT PRIMARILY BASIC
21	SCIENCE OR APPLIED SCIENCE TO SOME DEGREE, BUT THEY HAVE
22	NO ABILITY THEMSELVES TO COMMERCIALIZE PRODUCTS. IN
23	ORDER FOR ANY DISCOVERY MADE BY A NONPROFIT TO REACH THE
24	MARKETPLACE, THEY HAVE TO LICENSE THEIR TECHNOLOGY TO A
25	COMPANY OF ONE SORT OR ANOTHER WHO WILL USE THAT

1	TECHNOLOGY AS THE BASIS FOR A PRODUCT OR A PRODUCT LINE.
2	SO IN THIS CASE THE ONLY POSSIBILITY FOR
3	REMUNERATION TO THE INVENTOR IN A GIVEN NONPROFIT
4	ORGANIZATION WOULD BE AS A RESULT OF ROYALTIES OR OTHER
5	FORMS OF PAYMENT THAT ARE ASSOCIATED WITH A LICENSE TO A
6	COMMERCIAL ENTERPRISE BECAUSE THEY HAVE NO ABILITY TO
7	COMMERCIALIZE IT THEMSELVES. THAT'S DIFFERENT IN THE
8	CASE OF A FOR-PROFIT ENTITY, AS YOU CAN SEE ON THE
9	LEFT-HAND SIDE OF THE SLIDE. BASIC SCIENCE IS DONE IN A
10	FOR-PROFIT ORGANIZATION, QUITE GOOD BASIC SCIENCE
11	OFTENTIMES. IF IT LEADS TO INVENTIONS, THE COMPANY HAS
12	THE SAME ABILITY TO LICENSE THAT TECHNOLOGY TO A THIRD
13	PARTY AS A NONPROFIT DOES, AND THAT FREQUENTLY DOES
14	HAPPEN FOR A VARIETY OF DIFFERENT REASONS, EITHER THE
15	COMPANY CAN'T AFFORD THE LARGE PHASE 3 CLINICAL TRIALS
16	REQUIRED TO COMMERCIALIZE THE PRODUCT OR IT DOESN'T FIT
17	WITH THEIR PRODUCT LINE. FOR ONE REASON OR ANOTHER,
18	COMPANIES WILL LICENSE THEIR TECHNOLOGY TO THIRD PARTIES.
19	HOWEVER, AND INCREASINGLY SO AS THE BIOTECH
20	INDUSTRY MATURES, THE COMPANIES ACTUALLY TAKE THIS
21	INVENTION, TURN IT INTO A PRODUCT, DO PRECLINICAL WORK
22	PRODUCT DEVELOPMENT, AND EVENTUALLY MARKET THE PRODUCT
23	THEMSELVES. CALIFORNIA HAS BEEN FORTUNATE TO HAVE A
24	NUMBER OF VERY FINE BIOTECHNOLOGY COMPANIES THAT HAVE
25	GONE THROUGH THIS ENTIRE PROCESS AND ARE TODAY FULLY WHAT

1	WE'VE CALLED A FULLY INTEGRATED COMPANY, DOING EVERYTHING
2	FROM RESEARCH THROUGH DEVELOPMENT TO MARKETING.
3	GENENTECH IS THE PREMIERE EXAMPLE OF THAT. AMGEN,
4	CHIRON, A NUMBER OF COMPANIES IN CALIFORNIA NOW
5	SUCCESSFULLY HAVE TRAVERSED THIS ENTIRE PATHWAY AND
6	BECOME ROBUST COMMERCIAL ENTERPRISES.
7	WE THINK IT'S IMPORTANT THAT WE ENCOURAGE
8	COMPANIES TO ACTUALLY CARRY THESE ACTIVITIES OUT IN
9	CALIFORNIA RATHER THAN LICENSE THEIR TECHNOLOGY BECAUSE A
10	LOT OF THE ECONOMIC ACTIVITY ASSOCIATED WITH THE BUSINESS
11	IS ACTUALLY CONTAINED IN THE BOXES THAT ARE BELOW THE
12	BLUE CIRCLE IN THE MIDDLE HERE, THE PRECLINICAL WORK,
13	PRODUCT DEVELOPMENT, AND OBVIOUSLY MARKETING AND
14	MANUFACTURING IS ANOTHER KEY ISSUE.
15	SO AS WE THOUGHT ABOUT THE WHOLE PROCESS FOR
16	THE FOR-PROFIT POLICY, WE WANTED TO BUILD SOME INCENTIVE,
17	AND WE COULDN'T DO IT IN AN OVERLY GENEROUS WAY, BUT SOME
18	INCENTIVES, AT LEAST, FOR COMPANIES TO FORWARD INTEGRATE
19	THEMSELVES AND BECOME ROBUST, FULLY INTEGRATED COMPANIES
20	HOPEFULLY IN CALIFORNIA.
21	SO HOW ABOUT THE RETURN TO THE STATE? THIS IS
22	THE OTHER BIG ISSUE WITH RESPECT TO THE ECONOMICS IS HOW
23	THE STATE WILL BENEFIT IN A DIRECT WAY FROM THE INVENTION

63

WORLD. SO IN THIS CASE OF NONPROFITS, AS I SAID BEFORE,

OF TECHNOLOGY AND ITS APPLICATION IN THE COMMERCIAL

24

25

- 1 THEY HAVE ONLY ONE WAY TO GET REVENUE. THAT'S TO LICENSE
- THEIR TECHNOLOGY TO A COMPANY, HOPEFULLY HAVE THAT
- 3 COMPANY SUCCESSFULLY DEVELOP THE TECHNOLOGY, AND AT THAT
- 4 POINT RECEIVE ROYALTIES ON THE SALES OF PRODUCTS. AND
- 5 WHEN THEY DO, WE WILL ASK THEM TO SHARE WITH US 25
- 6 PERCENT OF THEIR NET REVENUES FROM THOSE ROYALTY-BEARING
- 7 AGREEMENTS THAT THEY HAVE WITH COMPANIES. SO 25 PERCENT
- 8 GOES TO THE STATE, 75 PERCENT IS RETAINED BY THE INVENTOR
- 9 ORGANIZATION.
- 10 WE ALSO REQUIRE AGAIN, AS I SAID BEFORE, THAT
- 11 THEY SHARE PUBLICATION-RELATED BIOMEDICAL MATERIALS. IN
- 12 THIS CASE WITH A NONPROFIT, AS I SAID, NO
- 13 SELF-DEVELOPMENT IS ANTICIPATED. IT COULD OCCUR ON A
- 14 RARE BASIS. A LOT OF BONE MARROW TRANSPLANTS, WHICH IS
- 15 STEM CELL TRANSPLANT, BY THE WAY, GOES ON WHOLLY WITHIN
- 16 SOME MEDICAL CENTERS THAT SPECIALIZE IN THAT TECHNOLOGY.
- 17 BUT FOR THE MOST PART, STEM CELL THERAPIES WILL BE
- 18 DEVELOPED IN THE COMPANY ENVIRONMENT, NOT IN THE
- 19 NONPROFIT ENVIRONMENT.
- IN THE CASE OF THE FOR-PROFIT, THE LICENSE, IF
- 21 A FOR-PROFIT ENTITY DECIDES TO LICENSE TECHNOLOGY TO A
- 22 THIRD PARTY --
- MR. BRUNNER: COULD I ASK A QUESTION ON THE
- 24 NONPROFIT? INVENTORS ARE THE INDIVIDUAL SCIENTISTS?
- DR. PENHOET: YES.

1	MR. BRUNNER: NOT THE ORGANIZATION?
2	DR. PENHOET: YES. THANK YOU FOR ASKING.
3	THAT'S A CLARIFICATION. INVENTORS ARE THE INDIVIDUAL
4	SCIENTISTS WHO INVENT SOMETHING. TYPICALLY IN MOST
5	CALIFORNIA NONPROFITS THE LICENSE TO THE TECHNOLOGY IS
6	MADE BY THE INSTITUTION, BUT THEY HAVE A POLICY WHICH
7	SAYS THEY WOULD SHARE LICENSING REVENUES WITH THE ACTUAL
8	INVENTORS WHO ARE THE, IN SOME CASES, FACULTY GRADUATE
9	STUDENTS, POST DOCS, AND TYPICALLY THAT'S ABOUT A THIRD
10	OF THE REVENUES GO TO THE INVENTORS THEMSELVES. SO THEY
11	GET A SHARE OF THE INVENTION REVENUE STREAM. IN THIS
12	CASE WE GET 25 PERCENT OF THE REVENUES WHICH ARE NOT
13	GIVEN TO THE INVENTORS THEMSELVES, BUT IT IS THE
14	INDIVIDUAL INVENTOR.
15	MR. BRUNNER: I THINK YOU MAY HAVE ANSWERED THE
16	SECOND PART OF MY QUESTION, AND THAT IS THE ORGANIZATION
17	THAT HAS MADE THE APPLICATION ALSO GETS PART OF THE
18	REVENUE OUT OF THIS; FOR INSTANCE, UC SAN FRANCISCO.
19	DR. PENHOET: A GOOD EXAMPLE. THEY BENEFIT THE
20	MOST ACTUALLY FROM BIOTECH INVENTIONS, SO THERE IS A
21	CLEAR HISTORY THERE. I'LL GIVE YOU A SPECIFIC EXAMPLE.
22	THE HEPATITIS B VACCINE, WHICH IS BROADLY USED, WAS
23	INVENTED AT UC SAN FRANCISCO AND LICENSED EVENTUALLY TO
24	MERCK. IF MERCK PAYS UC SAN FRANCISCO A DOLLAR, UC SAN
25	FRANCISCO, AND IT HAD BEEN FUNDED BY CIRM, IT WAS NOT, OF

- 1 COURSE, IF IT HAD BEEN FUNDED BY CIRM AND MERCK PAID UCSF
- 2 A DOLLAR, UCSF WOULD PAY THE INVENTORS 35 CENTS, LET'S
- 3 SAY, WHICH WOULD BE THEIR FACULTY MEMBERS. THEY WOULD
- 4 HAVE 65 CENTS LEFT. THEY WOULD SEND 25 PERCENT OF THE 65
- 5 CENTS TO US AFTER PAYING THE INVENTORS.
- 6 MR. BRUNNER: THANK YOU.
- 7 DR. PENHOET: SO WE WOULD GET A QUARTER OF
- 8 THAT, WHICH IS 16 CENTS, I GUESS.
- 9 BUT IN THE CASE OF THE FOR-PROFIT ENTITIES, IF
- 10 THEY LICENSE TO THIRD PARTIES, THEY HAVE THE SAME
- 11 REQUIREMENT TO GIVE 25 PERCENT OF WHATEVER THEY GET, BUT
- 12 IN THEIR CASE THEY ACTUALLY DON'T PAY INVENTORS GENERALLY
- 13 WITHIN THEIR COMPANIES, BUT THEY'VE HAD TO PAY FOR ALL
- 14 THE EXPENSES OF THE INVENTORS, INCLUDING THEIR SALARIES,
- 15 ETC., GOING FORWARD. THEY'RE REQUIRED TO SHARE THEIR
- 16 PUBLICATION-RELATED MATERIALS. AND WE HAVE A DIFFERENT
- 17 FORMULA NOW IF THEY SELF-DEVELOP RATHER THAN LICENSE OUT,
- 18 AND THAT'S PROBABLY THE MOST IMPORTANT UNIQUE PART OF THE
- 19 REQUIREMENTS FOR THE FOR-PROFIT COMPANIES IS THE
- 20 DIFFERENCE IN HOW THEY PAY US.
- SO FIRST OF ALL, THEY HAVE A FINITE RETURN OR A
- 22 CAP RETURN. AND AT THE TIME OF THE CREATION OF REVENUES,
- THEY WILL PAY US BACK THREE TIMES AS MUCH MONEY AS WE PUT
- 24 INTO THEIR PROJECT, WHATEVER IT IS. IF THEY TOOK \$1,
- THEY'RE STILL REQUIRED TO MEET ALL THE ACCESS

1	REQUIREMENTS,	THE	SHARING	REQUIREMENTS,	AND	ALL	THE	OTHER
---	---------------	-----	---------	---------------	-----	-----	-----	-------

- 2 THINGS I SPOKE OF; BUT IF THEY COMMERCIALIZE SOMETHING,
- 3 THEY HAVE A TOTAL EXPOSURE TO US OF THREE TIMES MORE
- 4 MONEY THAN THEY TOOK FROM US IN THE FIRST PLACE. IF IT
- 5 BECOMES A VERY SUCCESSFUL PRODUCT, THEY WILL PAY US THREE
- 6 TIMES AGAIN IF THEY REACH \$250 MILLION IN SALES IN A
- 7 GIVEN YEAR. AND IF IT BECOMES A VERY SUCCESSFUL PRODUCT,
- 8 AND IT REACHES \$500 MILLION A YEAR, THEY WILL PAY ANOTHER
- 9 THREE TIMES, AND OVER \$500 MILLION PAY A 1-PERCENT
- 10 ROYALTY IF IT'S COVERED BY A PATENT.
- 11 SO IF IT BECOMES A \$500 MILLION PRODUCT, WE
- 12 WILL GET NINE TIMES OUR MONEY BACK PLUS 1 PERCENT OF
- 13 EXCESS OVER \$500 MILLION FROM THE COMPANY.
- MS. POTTER: IS THIS CONSTANT DOLLARS, THIS 250
- 15 MILLION, THE 500 MILLION, IS THAT IN CURRENT DOLLARS?
- DR. PENHOET: THAT'S IN CURRENT DOLLARS.
- MS. POTTER: OKAY.
- DR. PENHOET: SO WE DON'T HAVE AN INFLATIONARY
- 19 FACTOR BUILT IN, MS. POTTER. YOU KNOW, IF WE HAVE A
- 20 HIGHLY INFLATIONARY PERIOD, I ASSUME THAT WE MIGHT HAVE
- 21 TO GO BACK AND READJUST THESE NUMBERS, BUT THOSE ARE THE
- 22 NUMBERS THAT WE HAVE AT THE PRESENT TIME.
- AND THEN IF I COULD HAVE THE NEXT SLIDE, SCOTT.
- 24 THIS JUST GIVES YOU A PICTORIAL REPRESENTATION OF THE
- 25 WORDS I JUST SPOKE TO YOU. IF IT'S COMMERCIALIZED AND

1	BLOCKBUSTER STATUS IS ACHIEVED, IF YOU GO DOWN TO THE
2	LEFT-HAND SIDE, IT GIVES THE FLOW CHART FOR IF WE
3	INVESTED LESS THAN \$5 MILLION IN THE INVENTION, THEN IT'S
4	WHAT I JUST TOLD YOU. IF WE HAVE INVESTED, CIRM HAS
5	INVESTED MORE THAN FIVE MILLION AND THERE'S NO PATENT,
6	THEN IT GOES TO THE LOWER LEFT-HAND BOX. IF THERE IS A
7	PATENT INVOLVED, THEN IT GOES TO THE RIGHT-HAND BOX, AS
8	YOU CAN SEE HERE.
9	SO IT'S A LITTLE BIT OF A COMPLICATED SCHEME
10	THAT I THINK ADDRESSES THE MAJOR CONCERNS THAT WE HEARD
11	FROM BOTH SIDES IN THIS THING. I THINK THE MOST
12	IMPORTANT THING TO REALIZE IS THAT INDUSTRY, ONE OF THEIR
13	MOST IMPORTANT POINTS WAS THEY REALLY NEED TO KNOW WHAT
14	THEIR TOTAL EXPOSURE WOULD BE BECAUSE WE STILL EXPECT
15	THAT THEIR PRIMARY SOURCES OF FUNDING WON'T BE US. IT
16	WILL BE THE VENTURE CAPITAL COMMUNITY, ETC., AND THEY
17	NEED SOME ASSURANCE ABOUT WHAT THEIR TOTAL EXPOSURE WOULD
18	BE TO GO FORWARD. AND THEY HAVE THE OPTION TO CHOOSE, BY
19	THE WAY, WHETHER THEY LICENSE IT OR WHETHER THEY
20	COMMERCIALIZE THE PRODUCTS THEMSELVES.
21	SO WE'VE ESSENTIALLY, AS I SAID, JUST TO
22	REVIEW, WE HAVE A GROUP OF POLICIES WHICH ARE COMMON FOR
23	THE FOR-PROFIT AND NOT-FOR-PROFIT. THEY HAVE TO DO WITH
24	ACCESS, WITH SHARING BIOMEDICAL MATERIALS, WITH PRICING
25	FOR GOVERNMENTAL AGENCIES, ETC. THOSE ARE COMMON TO BOTH

1	POLICIES. THE PRIMARY DIFFERENCE IS IN THE CASE OF
2	FOR-PROFIT ENTITIES, WE HAVE THIS SCHEME THAT'S IN FRONT
3	OF YOU HERE. AND THAT'S WHAT WE HAVE ENDED UP WITH AFTER
4	A LOT OF DISCUSSION WITH MANY DIFFERENT GROUPS.
5	I THINK IT DOES REPRESENT A REASONABLE
6	COMPROMISE BETWEEN THE GOALS OF VARIOUS DIFFERENT GROUPS
7	INVOLVED, ALTHOUGH, AS I SAID BEFORE, WE DON'T HAVE
8	ANYBODY TOTALLY HAPPY WITH IT AT THE MOMENT. I THINK
9	MOST PEOPLE ACCEPT IT AS A REASONABLE COMPROMISE. IT'S
10	QUITE DIFFERENT THAN ANYTHING THAT'S BEEN DONE BEFORE.
11	THE FEDERAL GOVERNMENT STILL DOESN'T REQUIRE ANY DIRECT
12	RETURN, BUT I THINK PEOPLE ACCEPT THIS AS A FAIR BARGAIN.
13	IF THEY'RE GOING TO GET THEIR WORK FUNDED BY THE STATE OF
14	CALIFORNIA, THEN A DIRECT RETURN TO THE STATE IS
15	REASONABLE AND, FRANKLY, WAS CALLED FOR IN PROP 71.
16	BE HAPPY TO ANSWER ANY OTHER QUESTIONS YOU
17	HAVE.
18	CHAIRMAN CHIANG: THANK YOU. ANY QUESTIONS.
19	MS. POTTER: I JUST HAVE A COUPLE OF COMMENTS,
20	AND IT TOUCHES ON THE BENEFIT THAT MAY BE SLIGHTLY
21	UNDERESTIMATED. AND WHERE IS BOB? BOB HAD MENTIONED
22	THAT EARLIER IN HIS COMMENTS. BUT ONE OF THE THINGS THAT
23	HIT ME AS YOU WERE GOING THROUGH YOUR PRESENTATION, THE
24	ANALYSIS OF NOT ONLY THE ROYALTY STREAM THAT WILL BE
25	COMING TO THE STATE, BUT THE TECHNOLOGY BENEFIT TO PUBLIC

1	UNIVERSITIES, NONPROFIT UNIVERSITIES, COULD BE RATHER
2	SUBSTANTIAL. AND I DON'T KNOW IF THAT WAS CAPTURED IN
3	THE ANALYSIS THAT BOB WALKED THROUGH.
4	I THINK THERE'S ONE OTHER PIECE AS WELL, AND
5	THAT IS THAT, AND MY MEMORY MAY BE A LITTLE FUZZY BECAUSE
6	IT'S BEEN A LONG TIME SINCE I'VE WORKED WITH MEDICAID
7	LEGISLATION AND PRICING, BUT THE REQUIREMENT FOR THE
8	COMPANIES TO SET THESE PRODUCTS AT A CERTAIN PRICE LEVEL
9	FOR THE STATE OF CALIFORNIA WILL BY DEFINITION PROVIDE
10	BENEFIT TO THE FEDERAL GOVERNMENT BECAUSE I THINK THE LAW
11	STILL REQUIRES THAT THE FEDERAL GOVERNMENT BE GRANTED
12	BEST PRICING OR AT LEAST PRICING THAT DOESN'T EXCEED
13	WHAT'S OFFERED TO STATES. IT MAY HAVE CHANGED A LITTLE
14	BIT, BUT THAT IS A HUGE, HUGE BENEFIT THAT I HAVEN'T
15	HEARD TALKED ABOUT.
16	DR. PENHOET: YOU ARE RIGHT ABOUT THAT. AND WE
17	HAD TO BE VERY CAREFUL IN CONSTRUCTING THIS. AND ONE OF
18	THE REASONS WE ENDED UP WITH CALRX AS THE GUIDELINE FOR
19	WHAT WE DO IS THAT IN ORDER TO ACTUALLY OPERATE IN A
20	FEDERAL SYSTEM AT THE MOMENT TO ENSURE LOWEST PRICES FOR
21	FEDERALLY ACCESSED DRUGS AND OTHER THERAPIES, YOU HAVE TO
22	HAVE IT. IT'S AN ENORMOUSLY COMPLEX SYSTEM OF REBATE,
23	AND YOU'VE DEALT WITH THIS ONE IN YOUR LIFE AT GENENTECH,
24	OF REBATES AND A BASKET OF PRODUCTS, ETC. AND IT TURNED
25	OUT IT WAS UNWORKABLE FOR US SIMPLY TO USE THE MEDICAID

1 BEST PRICE FROM THE FEDERAL STATUES BECAUSE WE WOULD HAVE 2 HAD TO PUT A WHOLE VERY COMPLICATED SYSTEM IN PLACE IN 3 ORDER TO MEASURE WHAT THAT WAS. WE'VE TRIED TO COME UP 4 WITH THE BEST SURROGATE WHILE NOT TRIPPING A TOTALLY 5 DESTRUCTIVE BEST PRICE 6 MS. POTTER: EXACTLY. 7 DR. PENHOET: AS YOU CAN IMAGINE. AS A 8 PRACTICAL MATTER, IF TOO MANY PEOPLE HAVE MOST FAVORED 9 NATION CLAUSES IN THEIR AGREEMENTS, AND EACH ONE AGREES 10 TO A BETTER PRICE, AND PRETTY SOON THE PRICE BECOMES 11 ZERO, AND SO WE WANTED TO BE CAREFUL NOT TO TRIP THAT 12 SORT OF DESTRUCTIVE PRICING SPIRALING DOWN TO NO PRICE. 13 BUT IF CALRX NEVER BECOMES IMPLEMENTED, AND IT 14 MIGHT NOT FOR A VARIETY OF DIFFERENT REASONS, WE WILL 15 HAVE TO GO BACK AND REVISIT THIS ISSUE FOR SURE. 16 MS. POTTER: VERY WELL THOUGHT OUT. 17 DR. PENHOET: THIS IS A DIRECT RETURN TO THE 18 WE DO TEND TO SOMETIMES FORGET THAT THE 19 UNIVERSITY OF CALIFORNIA IS PART OF THE STATE OF 20 CALIFORNIA, AND UCSF IN PARTICULAR HAS BENEFITED 21 TREMENDOUSLY FROM THE INVENTIONS IT MADE IN THE BIOTECH 22 WORLD, HUNDREDS OF MILLIONS OF DOLLARS. AND SO HOPEFULLY

INTEREST.

23

24

25

THEY'LL BE HAPPY TO SHARE SOME OF THAT DIRECTLY WITH THE

STATE, BUT ALSO USE THE REST PRODUCTIVELY IN THE STATE'S

1	CHAIRMAN CHIANG: THANK YOU VERY MUCH.
2	DR. PENHOET: THANK YOU VERY MUCH.
3	CHAIRMAN CHIANG: I THINK THAT
4	DR. PENHOET: ONE POINT. I MAY HAVE MISSPOKE.
5	THE FUNDING THAT GENERATED FROM THIS PROGRAM GOES
6	DIRECTLY TO THE GENERAL FUND OF THE STATE, NOT TO CIRM.
7	THANK YOU, TAMAR, FOR THAT CLARIFICATION.
8	CHAIRMAN CHIANG: THANK YOU FOR YOUR
9	PRESENTATION. ANY PUBLIC COMMENT? WE'LL GO TO THE NEXT
10	ITEM, WHICH IS BSA, CIRM PRESENTATION OF THE BUREAU OF
11	STATE AUDITS REPORT REGARDING CIRM.
12	MR. CORDINER: GOOD MORNING, MR. CHAIRMAN,
13	MEMBERS. MY NAME IS DOUG CORDINER. I'M THE CHIEF DEPUTY
14	FOR THE BSA. WHAT I'D LIKE TO DO TODAY IS JUST QUICKLY
15	STEP THROUGH THE FINDINGS THAT WE HAD DURING OUR AUDIT
16	THAT WAS ISSUED IN FEBRUARY OF 2007 AND REITERATE THE
17	RECOMMENDATIONS WE MADE. AND ALSO I'D LIKE TO GIVE YOU
18	THE STATUS, ACCORDING TO CIRM, BASED ON ITS SIX-MONTH
19	RESPONSE. I'D LIKE TO PREFACE MY REMARKS ABOUT THE
20	STATUS SAYING THAT THESE ARE ASSERTIONS MADE BY CIRM.
21	WE'VE HAD NO OPPORTUNITY TO GO BACK IN AND VERIFY SOME OF
22	THESE CLAIMS. AND IN THE FUTURE WE ARE AT THE SIX-MONTH
23	POINT. OUR AUDITS HAVE A FOLLOW-UP PROCESS THAT OCCURS
24	AT 90 DAYS, SIX MONTHS, AND ONE YEAR. AND SO WE WILL BE
25	IN CONTACT WITH THE AGENCY AND HOPEFULLY WE'LL GET SOME

1	UNDERLYING INFORMATION REGARDING THE STATUS OF SOME OF
2	THESE RECOMMENDATIONS.
3	THAT SAID, I'LL GO THROUGH THESE. AND IF YOU
4	HAVE QUESTIONS, JUST STOP ME ANYWHERE YOU'D LIKE.
5	OUR FIRST FINDING WAS WE WERE ASKED TO LOOK AT
6	THE STRATEGIC PLAN, AND WE FOUND THAT CIRM DID A VERY
7	THOROUGH JOB OF STRATEGIC PLANNING OUT FOR A TIME HORIZON
8	OF TEN YEARS. PART OF THAT PLAN INDICATES THAT THEY WERE
9	GOING TO MEASURE THEIR SUCCESS IN REACHING THE VARIOUS
10	GOALS SET OUT IN THAT PLAN AT A THREE- AND SEVEN-YEAR
11	POINT IN THE PLAN'S HORIZON. WE THOUGHT THAT WAS ALL
12	WELL AND GOOD, ALTHOUGH WE NOTED THAT WE'D LIKE TO SEE
13	SOME ANNUAL MEASUREMENTS BASED ON GRANTEES' REPORTED
14	INFORMATION AS TO WHERE THEY WERE AT IN REACHING THE
15	VARIOUS GOALS. AND SO THAT WAS THE RECOMMENDATION WE
16	MADE.
17	WE RECOMMENDED THAT THE INSTITUTE FULFILL ITS
18	PLANS TO DEVELOP A PROCESS TO TRACK MANAGEMENT
19	INFORMATION REPORTED INITIALLY BY GRANTEES, THEREBY
20	PROVIDING ACCOUNTABILITY AND ENABLING IT TO ACCESS ANNUAL
21	PROGRESS IN MEETING STRATEGIC GOALS AND INITIATIVES.
22	AND BASED ON ITS SIX-MONTH RESPONSE, THE CIRM
23	INDICATED THAT THEY ARE WHAT'S CORE TO THEM DOING THIS
24	IS TO PROVIDE A CORE ELEMENT IN ITS SCIENTIFIC
25	INFORMATION TRACKING AND MANAGEMENT REPORTING. THEY'VE

1	ISSUED A REQUEST FOR PROPOSALS, AND THEY DID THAT IN MAY.
2	AND THEY DREW RESPONSES FROM FIVE FIRMS, AND CIRM WILL
3	SEEK APPROVAL OF THE APPROVED SYSTEM FROM THE GOVERNING
4	BOARD, AND THEY ANTICIPATE THAT MEETING TO OCCUR IN
5	OCTOBER AND DECEMBER. SO THEREFORE, WE'VE GIVEN A STATUS
6	TO THAT OF PENDING BECAUSE THE OUTCOME IS STILL IN ISSUE.
7	THE SECOND FINDING WE HAD WAS THE COMMITTEE HAD
8	NOT COMPLETED PROVISIONS AT THAT TIME, WHICH WAS AS OF
9	DECEMBER, THEY HADN'T COMPLETED PROVISIONS OF ITS
10	INTELLECTUAL PROPERTY POLICIES REGARDING DISCOUNTED
11	PRICES AND ACCESS TO THERAPIES. AS YOU SAW IN THE
12	OVERHEAD, APPARENTLY THEY'VE MOVED A LITTLE BIT FURTHER,
13	BUT WHAT OUR RECOMMENDATION AT THAT TIME WAS WAS THAT THE
14	COMMITTEE ENSURE THAT IT FOLLOWS THROUGH WITH ITS PLAN TO
15	IDENTIFY THE APPROPRIATE STANDARD FOR PROVIDING UNINSURED
16	CALIFORNIANS ACCESS TO THERAPIES DEVELOPED USING
17	INSTITUTE FUNDS AND TO CONVEY CLEARLY TO GRANTEES ITS
18	EXPECTATIONS FOR PROVIDING ACCESS TO INTELLECTUAL
19	PROPERTY POLICIES.
20	IN ADDITION, THE COMMITTEE SHOULD IDENTIFY
21	PRACTICAL BENCHMARKS TO USE AS A STANDARD FOR DISCOUNT
22	PRICES FOR THERAPIES AND APPLY THAT STANDARD TO THE
23	POLICIES FOR GRANTS FOR NONPROFIT AND FOR-PROFIT
24	ORGANIZATIONS.
25	AGAIN, AT THE TIME AND THIS SIX-MONTH
	74

1	RESPONSE IS DATED SEPTEMBER 18, 2007. AT THAT TIME THE
2	COMMITTEE RESPONDED THAT THEY REMAIN COMMITTED TO
3	ENSURING THAT THERAPIES DEVELOPED BY CIRM-FUNDED RESEARCH
4	PROJECTS ARE ACCESSIBLE TO UNINSURED PATIENTS AND IS
5	EQUALLY COMMITTED TO SEEKING DISCOUNTED PRICES FOR
6	CALIFORNIA PATIENTS WHOSE DRUGS AND NONDRUG THERAPIES ARE
7	PURCHASED WITH PUBLIC FUNDS.
8	CIRM HELD INTERESTED PARTIES PUBLIC MEETINGS TO
9	REVIEW AND CONSIDER RELEVANT REGULATORY ISSUES AND
10	STANDARDS RAISED IN BOTH OF THESE ISSUES. THEY STATED
11	THAT THEY WERE CONTINUING TO DEVELOP APPROPRIATE
12	REGULATIONS GOVERNING BOTH NONPROFIT AND FOR-PROFIT
13	GRANTEES AIMED AT ENSURING ACCESS AND DISCOUNTS
14	DESCRIBED. THEREFORE, WE AGAIN GAVE IT A PENDING STATUS.
15	OUR THIRD RECOMMENDATION OR FINDING WAS A
16	PROVISION IN THE INSTITUTE'S INTELLECTUAL PROPERTY POLICY
17	ALLOWING RESEARCHERS ACCESS TO INSTITUTE-FUNDED
18	INVENTIONS WARRANTS FURTHER ATTENTION. AT THAT POINT IN
19	TIME, THERE WAS SOME INITIALLY THEY WERE GOING TO GIVE
20	UNFETTERED ACCESS, AND THEN THAT WAS TAKEN OFF THE TABLE,
21	AND THEY INSTITUTED SOME LANGUAGE AND THERE WAS
22	CONSIDERABLE DEBATE ABOUT SOME OF THE TERMINOLOGY USED;
23	BUT, IN ESSENCE, THE ACCESS WILL BE GRANTED UNDER
24	REASONABLE TERMS. AND THERE WAS DOUBT AS TO WHAT THAT
25	REALLY TRULY MEANT.

1	SO WHAT WE DID THERE IS WE RECOMMENDED THAT THE
2	COMMITTEE MONITOR THE EFFECTIVENESS OF ITS POLICY TO MAKE
3	INSTITUTE-FUNDED PATENTED INVENTIONS READILY ACCESSIBLE
4	ON REASONABLE TERMS TO OTHER GRANTEE ORGANIZATIONS FOR
5	NONCOMMERCIAL PURPOSES TO ENSURE AND TO ENSURE THAT IT
6	DOES NOT INHIBIT THE ADVANCE OF STEM CELL RESEARCH.
7	BASED ON THE RESPONSE TO THAT RECOMMENDATION,
8	CIRM SAID THAT ITS REGULATIONS REQUIRE GRANTEES WHO
9	LICENSE CIRM-FUNDED PATENTED INVENTIONS TO MAKE SUCH
10	INVENTIONS AVAILABLE TO OTHER GRANTEE ORGANIZATIONS AND
11	NONCOMMERCIAL FOR NONCOMMERCIAL RESEARCH PURPOSES. AS
12	PART OF ITS GRANTS MANAGEMENT PROCESS, CIRM WILL MONITOR
13	COMPLIANCE WITH THESE REGULATIONS BY REQUIRING GRANTEES
14	TO SUBMIT ANNUAL REPORTS THAT IDENTIFY LICENSED PATENTED
15	INVENTIONS AS WELL AS ANY REQUEST FOR ACCESS BY OTHER
16	SCIENTISTS FOR NONCOMMERCIAL RESEARCH PURPOSES. BASED ON
17	THAT RESPONSE, WE GAVE THE STATUS OF PARTIAL CORRECTIVE
18	ACTION. AGAIN, THE MONITORING, WE HAVEN'T SEEN THE
19	OUTCOME OF THAT, SO WE WOULD NEED TO SEE THAT TO GO
20	FURTHER IN OUR STATUS.
21	OUR FOURTH FINDING WAS THE INSTITUTE IS STILL
22	DEVELOPING A POLICY FOR ADMINISTERING GRANTS TO
23	FOR-PROFIT ENTITIES. AGAIN, AS WAS JUST SAID, THEY'VE
24	MOVED FURTHER ALONG IN THAT ENDEAVOR SINCE WE WERE IN THE
25	AGENCY. BUT WHAT WE RECOMMENDED WAS THAT THE INSTITUTE

1	COMPLETE THE DEVELOPMENT OF ITS GRANT ADMINISTRATION
2	POLICY TARGETED TOWARDS FOR-PROFIT ORGANIZATIONS. IT WAS
3	IN ITS GENESIS OF DOING THAT WHEN WE LEFT.
4	AND WHAT THEY SAID IN THEIR SIX-MONTH RESPONSE
5	WAS THAT CIRM BEGAN DRAFTING A GRANTS ADMINISTRATION
6	POLICY FOR FOR-PROFIT INSTITUTIONS IN DECEMBER OF '06 AND
7	PROGRESS IS BEING MADE TOWARDS ITS COMPLETION. CIRM IS
8	HOLDING INTERESTED PARTY MEETINGS. IN FACT, IT HELD ONE
9	ON SEPTEMBER 7TH, AND THE PURPOSE THERE WAS TO PUBLICLY
10	DISCUSS THE ISSUES RELATED TO THIS POLICY.
11	AGAIN, WE GAVE THAT A PENDING BECAUSE WE DIDN'T
12	KNOW WHAT THE OUTCOME AT THAT POINT WAS.
13	OUR FIFTH ISSUE WE REPORTED ON WAS THAT THE
14	GRANTS REVIEW WORKING GROUP SUBSTANTIALLY FOLLOWED ITS
15	POLICY WHEN IT REVIEWED TRAINING GRANTS, BUT IT LACKED
16	VOTING RECORDS. WE REVIEWED A LOT OF THESE ACTIONS THAT
17	WERE TAKEN REGARDING THE GRANTS, AND WHAT WE FOUND WAS,
18	WHILE THE POLICIES SEEMED SOUND TO US, WE DIDN'T SEE THE
19	UNDERLYING DOCUMENTATION OF THE VOTES TAKEN. TO ITS
20	CREDIT, CIRM IMMEDIATELY INSTITUTED A CHANGE IN THEIR
21	POLICY. THEY'VE SINCE INSTITUTED WHERE EVERY VOTING
22	MEMBER MUST HAVE A RECORD KEPT OF THE VOTES MADE ON
23	GRANTING ANY OR MAKING A GRANT.
24	SO WE GAVE STATUS TO THAT AS CORRECTIVE ACTION
25	TAKEN.

1	ANOTHER ISSUE WE FOUND WAS THAT THE INSTITUTE
2	IS DEVELOPING POLICIES OR PROCEDURES TO ENSURE THAT
3	GRANTEES COMPLY WITH THE TERMS OF THEIR AWARDS. OUR
4	RECOMMENDATION WAS TO MONITOR THE PERFORMANCE OF GRANTEES
5	EFFECTIVELY, WE RECOMMEND THAT THE INSTITUTE COMPLETE THE
6	IMPLEMENTATION OF ITS GRANTS MONITORING PROCESS,
7	INCLUDING AUDITS, AND THE DEVELOPMENT OF RELATED
8	PROCEDURES. BASICALLY WHAT WE SAW WAS THAT THERE'S BOTH
9	A FINANCIAL ASPECT AND A PROGRAMMATIC ASPECT OF THEIR
10	MONITORING CAPABILITY. THEY ALSO HAVE THE CAPABILITY TO
11	GO IN AND HAVE AN AUDIT DONE OF A GRANTEE, BUT THEY
12	DIDN'T REALLY HAVE A FULLY ROBUST PROCESS FOR DOING THAT.
13	AND WHAT THEY RESPONDED TO US WAS THAT CIRM
14	TAKES VERY SERIOUSLY ITS OBLIGATION TO MONITOR THE
15	PERFORMANCE OF ITS GRANTEES AS PART OF THE GRANTS
16	MONITORING PROCESS. CIRM CONDUCTS A COMPLETE
17	ADMINISTRATIVE REVIEW PRIOR TO ISSUING FORMAL NOTICES OF
18	GRANT AWARD AND BEFORE FUNDS ARE RELEASED. FOR RESEARCH
19	GRANTS, CIRM HAS ALSO DEVELOPED A CODING SYSTEM FOR
20	MONITORING THE TYPES OF RESEARCH THAT IT FUNDS. FOR
21	FACILITIES GRANTS, CIRM HAS DEVELOPED A SET OF
22	PERFORMANCE MILESTONES THAT REQUIRE A COMPLETE
23	ADMINISTRATIVE REVIEW THROUGHOUT THE LIFE OF THE GRANT.
24	CIRM CONTINUES TO DEVELOP A WEB-BASED REPORTING SYSTEM
25	FOR GRANTEES TO FACILITATE THE GRANTS MONITORING PROCESS.
	Marco.

1	SO THEY DIDN'T SPEAK DIRECTLY TO WHAT WE WANTED
2	TO SEE, WHICH WAS THE FINANCIAL BASE, THE PROGRAMMATIC
3	BASE, AS WELL AS WHAT THEY INTENDED TO DO IN THE WAY OF
4	AUDITS. SO WHAT WE SAID ON OUR STATUS HERE IS IT'S
5	PARTIAL, AND WE NEED TO DO SOME FOLLOW-UP TO FIND OUT
6	EXACTLY WHAT THE ADMINISTRATIVE REVIEW ENTAILS.
7	THE NEXT ISSUE WE REPORTED ON WAS DEALING WITH
8	FAIR POLITICAL PRACTICES COMMISSION HAS QUESTIONED THE
9	EXCLUSION OF WORKING GROUPS FROM THE INSTITUTE'S CONFLICT
10	OF INTEREST CODE. THE CIRM'S POSITION IS THEY DON'T HAVE
11	TO. THEY SOUGHT AN EXEMPTION, AND IT'S IN THE LANGUAGE
12	OF THE PROPOSITION THAT THESE WORKING GROUPS ARE NOT
13	COVERED BY THE CONFLICT OF INTEREST POLICY AND,
14	THEREFORE, THEY NEEDN'T HAVE DISCLOSURE.
15	WHAT WE RECOMMENDED WAS THAT THE INSTITUTE,
16	BECAUSE THERE WAS THIS DISAGREEMENT BETWEEN THE FPPC AND
17	THE INSTITUTE, WE RECOMMENDED THAT THEY SEEK A FORMAL
18	OPINION FROM THE ATTORNEY GENERAL REGARDING WHETHER THE
19	EXEMPTIONS CREATED FOR WORKING GROUPS FROM CONFLICT OF
20	INTEREST LAWS WERE INTENDED TO EXEMPT THEM FROM THE
21	CONFLICT OF INTEREST PROVISIONS THAT APPLY IF THE
22	RECOMMENDATIONS OF AN ADVISORY BODY ARE ADOPTED ROUTINELY
23	AND REGULARLY, WHICH WAS THE FPPC'S POSITION, BY THE
24	DECISION-MAKING BODY TO WHICH THEY ARE MADE.
25	AND THE RESPONSE WE GOT BACK WAS THAT CIRM HAD

1	GIVEN CAREFUL CONSIDERATION TO THE RECOMMENDATION, BUT
2	HAD DECIDED THAT IT WAS NOT APPROPRIATE TO IMPLEMENT IT.
3	ITS POSITION IS THAT THEY NEEDN'T SEEK THAT OPINION; AND,
4	THEREFORE, WE GAVE IT A STATUS OF NO ACTION TAKEN.
5	NEXT ISSUE WE REPORTED ON WAS THE INSTITUTE
6	HADN'T INCLUDED IN ITS CONFLICT OF INTEREST POLICY
7	SPECIALISTS IT MIGHT ENLIST TO ASSIST IT IN EVALUATING
8	GRANTS APPLICATIONS. WE RECOMMENDED THAT THE INSTITUTE
9	FOLLOW ITS PLANS TO AMEND ITS CONFLICT OF INTEREST
10	POLICIES TO INCLUDE SPECIALISTS INVITED TO PARTICIPATE IN
11	STEM CELL RESEARCH PROGRAM ACTIVITIES SUCH AS GRANT
12	APPLICATION REVIEW.
13	AND THEIR RESPONSE WAS TO THAT RECOMMENDATION
14	THAT THE CONFLICT OF INTEREST PROCEDURE FOR CIRM
15	EMPLOYEES INCORPORATES A MECHANISM FOR IDENTIFYING ALL
16	ENTITIES THAT HAVE APPLIED FOR FUNDING PURSUANT TO THE
17	RFA THAT REQUIRES EMPLOYEES TO REVIEW THIS LIST AND NOTE
18	ANY CONFLICTS AND DISQUALIFIES EMPLOYEES WHO IDENTIFY A
19	CONFLICT OF INTEREST WITH RESPECT TO A GIVEN APPLICATION
20	FROM REVIEWING THAT APPLICATION. I GOT ON THE I'M
21	SORRY. I GOT AHEAD OF MYSELF.
22	THE RESPONSE TO THAT PARTICULAR RECOMMENDATION
23	WAS THAT THE INSTITUTE HAS ALWAYS UNDERSTOOD THAT THE
24	CONFLICT OF INTEREST POLICIES AND PROCEDURES APPLICABLE
25	TO REGULAR WORKING GROUP MEMBERS APPLY EQUALLY TO

1	SPECIALISTS AND HAS TREATED SPECIALISTS ACCORDINGLY.
2	NEVERTHELESS, THE INSTITUTE AGREED WITH THE AUDIT
3	RECOMMENDATION, AND IN MARCH THE ICOC ADOPTED A CONFLICT
4	OF INTEREST POLICY FOR THE GRANTS WORKING GROUP WHICH
5	SPECIFICALLY INCLUDES SPECIALISTS. THEREFORE, WE GAVE A
6	STATUS OF CORRECTIVE ACTION TAKEN ON THAT ONE.
7	OUR NEXT ISSUE WAS INSTITUTE EMPLOYEES MAY NOT
8	HAVE THE INFORMATION THEY NEED TO COMPLY WITH THE
9	CONFLICT OF INTEREST POLICY. AND WE MADE A
10	RECOMMENDATION THAT TO PROVIDE EMPLOYEES WITH THE
11	INFORMATION THEY NEED TO DISCLOSE ALL PERTINENT CONFLICT
12	OF INTEREST, WE RECOMMENDED THAT THE INSTITUTE DEVELOP
13	THE NECESSARY PROCEDURES TO ENSURE THAT ITS EMPLOYEES ARE
14	AWARE OF THE COMPANIES THAT ARE APPLYING FOR FUNDING. AT
15	THE TIME WE LOOKED AT IT, THAT WASN'T APPARENT, SO
16	SOMEBODY MIGHT HAVE A CONFLICT AND NOT EVEN KNOW IT
17	BECAUSE THEY WOULDN'T KNOW WHO IT WAS THAT WAS APPLYING
18	FOR FUNDING IN ORDER TO RECUSE THEMSELF.
19	AND AS I JUST READ, BECAUSE I DID GET AHEAD OF
20	MYSELF, THEY DID TAKE ACTION TO MAKE THAT INFORMATION
21	KNOWN AND, THEREFORE, WE GAVE THAT STATUS A CORRECTIVE
22	ACTION TAKEN AS WELL.
23	THE NEXT ISSUE IS THE INSTITUTE COULD IMPROVE
24	STEPS TO DETECT CONFLICT OF INTEREST BEFORE MEETINGS OF
25	THE GRANTS REVIEW WORKING GROUP. WHAT WE RECOMMENDED
	81

1	THERE WAS THAT TO ENSURE COMPLIANCE WITH THE CONFLICT OF
2	INTEREST POLICIES, WE RECOMMENDED THAT THE INSTITUTE
3	REVIEW ITS PROCEDURES FOR REVIEWING GRANTS TO INCLUDE A
4	REVIEW OF STATEMENTS OF ECONOMIC INTEREST OR THE FORM
5	700, FOR SOME OF YOU THAT KNOW IT BETTER BY THAT TERM,
6	FOR COMMITTEE MEMBERS AND FOR WORKING GROUPS BEFORE EVERY
7	GRANTS REVIEW MEETING. MOREOVER, WE RECOMMENDED IT
8	REVISE ITS PROCEDURES FOR GRANTS REVIEW MEETINGS TO
9	ENSURE THAT IT RETAINS DOCUMENTATION REGARDING CONFLICT
10	OF INTEREST OF THE WORKING GROUPS, INCLUDING INFORMATION
11	THAT IT TOOK APPROPRIATE RECUSAL ACTIONS.
12	AND THEIR RESPONSE TO THAT RECOMMENDATION WAS
13	THE CURRENT PROCEDURES TO IDENTIFY CONFLICT OF INTEREST
14	OF MEMBERS OF THE GRANTS WORKING GROUP INCLUDE ALL STAFF.
15	AND IN ADDITION, CIRM NOW DOCUMENTS THE RECUSAL ACTIONS
16	OF EACH MEMBER, INCLUDING ANY SPECIALISTS, WITH RESPECT
17	TO EACH APPLICATION REVIEWED TO ENSURE THAT NO ONE
18	PARTICIPATING IN THE REVIEW OF A PARTICULAR APPLICATION
19	HAS A CONFLICT. THE INSTITUTE MAINTAINS SUCH RECORDS FOR
20	LATER REVIEW.
21	AGAIN, WE GAVE THAT A STATUS OF CORRECTIVE
22	ACTION TAKEN.
23	THEN WE GOT INTO THE AREAS OF MORE ITS
24	ADMINISTRATION OF THE GRANTS AND ONGOING TRAVEL KIND OF
25	RECOMMENDATIONS. THE FIRST OF THESE IS THE INSTITUTE'S

1	CONTRACTING POLICY AND TRAVEL REIMBURSEMENT POLICY DIDN'T
2	PROVIDE ADEQUATE CONTROLS AT THE TIME WE LOOKED AT IT.
3	WHAT WE RECOMMENDED WAS TO ENSURE THAT ADEQUATE CONTROLS
4	OVER ITS CONTRACTING AND TRAVEL REIMBURSEMENTS, THE
5	INSTITUTE SHOULD ENSURE THAT IT FOLLOWS ITS NEWLY REVISED
6	POLICIES THAT ADDRESS SOME OF THE CONCERNS RAISED IN OUR
7	AUDIT. THE INSTITUTE SHOULD ALSO AMEND ITS TRAVEL
8	REIMBURSEMENT POLICIES FURTHER TO ADDRESS REMAINING
9	CONCERNS THAT WE RAISED.
10	AND IN RESPONSE TO THAT, THE INSTITUTE STATED
11	THAT UNLIKE CIRM'S UNDER CIRM'S POLICY AND PRACTICE,
12	EMPLOYEES ARE NOT REIMBURSED FOR MEALS AT MEETINGS WHERE
13	MEALS ARE PROVIDED WITHOUT PRIOR AUTHORIZATION. ONE OF
14	THE ISSUES WE HAD IS THERE WAS DOUBLE. IT SEEMED LIKE
15	THEY WERE GETTING A MEAL PROVIDED AND THEY WERE PUTTING
16	IT IN FOR REIMBURSEMENT FOR THE SAME MEAL.
17	CIRM CONTINUES TO MONITOR THE TRAVEL CLAIMS OF
18	STAFF WHO ATTEND MEETINGS TO ENSURE THAT REIMBURSEMENT IS
19	NOT CLAIMED WHEN CIRM PROVIDES THE MEAL. THEREFORE, WE
20	GAVE THAT A CORRECTIVE ACTION STATUS.
21	THE INSTITUTE SALARY SURVEY AND SALARY SETTING
22	PROCESS DID NOT ENSURE THE COMPLIANCE WITH THE ACT. WE
23	LOOKED AT THEY DID A SALARY SURVEY, AND IN MANY CASES
24	IT CONTAINED SOME ERRORS AND OMISSIONS THAT WE FELT
25	UNDERMINED TTS DURBOSE AND SO WE RECOMMENDED TO ENSURE

1	THAT THE METHODOLOGY TO SET SALARY RANGES COMPLIES WITH
2	THE ACT, WE RECOMMENDED THAT THE INSTITUTE FOLLOW THROUGH
3	WITH ITS PLAN TO RESURVEY ANY POSITIONS WHOSE SALARY
4	RANGES WERE AFFECTED BY THE ERRORS, OMISSIONS, AND
5	INCONSISTENCIES IN ITS INITIAL SALARY SURVEY AND SALARY
6	SETTING ACTIVITIES.
7	AND THE ACTION TAKEN THERE, AT ITS APRIL 5TH,
8	2007, MEETING OF THE GOVERNANCE SUBCOMMITTEE OF THE ICOC,
9	A POLICY ITEM WAS ON THE AGENDA FOR THE APRIL 10TH, 2007,
10	MEETING, BUT THE ICOC WAS UNABLE TO TAKE UP THE MATTER
11	DUE TO TIME CONSTRAINTS. IN THE INTERIM THE CHAIRMAN
12	ASKED THAT I LOST MY PLACE. THIS WAS ANOTHER ONE THAT
13	WAS
14	THIS WAS A RECOMMENDATION WE MADE FOR TRAVEL
15	REIMBURSEMENT POLICIES THAT WILL RESULT IN REIMBURSEMENT
16	OF REASONABLE AND NECESSARY EXPENSES. WE FOUND THAT
17	SOMETIMES THE CLAIMS PUT IN EXCEEDED WHAT WE WOULD
18	CONSIDER TO BE REASONABLE FOR THE PURPOSES CLAIMED. AND
19	WE RECOMMENDED THAT THEY ADDRESS THOSE CONCERNS. AND
20	THAT GOT TABLED BECAUSE OF INSUFFICIENT TIME AT THE LAST
21	MEETING, SO WE HAVE THAT AS A PENDING ITEM AS WELL.
22	AS FOR THE RECOMMENDATION REGARDING THE SALARY
23	SURVEY, THE RESPONSE WE GOT WAS CIRM HAS ISSUED A REQUEST
24	FOR PROPOSAL TO CONTRACT WITH AN EXPERIENCED FIRM TO
25	REVIEW AND SURVEY ALL CIRM SALARIES. CIRM RECEIVED TWO

- 1 RESPONSIVE BIDS AND SIGNED A CONTRACT WITH MERCER HUMAN 2 RESOURCES CONSULTING ON APRIL 2D, 2007. A REPORT IS 3 ANTICIPATED WITHIN THE NEXT FEW WEEKS AND WILL BE 4 DISCUSSED WITH THE ICOC. 5 SO THERE, AGAIN, WE ASSIGNED A PENDING STATUS 6 TO THAT. 7 AND WITH THAT, I WILL ENTERTAIN ANY QUESTIONS 8 THAT YOU MIGHT HAVE. 9 CHAIRMAN CHIANG: THANK YOU FOR YOUR 10 PRESENTATION. ANY QUESTIONS, COMMENTS? VERY GOOD. 11 WOULD CIRM LIKE TO PROVIDE A RESPONSE? 12 DR. MURPHY: JUST ONE POINT OF CLARIFICATION. 13 I BELIEVE THAT WHAT THE REPORT SHOWED WAS THAT THERE WAS 14 A POTENTIAL FOR PEOPLE TO DOUBLE BILL ON MEALS, BUT I 15 DON'T BELIEVE THERE WAS EVER A CASE WHERE THAT WAS SHOWN. 16 BUT I THINK THE CAUTION THAT YOU RECOMMENDED THAT WE 17 SHOULD HAVE IN PLACE, RULES THAT WOULD PREVENT SOMEONE 18 FROM COLLECTING ON A MEAL THAT WAS ALREADY PROVIDED BY 19 CIRM, IS VERY APPROPRIATE, BUT I DON'T BELIEVE THERE WAS 20 EVER A CASE WHERE THAT WAS SHOWN. 21 MR. CALLOWAY: ACTUALLY THERE WERE TWO CASES WE 22 IDENTIFIED. 23 CHAIRMAN CHIANG: IF YOU DON'T MIND, IF YOU CAN
- 25 MR. CALLOWAY: MY NAME IS NORM CALLOWAY.

IDENTIFY YOURSELF FOR THE RECORD.

24

1	WITH THE BUREAU OF STATE AUDITS. AS MY MEMORY SERVES ME,
2	THERE WERE TWO CASES WHERE WE FOUND AN ATTENDEE TO A
3	CONFERENCE HAD RECEIVED REIMBURSEMENT FOR A MEAL WHILE AT
4	THAT SAME CONFERENCE THERE WERE MEALS PROVIDED BY CIRM
5	FOR THE GROUP AS WELL.
6	CHAIRMAN CHIANG: THANK YOU.
7	MR. KLEIN: MR. CHAIRMAN, I'D LIKE TO SAY WE'LL
8	STRIVE FOR PERFECTION, BUT WE'VE HAD OVER A HUNDRED
9	PUBLIC MEETINGS. AND IF THERE'S ONLY TWO PEOPLE WHO MADE
10	THE MISTAKE, AND I'M SURE WE WENT BACK AND CORRECTED A
11	MISTAKE IF IT WAS MADE. OUT OF THOSE HUNDRED PUBLIC
12	MEETINGS, WE'RE GETTING PRETTY CLOSE TO A PERFECT RECORD.
13	I WOULD LIKE TO RESPOND ON ONE OTHER POINT THAT
14	WAS MENTIONED. AND THAT IS AS TO THE QUESTION OF AN
15	ATTORNEY GENERAL'S OPINION ON THE ISSUE OF WHETHER THE
16	GRANTS WORKING GROUPS ARE ADVISORY BODIES. FIRST OF ALL,
17	IT'S IMPORTANT TO NOTE THAT THE INITIATIVE APPROVED BY
18	SEVEN MILLION PEOPLE SAYS THAT THEY'RE ADVISORY BODIES,
19	AND THE TRIAL COURT, COURT OF APPEALS, AND THE SUPREME
20	COURT, WHICH HAD NOT YET ISSUED ITS OPINION AT THE TIME
21	THEIR REPORT WAS DONE, CAME OUT AND SAID VERY
22	SPECIFICALLY THAT THIS IS AN ADVISORY BODY AND WENT
23	THROUGH FACTUALLY AND REVIEWED THE PEER REVIEW PROCESS
24	THAT HAD OCCURRED TO THAT DATE AND SAID IT IS PERFORMING
25	PROPERLY, CONSTITUTIONALLY, AND STATUTORILY AS AN

1	ADVISORY BODY.
2	FURTHERMORE, I'D LIKE TO ASK TAMAR PACHTER, OUR
3	GENERAL COUNSEL, WHO CAME FROM THE ATTORNEY GENERAL'S
4	OFFICE, TO COMMENT ON THE POLICY OF THE ATTORNEY
5	GENERAL'S OFFICE AS NOT ISSUING OPINIONS ON
6	HYPOTHETICALS; THAT IS, WE THINK THAT SINCE ALL THREE
7	LEVELS OF OUR COURT SYSTEM HAS ACTUALLY LOOKED AT THE
8	FACTS, IT'S HARD TO GET BETTER THAN OUR COURT SYSTEM,
9	INCLUDING THE SUPREME COURT, AND WOULD LIKE TO DRAW YOUR
10	ATTENTION TO WHAT THE IMPEDIMENT IS TO GETTING THE
11	ATTORNEY GENERAL TO RULE ON HYPOTHETICALS.
12	MS. PACHTER: MORNING. I THINK AS MS. HOWELL
13	NOTED IN HER ORIGINAL REPORT, AT THE TIME THE REPORT WAS
14	ISSUED, THE OPINION OF THE TRIAL COURT FINDING WAS THAT
15	THE WORKING GROUPS WERE, IN FACT, ADVISORY GROUPS AND
16	WERE NOT SUBJECT TO. WHAT WE'RE TALKING ABOUT HERE IS
17	THE POLITICAL REFORM ACT AND THE OTHER CALIFORNIA
18	STATUTES THAT REGULATE CONFLICTS OF INTEREST. I DON'T
19	WANT ANYONE TO BE LEFT WITH THE IMPRESSION THAT THE
20	WORKING GROUPS ARE NOT SUBJECT TO ANY CONFLICT OF
21	INTEREST REGULATION BECAUSE THEY ARE. THEY'RE SUBJECT TO
22	VERY STRICT CONFLICT OF INTEREST POLICIES DISCLOSURES
23	THAT WERE PASSED BY THE ICOC.
24	IN FACT, THEY ARE BROADER THAN MOST OF THE
25	DISCLOSURES REQUIRED BY CALIFORNIA LAW IN THAT THEY'RE

1	REQUIRED TO DISCLOSE, IN ADDITION TO THEIR FINANCIAL
2	CONFLICTS OF INTEREST, THEIR PERSONAL AND PROFESSIONAL
3	CONFLICTS OF INTEREST. WE MAINTAIN VERY STRICT RECORDS
4	OF THOSE WITH RESPECT TO EVERY MEETING HELD BY THE
5	WORKING GROUP. THE MEMBERS ARE REQUIRED TO CERTIFY BOTH
6	IN ADVANCE AND AT THE CONCLUSION OF THE MEETING THAT THEY
7	DIDN'T PARTICIPATE IN THE REVIEW OF ANY APPLICATION WITH
8	WHICH THEY HAVE A CONFLICT OF INTEREST. WE HAVE RECORDS
9	OF THOSE THAT ARE AVAILABLE TO THE BSA AUDITORS AT ANY
10	TIME TO REVIEW.
11	SO I DON'T WANT ANYBODY TO BE LEFT WITH THE
12	IMPRESSION THAT THE WORKING GROUP MEMBERS ARE NOT SUBJECT
13	TO CONFLICT OF INTEREST REGULATIONS. THE ONLY ISSUE HERE
14	IS WHETHER THEY'RE SUBJECT TO THE SAME REGULATIONS THAT
15	APPLY TO ALL OF YOU, THAT APPLY TO US AS EMPLOYEES OF THE
16	STATE OF CALIFORNIA. THEY ARE NOT EMPLOYEES OF THE STATE
17	OF CALIFORNIA. AND AS YOU HEARD DR. MURPHY SAY EARLIER,
18	THEY ARE ALL OUT-OF-STATE SCIENTISTS. SO NONE OF THEM
19	ARE CITIZENS OF THE STATE OF CALIFORNIA.
20	SO AT THE TIME MS. HOWELL WROTE THE REPORT,
21	THERE WAS A TRIAL COURT DECISION FROM JUDGE SABRANO IN
22	ALAMEDA COUNTY THAT SAID THE WORKING GROUPS WERE, IN
23	FACT, ADVISORY AND THAT THE POLITICAL REFORM ACT IN
24	SECTION 1090 DID NOT APPLY TO THEM. AND THE REPORT NOTED
25	AT THAT TIME THAT THAT WAS AN INTERMEDIATE DECISION AND

1	WAS ON APPEAL.
2	THAT DECISION IS NOW FINAL. IT WAS AFFIRMED BY
3	COURT OF APPEAL HERE IN SAN FRANCISCO, AND THE STATE
4	SUPREME COURT DENIED REVIEW IN MAY. THAT'S NOW A FINAL
5	DETERMINATION OF LAW. WE DON'T THINK REVIEW BY THE
6	ATTORNEY GENERAL IS EITHER NECESSARY OR SOMETHING AT THIS
7	POINT THAT THEY WOULD CONSIDER TAKING ON. EVEN IF THERE
8	HADN'T BEEN A RULING FROM THE STATE SUPREME COURT, THE
9	WAY THE FPPC RULES AND REGULATIONS OPERATE WITH RESPECT
10	TO ADVISORY BODIES IS IT'S BACKWARD LOOKING. SO YOU HAVE
11	TO LOOK BACKWARD TO SEE WHETHER THE ADVISORY BODIES'
12	RECOMMENDATIONS HAVE, IN FACT, BEEN ADOPTED WHOLESALE BY
13	THE DECISION MAKER.
14	AND SINCE WE HAVE NO SUCH PATTERN, AND THAT'S
15	WHAT WE SAID TO THE AUDITORS IN OUR SIX-MONTH LETTER,
16	SINCE IN NO CASE HAS THE ICOC ADOPTED THE RECOMMENDATIONS
17	OF THE GRANTS WORKING GROUP WITHOUT SOME CHANGE, THERE IS
18	NO PATTERN TO LOOK AT THAT ANYBODY COULD LOOK AT TO
19	DETERMINE THAT THE WORKING GROUP WOULD BE SUBJECT TO
20	EITHER THE POLITICAL REFORM ACT SECTION 1090 OR ANY OTHER
21	STATE REGULATION OF CONFLICTS OF INTEREST.
22	SO BOTH THE DETERMINATION BY THE STATE COURTS
23	AND THE FACT THAT THERE'S NO PATTERN MAKES IT UNNECESSARY
24	AND HIGHLY UNLIKELY THAT THE AG'S OFFICE WOULD RENDER AN
25	OPINION IN THIS CASE.

1	IN ADDITION, I WOULD LIKE TO NOTE THAT,
2	ALTHOUGH SOME INITIAL RESERVATIONS WERE EXPRESSED BY THE
3	FPPC ABOUT WHETHER THE MEMBERS OF THE GRANTS WORKING
4	GROUP SHOULD BE SUBJECT TO THE POLITICAL REFORM ACT, THEY
5	HAVE TAKEN NO FURTHER ACTION WITH RESPECT TO THAT AT ALL,
6	AND THAT'S THEIR LAW.
7	IF THERE ARE ANY OTHER QUESTIONS, I'D BE HAPPY
8	TO ANSWER THEM.
9	CHAIRMAN CHIANG: THANK YOU.
10	MR. CALLOWAY: MR. CHAIRMAN, IF I MAY. AT THE
11	REQUEST OF DR. MURPHY, REGARDING THE MEALS THAT WERE
12	REIMBURSED TO AN INDIVIDUAL AS WELL AS GROUP MEALS, AS I
13	SIT HERE TODAY, MY MEMORY DOESN'T TELL ME THAT THOSE WERE
14	CIRM STAFF. IT COULD HAVE BEEN WORKING GROUP MEMBERS OR
15	SOMEONE ELSE. SO I DIDN'T WANT TO GIVE THE IMPRESSION
16	THAT SOMEHOW STAFF WAS ABUSING THE TRAVEL POLICY.
17	CHAIRMAN CHIANG: VERY GOOD. THAT CONCLUDES
18	THIS MATTER. LET ME ASK THE MEMBERS OR THE REPORTER IF
19	YOU NEED A TEN-MINUTE BREAK.
20	THE REPORTER: THE REPORTER IS FINE.
21	CHAIRMAN CHIANG: MEMBERS? VERY GOOD. WE WILL
22	PROCEED. WE HAVE THREE ADDITIONAL ITEMS. CONSIDERATION
23	OF THE DRAFT AGENDA FOR THE NEXT MEETING. DO THE MEMBERS
24	HAVE ANY REQUESTS FOR INCLUSION OF ANY SPECIFIC ITEMS FOR
25	THE NEXT MEETING?

1	MS. POTTER: I'D LIKE TO SEE I'M SORRY ABOUT
2	THAT. I'D LIKE TO SEE A DISCUSSION OF THE UPDATE AND
3	RESPONSE TO THIS LAST AUDIT. I THINK IT WOULD BE
4	BENEFICIAL FOR THE COMMITTEE TO SEE SOME DETAILED WORK
5	AROUND THAT. IT STRUCK ME, AS I WAS LISTENING TO
6	EVERYTHING, THAT YOU ARE STARTING A SMALL COMPANY IN SO
7	MANY RESPECTS. AND, BOY, THESE LITTLE THINGS WILL JUST
8	CHASE YOU FOR THE LONGEST TIME. BUT THE PROGRESS IS
9	CLEAR, IT'S OBVIOUS, BUT I THINK THE COMMITTEE WOULD GET
10	A LOT OF BENEFIT FROM AN UPDATE.
11	CHAIRMAN CHIANG: SMALL COMPANY, YOU WORK FOR
12	GENENTECH.
13	MS. POTTER: I STARTED THREE OR FOUR OTHERS, SO
14	I FELT YOUR PAIN. IT IS A TREMENDOUS AMOUNT OF WORK.
15	CHAIRMAN CHIANG: ANY OTHER REQUESTS? VERY
16	GOOD. THAT CONCLUDES THAT MATTER. THE NEXT ITEM IS
17	PUBLIC COMMENT.
18	MR. SIMPSON: JOHN SIMPSON FROM THE FOUNDATION
19	FOR TAXPAYER AND CONSUMERS RIGHTS. MR. CHAIRMAN, I DID
20	WANT TO THANK YOU FOR ACKNOWLEDGING THE CONFLICT OF
21	INTEREST SITUATION THAT APPARENTLY SURFACED LAST WEEK AND
22	CALLING FOR THE FPPC TO INVESTIGATE THAT. I WANTED TO
23	BRING THE BOARD MEMBERS UP TO DATE A LITTLE BIT ON OUR
24	ORGANIZATION'S POSITION. WE HAVE, IN FACT, FILED A
25	FORMAL COMPLAINT WITH THE FPPC. WE BELIEVE THAT DR. REED

1	IN INTERVENING, AS WAS DEMONSTRATED IN AN AUGUST 2D
2	LETTER, IN THE DELIBERATIONS SURROUNDING A GRANT THAT HIS
3	INSTITUTION WAS TO RECEIVE OR HE HOPED WOULD RECEIVE,
4	CLEARLY VIOLATED STATE CONFLICT OF INTEREST LAWS, CIRM'S
5	OWN POLICIES WHICH HE HAD SIGNED. AND WE BELIEVE,
6	FRANKLY, THAT HE SHOULD RESIGN.
7	WE WOULD GO FURTHER THAN THAT. AND IN YOUR
8	ROLE, MR. CHAIRMAN, AS CONTROLLER, I BELIEVE YOU ARE THE
9	APPOINTING AUTHORITY WITH THIS PARTICULAR SEAT. YOUR
10	PREDECESSOR, STEVE WESTLY, DID, IN FACT, APPOINT DR.
11	REED. AND I WOULD REQUEST, SIR, THAT IF HE DOES NOT
12	RESIGN, THAT YOU REMOVE HIM.
13	THE SECOND THING THAT BECAME CLEAR AFTER THIS
14	LETTER WAS MADE AVAILABLE THROUGH A PUBLIC RECORDS ACT
15	WAS THAT CHAIRMAN KLEIN, IN FACT, CONSULTED WITH DR. REED

I WANTED TO PUT THAT BEFORE YOU SO YOU WERE

25

- 1 AWARE OF THAT AND HOW SERIOUSLY WE BELIEVE THIS CONFLICT
- 2 WAS. AGAIN, I WOULD LIKE TO THANK YOU FOR CALLING THAT
- 3 IT BE INVESTIGATED BY THE FPPC, BUT AS I SAY, WE HAVE
- 4 ALSO ALREADY PUT IN A COMPLAINT ON THAT AS WELL. THANK
- 5 YOU VERY MUCH.
- 6 CHAIRMAN CHIANG: THANK YOU, JOHN. LET ME
- 7 RESPOND TO THOSE COMMENTS. LIKE YOU, I DO SHARE CONCERN
- 8 ABOUT THE INTEGRITY OF THE PROCESS. SECOND
- 9 CLARIFICATION. I CANNOT REMOVE MR. REED. HE IS SET FOR
- 10 A PERIOD OF TIME. I CAN'T MAKE THE REQUEST THAT HE
- 11 RESIGN. HOWEVER, THIRD, AS A LAWYER, I ALSO STRONGLY
- 12 BELIEVE IN THE RIGHTS AFFORDED ALL PARTICIPANTS IN THIS
- 13 COUNTRY OR RESIDENTS OF THIS COUNTRY AND BELIEVE THAT DUE
- 14 PROCESS IS CRITICAL IN THE EXAMINATION OF THIS. AND
- 15 THAT'S WHY, LIKE YOU, I WANT A FULL REVIEW BY THE FAIR
- 16 POLITICAL PRACTICES COMMISSION TO EXAMINE THE FACTS AND
- 17 THE CONTEXT OF THE COMMUNICATION THAT TOOK PLACE. I'D
- 18 LIKE A FULL REVIEW BY AN INDEPENDENT REVIEWING AUTHORITY
- 19 IN THIS PARTICULAR MATTER.
- 20 SO AS I POINTED OUT, UPON A REVIEW BY THE FAIR
- 21 POLITICAL PRACTICES COMMISSION, I THINK IT'S CRITICAL IF
- THEY DO FIND WRONGDOING IN THIS PARTICULAR CIRCUMSTANCE,
- 23 THAT WE WILL CALL ANOTHER MEETING FOR THIS BOARD TO
- 24 REVIEW THAT PARTICULAR SITUATION AND TO COME TOGETHER,
- 25 WHETHER COLLECTIVELY OR INDIVIDUALLY, WHAT SHOULD TAKE

1	PLACE AND WHAT OUR RECOMMENDATIONS WOULD BE.
2	MR. REED: MY NAME IS DON REED, CALIFORNIANS
3	FOR CURES. I AM NOT RELATED TO DR. JOHN REED, BUT I
4	WOULD BE PROUD TO CLAIM HIM AS KIN. HE'S A GOOD MAN. I
5	KNOW HIM A LITTLE BIT, AND HE HAS DONE A TREMENDOUS
6	CONTRIBUTION TO THE FIELD OF SCIENCE, IN STEM CELLS IN
7	PARTICULAR.
8	EVERY STEP OF THE CALIFORNIA INSTITUTE FOR
9	REGENERATIVE MEDICINE HAS BEEN TAKEN UNDER THE FULL BLAZE
10	OF PUBLIC SCRUTINY. EVERY CONCEIVABLE OBJECTION HAS BEEN
11	MET AND RAISED AND PUBLICLY WRESTLED OUT, AND THIS WILL
12	BE NO EXCEPTION. PERHAPS THAT IS FOR THE BEST, BUT I
13	HAVE TO SAY THIS IS NOT MERELY A TEMPEST IN A TEAPOT.
14	THIS IS FAR SMALLER THAN THAT. IT SEEMS TO ME TO BE
15	VISIBLE ONLY UNDER A MICROSCOPE.
16	WHAT ACTUALLY HAPPENED, AND ONLY ACCESS TO
17	INFORMATION I HAVE IS PUBLIC INFORMATION, IS THERE WAS
18	A DR. REED, MEMBER OF THE ICOC, ACTED PERFECTLY
19	APPROPRIATELY BY NOT INVOLVING HIMSELF IN THE
20	DELIBERATIONS FOR HIS GRANT. THE GRANT WAS APPROVED.
21	AFTER THAT, ON THE RECOMMENDATIONS OF STAFF, IT WAS
22	DISAPPROVED. THE REASON GIVEN WAS THAT THE GRANT PERSON,
23	THE GRANTEE RECIPIENT, WAS NOT A, QUOTE, UNQUOTE,
24	FULL-TIME EMPLOYEE.
25	NOW, THAT DEFINITION, FULL-TIME EMPLOYEE, IS
	94

1	HIGHLY SUBJECTIVE. IF THE SAME RECOMMENDATION, SAME
2	STANDARD HAD BEEN APPLIED TO HARVARD, ACCORDING TO THE
3	SAN DIEGO TRIBUNE, NONE OF THEIR SCIENTISTS WOULD HAVE
4	BEEN ELIGIBLE, BEEN CALLED FULL-TIME EMPLOYEES EVEN
5	THOUGH THEY ALL WORK FULL TIME FOR THE COLLEGE BECAUSE
6	THEY ALL BRING THEIR OWN FUNDING FROM SOMEWHERE ELSE.
7	SO HERE WE HAVE A SITUATION WHERE A PERFECTLY
8	GOOD AND VALUABLE GRANT WOULD BE TURNED DOWN BECAUSE OF A
9	SUBJECTIVE, BASICALLY AN OPINION. SO WHAT IS THE PERSON
10	SUPPOSED TO DO? HE CAN NO LONGER INFLUENCE IT AS AN ICOC
11	MEMBER AND MADE NO ATTEMPT TO SO DO. HOWEVER, HE IS ALSO
12	A PERSON WHO IS A MEMBER OF THE COLLEGE. WHAT'S HE
13	SUPPOSED TO DO? HE CALLED UP BOB KLEIN AND SAID, "I
14	DON'T KNOW WHAT TO DO. WHAT AM I SUPPOSED TO DO?" AND
15	BOB SAID, "GET IT INTO THE PUBLIC ARENA. LET THE FACTS
16	BE KNOWN." TO ME THIS IS THE JUST AND HONORABLE THING TO
17	DO. AND THAT WAS WHAT WAS DONE.
18	THIS WAS NOT A SECRET, BEHIND-THE-DOORS DEAL.
19	THERE WAS NO ATTEMPT TO MISLEAD. HE PUT IT IN WRITING IN
20	A PUBLICLY ACCESSIBLE LETTER. THIS WILL BE INVESTIGATED
21	AND RIGHTLY SO. CALIFORNIA HAS A RIGHT TO KNOW
22	EVERYTHING THAT'S GOING ON, BUT THAT THESE TWO INCREDIBLE
23	MEN SHOULD BE EVEN SUGGESTED THAT THEY RESIGN I FIND

OF A CHILD. WE CALL THE PERSON A HERO. WHAT ABOUT

LUDICROUS. WE HAVE A WORD FOR SOMEONE WHO SAVES THE LIFE

24

25

1	PEOPLE WHO MAY MAKE IT POSSIBLE FOR MILLIONS OF LIVES TO
2	BE SAVED AND SUFFERING EASED?
3	MY SON IS PARALYZED. I SEE THE HELL HE GOES
4	THROUGH EVERY DAY. STEM CELL RESEARCH, OF WHICH
5	CALIFORNIA IS THE NO. 1 FUNDER IN THE WORLD, OFFERS HOPE
6	THAT HE MAY ONE DAY FULFILL CHRISTOPHER REEVE'S
7	PREDICTION. CHRISTOPHER REEVE SENT A LETTER TO MY FAMILY
8	WE'LL ALWAYS TREASURE. IT SAID, "ONE DAY ROMAN AND I
9	WILL STAND UP FROM OUR WHEELCHAIRS AND WALK AWAY FROM
10	THEM FOREVER." A CURE DID NOT COME IN TIME FOR
11	CHRISTOPHER REEVE. OUR CHAMPION HAS FALLEN, BUT THE
12	FLAME OF HIS FAITH STILL LIGHTS OUR WAY. WE GO FORWARD,
13	WE WILL PREVAIL BECAUSE OF CALIFORNIA'S TREMENDOUS
14	INITIATIVE.
15	THIS ATTEMPT AT BLIGHT ON THE NAME OF THE TWO
16	GOOD MEN IS RIDICULOUS, AND I HOPE IT WILL BE GIVEN THE
17	SHORT SHRIFT IT DESERVES. THANK YOU.
18	CHAIRMAN CHIANG: ANY ADDITIONAL COMMENTS?
19	DR. MURPHY: LET ME COMMENT AS WELL. MR.
20	REED'S SUMMARY OF WHAT HAPPENED IS ABSOLUTELY CORRECT,
21	BUT I WOULD JUST ADD ONE MORE THING. AND THAT IS, WHEN
22	THIS LETTER, WHICH JOHN REED HAS ADMITTED WAS A MISTAKE,
23	AND BOB SAYING TO JOHN WRITE A LETTER, WHICH NOW IN THE
24	FULLEST OF TIME SAYS THAT WAS A MISTAKE TOO, WHEN THAT
25	CAME TO THE INSTITUTE, THE INSTITUTE DID ITS JOB. IT

- 1 SAID WAS THERE A FOUL-UP, A TECHNICAL FOUL-UP? DID WE
- 2 MAKE A MISTAKE? AND THE FACT WAS THAT WE DID NOT. THE
- 3 GRANT, ALTHOUGH IT WAS A VERY HIGHLY RATED GRANT, WAS NOT
- 4 FUNDED.
- 5 SO THE FIREWALL THAT WAS SET UP WORKED. AND I
- 6 THINK THAT THAT IS A CREDIT TO THE STAFF, WHO ACTED
- 7 EXACTLY THE WAY THEY SHOULD ACT. CERTAINLY THERE WERE A
- 8 COUPLE OF MISTAKES MADE IN GETTING THIS THING TO THE
- 9 INSTITUTE. BUT I THINK THE PEOPLE OF CALIFORNIA SHOULD
- 10 BE VERY PROUD TO KNOW THAT THE STAFF DID EXACTLY WHAT IT
- 11 SHOULD HAVE DONE UNDER THESE CIRCUMSTANCES. NO HARM WAS
- 12 DONE. NO MONEY WAS FUNDED. IF WE HAD FUNDED THE GRANT,
- 13 IT WOULD HAVE BEEN A DIFFERENT STORY. IT WASN'T FUNDED.
- 14 THE THINGS WORKED EXACTLY AS THEY SHOULD.
- SO I WELCOME THE INVESTIGATION AS WELL, BUT I
- 16 WOULD SHARE MR. REED'S FEELING, THAT FOR THIS TO BE A
- 17 MADE A MAJOR EVENT IN THE FACE OF THE MAJOR THINGS THAT
- 18 ARE REALLY GOING ON IN THE STEM CELL INSTITUTE, THE VIEW
- 19 OF PEOPLE WOULD BE THE WRONG COURSE OF ACTION.
- 20 CHAIRMAN CHIANG: THANK YOU. COMMENTS? THAT
- 21 CONCLUDES PUBLIC COMMENTS. I'M SORRY. WE HAD A WRITTEN
- 22 SUBMISSION THAT I WILL HAVE DAVE O'TOOLE READ INTO THE
- 23 RECORD.
- MR. O'TOOLE: THIS IS A LETTER DATED NOVEMBER
- 25 25TH, 2007, FROM DAVID JENSON, PUBLISHER OF THE

1	CALIFORNIA STEM CELL REPORT.
2	"TO THE CITIZENS FINANCIAL ACCOUNTABILITY
3	OVERSIGHT COMMITTEE, THE TIME HAS COME FOR THE CALIFORNIA
4	INSTITUTE FOR REGENERATIVE MEDICINE TO OPEN ITS DOORS TO
5	MORE PUBLIC DISCLOSURE IN THE INTEREST OF GREATER PUBLIC
6	ACCOUNTABILITY AND TO AVOID FURTHER DAMAGE TO ITS
7	REPUTATION. SUCH A MOVE WOULD ENHANCE ITS PERFORMANCE AS
8	A CREDIBLE ADVOCATE FOR SOUND SCIENTIFIC RESEARCH AND
9	HELP TO PREVENT FUTURE SCANDALS INVOLVING THIS \$3 BILLION
10	PROGRAM. I'M ASKING YOUR PANEL TO MAKE SUCH A
11	RECOMMENDATION TO CIRM.
12	"WITHIN THE LAST WEEK, CALIFORNIANS HAVE SEEN
13	STORIES IN THE MEDIA CONCERNING AN ATTEMPT BY A CIRM
14	DIRECTOR TO PRIVATELY INFLUENCE THE AWARD OF \$638,000 TO
15	HIS INSTITUTION. THAT ATTEMPT WAS MADE AT THE SUGGESTION
16	OF THE CHAIRMAN OF THE CIRM OVERSIGHT COMMITTEE, ROBERT
17	KLEIN, WHO IS ALSO AN ATTORNEY. HIS ADVICE WAS IN CLEAR
18	VIOLATION OF CIRM'S CONFLICT OF INTEREST POLICY, A FACT
19	THAT HE NOW ACKNOWLEDGES. DISCLOSURE OF A LOBBYING
20	EFFORT FIRST REPORTED BY THE CALIFORNIA STEM CELL REPORT
21	HAS GENERATED CALLS FOR THE RESIGNATION OF KLEIN AND THE
22	DIRECTOR JOHN REED OF THE BURNHAM INSTITUTE.
23	"ONE ORGANIZATION, THE FOUNDATION FOR TAXPAYER
24	AND CONSUMER RIGHTS, HAS FILED A COMPLAINT WITH THE FAIR
25	POLITICAL PRACTICES COMMISSION. KLEIN AND REED'S ACTIONS

	BARRISTERS' REPORTING SERVICE
1	ARE PART OF A LARGER ISSUE AT CIRM. THE CONFLICTS OF
2	INTERESTS THAT ARE BUILT INTO THE STRUCTURE BY PROP 71,
3	WHICH THE CALIFORNIA STATE AUDITOR HAS TOUCHED ON, FOR
4	EXAMPLE, CURRENTLY A MAJORITY OF ITS DIRECTORS, OVERSIGHT
5	COMMITTEE MEMBERS ARE LINKED TO ITS INSTITUTIONS THAT
6	COULD BENEFIT FROM THE \$227 MILLION IN LAB CONSTRUCTION
7	GRANTS SCHEDULED TO BE GIVEN OUT NEXT YEAR. AND THE
8	OVERSIGHT COMMITTEE IS THE GROUP THAT APPROVED THE
9	CRITERIA FOR THE LAB GRANTS.
10	"CIRM HAS REFUSED TO DISCLOSE THE NAMES OF THE
11	INSTITUTIONS THAT HAVE APPLIED FOR THE GRANTS UNTIL WELL
12	AFTER THEY UNDERGO THE MOST IMPORTANT STAGES OF REVIEW, A
13	MOVE THAT MAKES IT'S IMPOSSIBLE FOR THE PUBLIC TO COMMENT
14	PROPERLY.
15	"IT IS ALSO A CASE OF UNNECESSARY SECRECY THAT
16	ONLY FOSTERS SUSPICION AND THE WORST SORT OF SPECULATION,
17	PARTICULARLY IN LIGHT OF KLEIN'S AND REED'S ACTIONS.
18	CIRM'S JUSTIFICATION FOR THE SECRECY IS WEAK. IT DOES
19	NOT WANT TO EMBARRASS ANY UNSUCCESSFUL APPLICANTS, ALL OF
20	WHICH ARE MAJOR PUBLIC AND PRIVATE NONPROFIT
21	INSTITUTIONS. IT IS A POLICY THAT SEEMS TO HAVE BEEN

- ZI INSTITUTIONS. IT IS A POLICY THAT SEEMS TO HAVE BEEN
- 22 ADOPTED WITHOUT DUE CONSIDERATION FROM A SIMILAR POLICY
- 23 REGARDING APPLICATIONS FROM INDIVIDUAL RESEARCHERS.
- 24 HOWEVER, APPLICATIONS FROM THE MAJOR LAB GRANTS ARE MUCH
- 25 DIFFERENT THAN THOSE FROM THE MEN AND WOMEN WHO DIRECT

1	STEM CELL RESEARCH LABS. THE APPLICATIONS FOR LAB						
2	CONSTRUCTION FUNDS COME FROM HUGE INSTITUTIONS, SUCH AS						
3	THE UNIVERSITY OF CALIFORNIA AND OTHER MAJOR EDUCATIONAL						
4	AND RESEARCH ENTERPRISES. THEIR NAMES AND APPLICATIONS						
5	SHOULD BE PART OF THE PUBLIC RECORD. EQUATING THE						
6	SENSITIVITIES OF UC BERKELEY ARE RATHER LIKE						
7	INSTITUTIONAL APPLICANTS FOR LAB GRANTS TO THE						
8	SENSITIVITIES OF AN INDIVIDUAL RESEARCHER WOULD SEEM TO						
9	DEFY COMMON SENSE. AND IF PROPRIETARY INFORMATION EXISTS						
10	IN THE APPLICATION, IT CAN EASILY BE EXCISED BEFORE						
11	RELEASE.						
12	"IN KEEPING WITH THE SENSE OF THE STATE						
13	AUDITOR'S REPORT, CIRM SHOULD ALSO MAKE PUBLIC THE						
14	ECONOMIC DISCLOSURE STATEMENTS OF THE PERSONS WHO REVIEW						
15	THE GRANTS. PUBLIC DISCLOSURE OF THOSE DOCUMENTS WILL						
16	ASSURE BOTH SCIENTISTS WHOSE APPLICATIONS ARE BEING						
17	REVIEWED AND THE PUBLIC WHOSE MONEY IS BEING SPENT OF THE						
18	ESSENTIAL FAIRNESS OF THE PROCESS. CIRM HAS RESISTED						
19	SUCH DISCLOSURES. IT SAYS IT IS ALREADY MORE OPEN THAN						
20	THE NATIONAL INSTITUTES OF HEALTH, BUT CIRM AND THE NIH						
21	ARE NOT COMPARABLE.						
22	"THE PRESIDENT AND THE CONGRESS CAN AND DO						
23	INTERVENE IN NIH MATTERS AND SETS BUDGET. IN CALIFORNIA						
24	THE GOVERNOR AND LEGISLATURE ARE BARRED FOR ALL PRACTICAL						
25	PURPOSES FROM EXERCISING SUCH OVERSIGHT BECAUSE OF THE						

1	PROVISIONS OF PROP 71. EVEN THE TINIEST ALTERATIONS IN					
2	CIRM REQUIRE AN UNPRECEDENTED SUPER MAJORITY VOTE OF THE					
3	LEGISLATURE AND SIGNATURE OF THE GOVERNOR. IT'S FUNDING					
4	IS CONTINUOUSLY APPROPRIATED AND NOT SUBJECT TO THE					
5	NORMAL BUDGET PROCESS. ALL THAT MEANS IS THAT CIRM HAS A					
6	SPECIAL RESPONSIBILITY TO DEMONSTRATE ACCOUNTABILITY AND					
7	SHOW THE PUBLIC THAT IT IS PERFORMING WITH THEIR BEST					
8	INTERESTS IN MIND.					
9	"I URGE YOU TO RECOMMEND TO CIRM THAT IT					
10	IDENTIFY FORTHWITH THE APPLICANTS FOR ITS UPCOMING ROUND					
11	OF LAB CONSTRUCTION GRANTS AND TO RELEASE THE STATEMENTS					
12	OF ECONOMIC INTEREST FROM ITS PANELS, GRANTEE REVIEWERS.					
13	SINCERELY, DAVID JENSON."					
14	CHAIRMAN CHIANG: THANK YOU VERY MUCH. WE WILL					
15	GO TO BOB.					
16	MR. KLEIN: I'D LIKE TO RESPOND TO A COUPLE OF					
17	ITEMS RAISED IN THE LETTER. FIRST OF ALL, I'D LIKE TO					
18	EMPHASIZE THAT, AS WE INDICATED BEFORE, THE NAMES OF ALL					
19	THE INSTITUTIONS ARE ALREADY SCHEDULED TO BE RELEASED AT					
20	OUR JANUARY MEETING. THAT'S BEFORE THEY CAN ACTUALLY					
21	APPLY FOR ANY MONEY, BEFORE THEY CAN ACTUALLY SUBMIT AN					
22	APPLICATION THAT EVEN TELLS US WHAT THEY'RE APPLYING FOR.					
23	SO THEY'RE ONLY IN THE SCIENTIFIC PHASE RIGHT NOW WHERE					
24	THEY'VE SUBMITTED THEIR SCIENTIFIC REVIEW OF IDEAS.					
25	SECONDLY, I'D LIKE TO EMPHASIZE WHAT'S A					

1	QUESTION RIGHT NOW. IT'S JUST THE TIMING OF THE RELEASE						
2	OF NAMES, AND IT'S ALREADY A PUBLIC MATTER THAT A						
3	MATTER OF PUBLIC POLICY THAT ANYONE SUBMITS A GRANT THA						
4	SPECIFICALLY COMPETES FOR AN APPLICATION FOR DOLLARS						
5	UNDER THIS PROGRAM WILL BE FULLY DISCLOSED, AND THE GRANT						
6	DOLLARS WILL BE DISCLOSED. SO THAT DECISION HAS						
7	COMPLETELY BEEN MADE.						
8	ADDITIONALLY, IT IS IMPORTANT TO NOTE THAT,						
9	AGAIN, DR. REED, WHO IS A DEDICATED SCIENTIST, WHO IS TH						
10	PREEMINENT WORLD RECOGNIZED LEADER IN STEM CELL DEATH, A						
11	CRITICAL ISSUE AND PROVIDES CRITICAL INFORMATION TO THE						
12	BOARD, AND AS A SCIENTIST IS THE HEAD OF AN INSTITUTE, IS						
13	THE HEAD OF AN NIH-APPROVED CANCER MAJOR CANCER						
14	PROJECT AND WHO SERVES AS A VOLUNTEER ON THIS BOARD						
15	CERTAINLY DID MAKE A MISTAKE IN THAT HE SHOULD HAVE JUST						
16	LET SOMEONE FROM HIS INSTITUTE WRITE THIS LETTER AND SIGN						
17	THIS LETTER.						
18	WHEN HE CALLED ME ON MY CELL PHONE AND SAID						
19	THERE'S A MISTAKE THAT HAS BEEN MADE, A FACTUAL MISTAKE,						
20	I WANT TO EMPHASIZE SCIENTIFIC PEER REVIEW HAD ALREADY						
21	HAPPENED, IT WAS RATED SECOND HIGHEST BY A GROUP OF						
22	PEOPLE FROM COMPLETELY OUTSIDE THE STATE, NOT INVOLVED IN						
23	THE PROCESS, HE RECUSED HIMSELF COMPLETELY AT THE BOARD						
24	LEVEL. HE WAS NOT IN THAT PROCESS. THIS IS IN THE						
25	COMPLIANCE PROCESS LOOKING TO SEE WHETHER THE DEFINITION						
	102						

- 1 OF FULL-TIME EMPLOYMENT WAS MET. AND IN INDICATING TO
- 2 HIM THAT IT WAS A FACTUAL ERROR, I SAID, "LOOK, I'M NOT
- 3 INVOLVED IN THIS PROCESS. IF THERE'S A FACT THAT'S
- 4 WRONG, THERE'S A LETTER THAT NEEDS TO BE WRITTEN."
- NOW, IN FACT, I SHOULD HAVE SAID A LETTER
- 6 SHOULD BE WRITTEN AND YOU MUST BE SURE NOT TO WRITE IT
- 7 YOURSELF. NOW, THOSE WORDS WOULD HAVE SAVED ME A LOT OF
- 8 LEARNING; BUT, IN FACT, I DIDN'T STATE THOSE FEW WORDS.
- 9 AND WE HAVE LEARNED BY THIS. DR. RICHARD MURPHY HAS
- 10 STATED WE HAVE A FULL SYSTEM OF FIREWALLS AND
- 11 PROTECTIONS. THEY WORKED. THIS GRANT WAS DENIED. THERE
- 12 ARE NO STATE TAXPAYER DOLLARS INVOLVED. WE ARE LEARNING.
- 13 WE'VE BEEN THROUGH THOUSANDS OF DECISIONS WITH LEGAL
- 14 CONTENT. I AM PROUD OF THE RECORD THAT WE HAVE. WE WILL
- 15 LEARN. WE WILL MAKE MISTAKES ALONG THE WAY. WHAT'S
- 16 CRITICAL IS WE COMMIT OURSELVES TO LEARNING AND IMPROVING
- 17 OURSELVES FOR THE PEOPLE OF THE STATE OF CALIFORNIA. AND
- 18 I PASSIONATELY AM COMMITTED TO THAT TASK. BUT THANK YOU
- 19 VERY MUCH FOR YOUR REVIEW AND THE PRIVILEGE OF ADDRESSING
- 20 THAT COMMENT. THANK YOU.
- 21 CHAIRMAN CHIANG: THANK YOU. ANY OTHER PUBLIC
- 22 COMMENTS? WE'LL GO ITEM NO. 12. IT'S BOARD MEMBER TIME.
- 23 DO ANY BOARD MEMBERS HAVE ANY COMMENTS?
- MR. BRUNNER: JUST LIKE TO MAKE A COUPLE OF
- 25 COMMENTS. I'VE HAD THE OPPORTUNITY IN MY PROFESSIONAL

1	CAREER TO START A COMPANY AND ALSO START A STATE AGENCY						
2	THAT WAS BRAND-NEW AND WAS UNDER AN ENORMOUS AMOUNT OF						
3	PUBLIC SCRUTINY. SO I HAVE A PRETTY GOOD SENSE OF WHAT						
4	IT'S LIKE TO FULFILL THE MISSION OF THE AGENCY AND AT THE						
5	SAME TIME GO FROM BASICALLY ZERO TO A HUNDRED ON BUILDING						
6	INFRASTRUCTURE.						
7	IT'S A VERY DIFFICULT PROCESS AND ONE WHERE						
8	UNFORTUNATELY I'M SITTING HERE REMEMBERING BACK ON THE						
9	MISTAKES I MADE IN DOING IT AND ADMIRING HOW FEW MISTAKES						
10	YOU'VE MADE IN PROCEEDING AHEAD WITH THIS IMPORTANT						
11	FUNCTION.						
12	AS I READ THE FOUR CORNERS OF THE VARIOUS AUDIT						
13	REPORTS THAT HAVE BEEN PRESENTED TO US, I CAN SAY THAT,						
14	WHILE THERE HAVE BEEN SOME ISSUES RAISED, NONE OF THEM						
15	ARE FUNDAMENTAL. THEY'RE BASICALLY SOME PROCESS ISSUES						
16	THAT NEED CLEANING UP. THERE WILL ALWAYS BE PROCESS						
17	ISSUES THAT NEED TO BE CLEANED UP. THAT'S JUST INHERENT						
18	IN RUNNING ANY BUSINESS, WHETHER IT'S IN THE PUBLIC						
19	SECTOR OR PRIVATE SECTOR. I THINK OVERALL WHAT WE CAN						
20	GLEAN FROM THIS IS THAT YOU'VE DONE A VERY GOOD JOB. I						
21	PERSONALLY WANT TO COMPLIMENT YOU AND YOUR STAFF ON THE						
22	WORK YOU'VE DONE IN FURTHERING THIS IMPORTANT MISSION.						
23	THANK YOU.						
24	CHAIRMAN CHIANG: THANK YOU. ANY COMMENT?						
25	MS. POTTER: I JUST WANT TO ECHO THE COMMENTS						
	104						

1	OF MY FELLOW COMMITTEE MEMBER. THE WORK IS JUST						
2	MONUMENTAL. IT'S SIMPLY MONUMENTAL. I HAVE SEEN MANY						
3	COMPANIES COME AND GO AND GROW, AND THE PACE AT WHICH						
4	THIS ORGANIZATION HAS MOVED, THE RATE AT WHICH IT'S						
5	BROUGHT ON TALENT, THE DEGREE TO WHICH YOU HAVE DRAWN						
6	TALENT FROM AROUND THE WORLD TO THIS WONDERFUL STATE FOR						
7	A CAUSE THAT WE SO SINCERELY BELIEVE IN IS JUST JUST						
8	SHOULD BE COMMENDED.						
9	AS YOU CONTINUE TO WORK QUICKLY, YOU WILL HAVE						
10	TO BE EVEN MORE DILIGENT ABOUT MAKING SURE THAT YOUR						
11	PROCESSES ARE CLEAN AND ABSOLUTELY ABOVE REPROACH, THAT						
12	YOUR INTENT AND YOUR DESIRE COMES THROUGH A HUNDRED						
13	PERCENT. AND WHAT WILL COME WITH THAT IS THE RELATIONAL						
14	TYPES OF THINGS THAT YOU'RE GOING TO HAVE TO WORRY ABOUT						
15	WHETHER IT'S COMMITTEE MEMBERS OR ATTENDEES AT MEETINGS,						
16	ETC., ETC. SO THE ARMS OF WHERE YOU'RE GOING TO HAVE TO						
17	REACH WILL INDEED GET VERY FAR, BUT YOU WILL HAVE						
18	ADDITIONAL STAFFING AND MORE TALENT GOING FORWARD, AND I						
19	THINK THAT CHALLENGE WILL BECOME EVEN EASIER.						
20	BUT I CAN TELL YOU THAT I AM VERY PROUD, I'M						
21	VERY PROUD TO BE ON THIS COMMITTEE, I'M EXTREMELY PROUD						
22	FOR OUR WONDERFUL STATE, AND MOST IMPORTANTLY, I'M JUST						
23	THRILLED FOR THE PATIENTS WHO WILL SO GREATLY BENEFIT						
24	FROM WHAT YOU'RE DOING. SO I JUST COMMEND YOU AND ASK						
25	YOU TO JUST KEEP UP THE GOOD WORK, STAY DILIGENT, TAKE						

- 1 FULL ADVANTAGE OF ALL THE AUDIT OVERSIGHT AND
- 2 QUESTIONING. ALL THAT IS GOOD. TRANSPARENCY IS GOOD.
- 3 IT IS ALL GOOD. JUST KEEP GOING STRONG AND KEEP WORKING
- 4 HARD.
- 5 CHAIRMAN CHIANG: THANK YOU, MYRTLE. IN VIEW
- 6 OF DANIEL AND MYRTLE'S COMMENTS, LET ME TAKE UP ON THAT.
- 7 SO NO GOOD WORK GOES UNSUPPORTED. AND SO AS MYRTLE JUST
- 8 POINTED OUT, THERE'S GOING TO BE TREMENDOUS AUDIT
- 9 OVERSIGHT. AND AS THE TREASURER AND I STATED PRIOR TO
- 10 TAKING OFFICE, THAT WE WERE GOING ENGAGE IN A FINANCIAL
- 11 REVIEW OF ALL PROCEEDS, BOND PROCEEDS. SO I AM GOING TO
- 12 DIRECT MY STAFF TO REVIEW, TO AUDIT ADDITIONALLY THE GOOD
- WORK AT CIRM. I WANT TO MOVE THAT WORK VERY QUICKLY,
- 14 DIRECT THAT MY STAFF ENGAGE THAT WORK VERY QUICKLY SO
- 15 THAT WE CAN HAVE THOSE RESULTS BROUGHT BACK IN THE SPRING
- 16 MEETING.
- 17 AND ALONG THOSE THINGS TO HAVE COMMENTS, I'D
- 18 LIKE TO FOLLOW UP ON WHAT MYRTLE SAID EARLIER AND WHAT
- 19 BSA IDENTIFIED IN FOCUSING ON PREALLOCATION PROCEDURES:
- 20 GRANTS MANAGEMENT, FINANCIAL RISKS, CONFLICT OF INTEREST
- 21 VIOLATIONS, AND EXPENDITURE PRACTICES, AND COMPLIANCE.
- 22 THIS IS VERY EXCITING. IT'S POSITIVE IN LIGHT OF WHAT
- THE COURT'S DECISIONS ARE, AND SO WE GET TO A PLACE WHERE
- 24 WE CAN MAKE SURE THAT WE DO ENFORCE AND BRING TO LIGHT
- THE BEST PRACTICES THAT ARE TAKING PLACE.

1	SO THAT CONCLUDES MY REMARKS. AND EVERYBODY
2	HAVE WE ARE ADJOURNED AND HAVE SAFE HOLIDAYS.
3	(THE MEETING WAS THEN ADJOURNED AT 11:44
4	A.M.)
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
	107

### REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE CITIZENS FINANCIAL ACCOUNTABILITY OVERSIGHT COMMITTEE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

CALIFORNIA PUBLIC UTILITIES COMMISSION
505 VAN NESS AVENUE
SAN FRANCISCO, CALIFORNIA
ON
TUESDAY, NOVEMBER 27, 2007

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152

BARRISTER'S REPORTING SERVICE

1072 BRISTOL STREET

SUITE 100

COSTA MESA, CALIFORNIA

(714) 444-4100